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Abstract
In eukaryotic organisms, a large fraction of newly-synthesized proteins are destined for
the endomembrane system or for secretion. The entry gate for these proteins is the
endoplasmic reticulum (ER). Proteins are imported into the ER in an unfolded state,
where they fold and assemble into their native conformations before being exported to
the Golgi apparatus. Proteins which fail to fold or assemble correctly have a propensity
to aggregate in the ER, which is toxic for the cell. Accordingly, a quality control path-
way termed ER-associated protein degradation (ERAD) recognizes misfolded proteins
and retrotranslocates them across the ER membrane into the cytosol, where they are
ubiquitinated and degraded by the proteasome.
One of the biggest questions about ERAD is how substrates are retrotranslocated
across the ER membrane. Recent evidence implicates one of the central components
of ERAD, the Hrd1 ubiquitin ligase, in forming a retrotranslocon. Despite this, it is
still unknown if Hrd1 is sufficient for retrotranslocation of luminal ERAD substrates.
I created a novel reconstituted system to study retrotranslocation, in which luminal
substrates are encapsulated into liposomes and delivered to the luminal side of Hrd1
by SNARE-mediated fusion. The encapsulation was efficient and fusion was shown
to mix membrane proteins and luminal contents between liposomes, a technique that
has broad applications in membrane protein research. However, retrotranslocation by
Hrd1 could not be detected after fusion, which was most likely because of substrate
aggregation.
In another set of reconstitutions, Hrd1 reconstituted in nanodiscs bound misfolded
proteins on its luminal side, while Hrd1 reconstituted in liposomes bound misfolded
proteins with high affinity on its cytosolic side upon autoubiquitination. This was
dependent on autoubiquitination in the RING domain. Misfolded proteins could be
partially released from the cytoplasmic binding site by deubiquitination. Hrd1 was also
incorporated into planar lipid bilayers, and was shown to have channel activity and to
conduct ions in a voltage-dependent manner. This was dependent on autoubiquitina-
tion in its RING domain. Substrate addition stimulated channel gating and opened
the pore to diameters sufficient to fit multiple alpha helices. Remarkably, deubiquiti-
nation of Hrd1 closed the channel. Overall, this thesis provides strong evidence that
Hrd1 forms a protein-conducting channel in the ER membrane. A model is proposed,
whereby an affinity gradient between luminal and cytoplasmic binding sites provides
the driving force during retrotranslocation.
1 Introduction
1.1 The endomembrane/secretory pathway
Proteins are complex macromolecules consisting of linear chains of amino acids that
fold into a three-dimensional shape, which is critical for their function. Proteins per-
form a plethora of essential functions in the cell, ranging from enzymatic catalysis
to signaling and structural support. In the eukaryotic cell, approximately 30% of all
newly-synthesized proteins are targeted to the organelles of the endomembrane system
or for secretion into the extracellular space (Ghaemmaghami et al., 2003). This protein
trafficking pathway is referred to as the endomembrane/secretory pathway. All pro-
teins destined for the endomembrane/secretory pathway are synthesized by ribosomes
in the cytosol and are subsequently threaded into the endoplasmic reticulum (ER) in
an unfolded state through the Sec61 forward translocon (Figure 1.1) (Rapoport et al.,
2017). The Sec61 translocon is a protein-conducting channel consisting of an aqueous
pore, through which proteins containing specialized targeting sequences are imported
into the ER (Rapoport et al., 2017). After translocation into the ER, proteins fold
into their native structures with the assistance of chaperones, which are specialized
proteins that assist in the folding of other proteins (Figure 1.1). The oxidative envi-
ronment of the ER, along with chaperones called protein disulfide isomerases (PDIs),
facilitate the formation of disulfide bonds. Additionally, newly-imported proteins are
modified by the attachment of oligosaccharide chains onto asparagine residues, termed
N-glycosylation. N-glycosylation serves roles in chaperone binding, increasing solubil-
ity, and recognition by quality control machinery in the ER (Braakman and Hebert,
2013). After folding and modification in the ER, proteins are transported to the Golgi
apparatus by vesicular traffic, where they are further modified before being routed to
their final destination in the cell (Bonifacino and Glick, 2004).
7
Chapter 1 Introduction
Figure 1.1: Protein quality control at the beginning of the endomem-
brane/secretory pathway
Newly-synthesized proteins are co-translationally or post-translationally inserted into
the ER through the Sec61 translocon. In the ER, they are N-glycosylated and fold
with the assistance of chaperones. Correctly-folded proteins are exported to the Golgi
apparatus, whereas misfolded proteins are retained in the ER, where they bind to
receptors that activate the unfolded protein response (UPR), and are degraded in a
process termed ER-associated protein degradation (ERAD). See section 1.2 for details.
1.2 Protein quality control in the ER
Protein folding is under strict surveillance in the cell. Protein folding is a stochastic
process that proceeds towards the most thermodynamically-stable state (Balchin et al.,
2016). This process typically results in the protein achieving its natively-folded state,
normally under the assistance of chaperones. However, protein folding is an error-prone
process, in which folding intermediates can become kinetically trapped in partially-
folded states that expose hydrophobic amino acid residues to the aqueous environment
of the cell. This is especially relevant in the ER, where important folding steps such
as disulfide bond formation and prolyl isomeration are relatively slow, increasing the
likelihood that proteins accumulate in partially-folded or misfolded states (Balchin
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et al., 2016). Additionally, external factors such as heat stress, heavy metal stress,
oxidation, and mutations can give rise to protein misfolding (Berner et al., 2018).
Misfolded proteins have a propensity to irreversibly aggregate, which is toxic for the
cell and is linked to numerous diseases including Huntington’s disease and Parkinson’s
disease (Guerriero and Brodsky, 2012). Therefore, protein folding in the ER is overseen
by sophisticated quality control mechanisms that remove misfolded proteins before they
have the chance to aggregate.
There are two primary quality control systems in the ER (Figure 1.1). The unfolded
protein response (UPR) responds to the accumulation of misfolded proteins in the
ER through transcriptional responses that upregulate chaperone synthesis, attenuate
overall protein translation, and expand the volume of ER (Walter and Ron, 2011;
Hetz, 2012). Apart from the UPR, another quality control system of the ER, com-
posed of ubiquitin ligase complexes embedded in the ER-membrane, recognizes and
transports misfolded proteins out of the ER and ubiquitinates them on the cytosolic
side of the membrane (Mehrtash and Hochstrasser, 2018). Thereafter, these ubiquiti-
nated proteins are extracted from the membrane by the Cdc48 AAA ATPase complex
and shuttled to the proteasome for proteolysis (see section 1.3 for an overview of the
ubiquitin-proteasome system). This process is termed ER-associated protein degra-
dation, or ERAD. In addition to degrading misfolded proteins, ERAD also degrades
orphan subunits of multiprotein complexes and modulates sterol levels by degrading
enzymes involved in sterol biosynthesis (Ruggiano et al., 2014). ERAD is also hijacked
by viruses to degrade subunits of components involved in immune recognition and by
bacterial toxins to enable their retrograde transport out of the ER (Morito and Nagata,
2015). The two ER protein quality control pathways, UPR and ERAD, are linked, with
many ERAD components upregulated by the UPR upon ER stress (Hwang and Qi,
2018). In addition key UPR components become ERAD substrates under certain con-
ditions, demonstrating regulatory crosstalk between the two quality control pathways
(Hwang and Qi, 2018).
1.2.1 ERAD in Saccharomyces cerevisiae
ERAD is conserved across all eukaryotes but is best characterized and understood in
the yeast Saccharomyces cerevisiae. In S. cerevisiae, the process is coordinated by two
ubiquitin ligase complexes: Hrd1 and Doa10 (Figure 1.2). These complexes coordinate
the degradation of specific subsets of substrates, which are defined by the location of
their misfolded domain relative to the ER membrane. Substrates of the Hrd1 complex
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contain misfolded domains in the ER lumen or ER membrane, whereas substrates of
the Doa10 complex primarily contain misfolded domains in the cytosol, with select
substrates also containing misfolded domains in the ER membrane (Carvalho et al.,
2006; Vashist and Ng, 2004; Habeck et al., 2015) (Figure 1.2). Consequently, the
three pathways are termed ERAD-L (lumen), ERAD-M (membrane) and ERAD-C
(cytosol), referring to the location of the misfolded domain. Hrd1 and Doa10 and their
associated cofactors are highly conserved from yeast to humans (Christianson and Ye,
2014), indicating the importance of ERAD and the demonstrating the relevance of
investigating the molecular mechanisms of ERAD in the model organism S. cerevisiae.
All three pathways can be broken down into the same fundamental steps (Figure 1.2).
First, misfolded substrates are recognized by the Hrd1 or Doa10 complexes. Second,
substrates containing misfolded domains in the ER lumen are transported across the
membrane, or retrotranslocated. Third, the substrates are polyubiquitinated by Hrd1
or Doa10 on the cytosolic side of the membrane, in conjunction with specific E2 en-
zymes localized at the ER membrane. Fourth, the Cdc48 complex is recruited to the
polyubiquitinated substrate, which extracts the substrate from the membrane using
rounds of ATP hydrolysis. Finally, the extracted substrate is shuttled to the protea-
some, where it is degraded through regulated proteolysis (Berner et al., 2018; Mehrtash
and Hochstrasser, 2018).
This thesis deals with the retrotranslocation of misfolded luminal proteins across the
ER membrane, as this is one of the most intriguing mechanistic steps in ERAD. There-
fore, the introduction focuses on the ERAD-L pathway, dealt with by the Hrd1 com-
plex. ERAD-M, also coordinated by the Hrd1 complex, is discussed in section 1.7. For
a detailed review of Doa10-mediated ERAD, the reader is referred to reviews by Zattas
and Hochstrasser (2014) and Mehrtash and Hochstrasser (2018).
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Figure 1.2: Overview of ERAD pathways in S. cerevisiae
The three ERAD pathways in S. cerevisiae. The star indicates the misfolded domain.
The RING domain is involved in transfer of ubiquitin to the substrate. See text for
further details.
1.3 The ubiquitin-proteasome system (UPS)
The regulated degradation of proteins in eukaryotic cells is mediated by the covalent
attachment of a small, conserved protein called ubiquitin, which marks the protein for
proteolysis by by the proteasome. This attachment proceeds through an enzymatic
cascade, through which a ubiquitin-activating enzyme (E1), ubiquitin-conjugating en-
zymes (E2s), and ubiquitin ligases (E3s) coordinate to catalyze the attachment of
ubiquitin by formation of an isopeptide bond between the C-terminus of ubiquitin and
a lysine residue on the target protein (Komander and Rape, 2012) (Figure 1.3). The
attachment of ubiquitin to substrates requires energy. Energy is provided by ATP
hydrolysis of the E1, which forms a thioester bond with the C-terminus of ubiquitin,
thereby forming an activated ubiquitin-E1 complex (Figure 1.3). The activated ubiq-
uitin is then transferred to an E2 enyzme, which also forms a thioester bond between
its active site cysteine and the C-terminus of ubiquitin. Finally, an E3 ligase binds
both the substrate and E2 and facilitates transfer of ubiquitin from the E2 to a lysine
residue on the substrate (Pickart, 2001). E3 ligases are classified into different families
11
Chapter 1 Introduction
based on the type of active site domains they possess. The RING domain ligases are
the largest family of E3 ligases. RING E3s catalyze ubiquitin transfer directly from
the E2 to the substrate (Komander and Rape, 2012). The two other families of E3 lig-
ases, the HECT and RBR ligases, form a thioester intermediate with ubiquitin before
transferring ubiquitin to the substrate (Komander and Rape, 2012).
Figure 1.3: Ubiquitination cascade
Ubiquitination proceeds through a cascade of three enzymes termed E1, E2 and E3.
Attachment of at least four ubiquitin molecules to the substrate in the form of a K48-
linked chain targets the substrate for proteasomal degradation. See text for details.
Substrate specificity is determined by the E3 ligases, often in complex with other
cofactors (Ravid and Hochstrasser, 2008). This is evident by the large number of E3
ligases compared to E2s and E1s. In S. cerevisiae, there are approximately 60-100 E3
ligases, 11 E2s and only 1 E1 enzyme (Finley et al., 2012). In humans, approximately
40 E2s and at least 600 E3 ubiquitin ligases are predicted to exist (Stewart et al., 2016;
Zheng and Shabek, 2017), indicative of the greater substrate complexity in higher
eukaryotes. Substrates are recognized through structural elements known as degrons,
which are usually hydrophobic in nature and become exposed when proteins dissociate
from their binding partners or when they misfold (Ravid and Hochstrasser, 2008).
Ubiquitin can be attached as a single ubiquitin, known as monoubiquitination, or it can
be extended to form chains of multiple ubiquitin moeties, known as polyubiquitination.
Ubiquitin contains seven lysine residues (K6, K11, K27, K29, K33, K48 and K63),
any of which, as well as the free N-terminus, can be used as the attachment site
for the next ubiquitin (Komander and Rape, 2012). For RING ligases, the linkage
specificity is determined by the E2 enzyme (Komander and Rape, 2012; Stewart et al.,
2016). Polyubiquitin chains linked by Lys 48 (K48 chains) are the primary recognition
signal for the proteasome (Chau et al., 1989; Pickart, 2001). The proteasome is a
large multisubunit, ATP-dependent protease which degrades proteins containing K48
ubiquitin chains. It consists of a 20S core particle and a 19S regulatory particle (Finley,
2009). The 20S core particle contains the proteolytic sites, which are found in a narrow
constriction in the barrel-shaped core particle (Finley, 2009). The 19S regulatory
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particle is composed two multisubunit assemblies termed the lid and the base. The
base contains receptors for K48 ubiquitin chains and binding sites for external ubiquitin
adapters, as well as a hexameric AAA ATPase motor, which unfolds substrates and
translocates them into the core particle (Bard et al., 2018). The lid functions as
a scaffold and contains an essential deubiquitinating enzyme (DUB), which removes
ubiquitin chains from the substrate before they enter the AAA ATPase ring (Bard
et al., 2018).
1.4 Mechanism of ERAD-L in S. cerevisiae
1.4.1 Delivery of luminal glycosylated substrates to the Hrd1
complex
Recognition of misfolded proteins by the Hrd1 complex is best understood for luminal,
N-glycosylated substrates. In particular, two misfolded variants of the yeast vacuo-
lar proteases carboxypeptidase Y (CPY) and proteinase A (PrA), termed CPY* and
PrA*, are substrates of the Hrd1 complex and have been instrumental in determining
the molecular mechanisms of ERAD-L (Finger et al., 1993; Hiller et al., 1996; Bordallo
et al., 1998). During import into the ER, proteins are N-glycosylated by the oligosac-
charyl transferase complex (OST), which is located in the immediate vicinity of the
Sec61 translocon. The OST attaches a pre-synthesized Glc3Man9GlcNAc2 core glycan
en bloc to asparagine residues within the NxT consensus sequence (Helenius and Aebi,
2004) (Figure 1.4). The two terminal glucoses are then cleaved by glucosidases in the
ER lumen. The monoglucosylated protein becomes a substrate for calnexin and cal-
reticulin, two lectin chaperones in the ER lumen, which are often found in complex
with PDIs (Ellgaard and Helenius, 2003). After calnexin and calreticulin-assisted fold-
ing, the final glucose residue is cleaved by glucosidase II, producing a Man9GlcNAc2
glycan (Man9). An enzyme called UDP-glucose:glycoprotein glucosyltransferase (GT)
recognizes partially unfolded regions and reattaches a terminal glucose residue if the
protein has not correctly folded (Ellgaard and Helenius, 2003). This reengages the
protein with calnexin and calreticulin, which provides it another opportunity to fold
correctly. Interestingly, S. cerevisiae is the only known eukaryotic species that does not
possess the GT enzyme (Parodi, 2000). Thereafter, a mannosidase called Mns1 cleaves
off the terminal mannose residue, generating a Man8GlcNAc2 glycan (Man8). Mns1 is
a slow-acting enzyme, which has been suggested to provide proteins a time-window to
fold before being routed to the ERAD machinery (Jakob et al., 1998). This hypothesis,
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known as the the mannose timer model, seeks to explain how cells distinguish folding
intermediates from misfolded proteins in the ER (Helenius and Aebi, 2004).
The decisive step in whether a protein is exported from the ER or committed to ERAD
appears to lie with the removal of an additional mannose to generate a Man7GlcNAc2
glycan (Man7). This is performed by a mannosidase called Htm1, which is found in
complex with PDI (Clerc et al., 2009; Gauss et al., 2011) (Figure 1.4). Htm1 is thought
to sense the folding state of proteins through its association with PDI. It preferentially
demannosylates Man8 glycans on unfolded polypeptides, and disruption of PDI bind-
ing to Htm1 reduces Htm1 mannosidase activity and impairs degradation of ERAD-L
substrates (Gauss et al., 2011; Liu et al., 2016). Consistent with this observation, the
position of the glycan was found to be important for efficient substrate degradation,
indicating that Htm1/PDI recognizes Man8 glycans in a specific structural context,
presumably in the vicinity of unfolded regions (Spear and Ng, 2005; Kostova, 2005).
The resulting Man7 glycan contains a terminal α-1,6-linked mannose, which serves as
the recognition signal for Yos9, a lectin which is associated with the Hrd1 complex
(Quan et al., 2008). Thus, the Htm1/PDI complex is a surveillance complex that com-
mits Man8-containing glycoproteins with unfolded regions to Hrd1-mediated ERAD.
In contrast, correctly-folded proteins containing Man8 glycans avoid the Htm1/PDI
complex and are routed to the Golgi by association with sorting receptors in the ER
that recognize structural elements and/or glycan signals (Dancourt and Barlowe, 2010;
Xu and Ng, 2015).
Proteins containing a Man7 glycan are routed to the Hrd1 complex through the lectin
Yos9, which recognizes the exposed α-1,6-linked mannose through its sugar-binding
MRH domain (Buschhorn et al., 2004; Bhamidipati et al., 2005; Kim et al., 2005;
Szathmary et al., 2005; Denic et al., 2006; Quan et al., 2008). The substrate is also
bound to the ER-luminal Hsp70 chaperone Kar2, along with its Hsp40 cochaperones
Scj1 and Jem1 (Plemper et al., 1997; Brodsky et al., 1999; Nishikawa et al., 2001).
Yos9 also binds to Kar2 (Denic et al., 2006). Thus, the coordination of Yos9 binding to
Man7 glycans and Kar2 binding to unfolded polypeptides acts synergistically to deliver
substrates to the Hrd1 complex.
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Figure 1.4: N-glycan processing during protein folding in the ER
Trimming sequence of N-glycans in the ER lumen. The core N-glycan is attached to
an asparagine residue in the substrate and contains three terminal glucose moieties
in the A branch, which are cleaved by glucosidases Gls1 and Gls2. The terminal
mannose in the B branch is cleaved by Mns1, yielding a Man8 glycan. Misfolded
proteins are committed to ERAD by cleavage of the terminal mannose in the C branch
by Htm1/Pdi1, yielding a Man7 glycan. GlcNAc: N-acetylglucosamine. Glc: glucose.
Man: mannose. Figure modified from Xu and Ng (2015).
1.4.2 Recognition of non-glycosylated substrates by the Hrd1
complex
The ERAD system is also capable of degrading specific types of non-glycosylated sub-
strates. This was demonstrated by the observation that Hrd1 efficiently degrades a
variant of PrA* where the region containing the glycosylation site is deleted (Kane-
hara et al., 2010). The glycan independent pathway seems to have different struc-
tural determinants for degradation compared to glycan-dependent ERAD (Kanehara
et al., 2010). It relies strongly on Kar2 and its Hsp40 co-chaperones, and does not
require Yos9 and Htm1 (Kanehara et al., 2010). A similar pathway seems to exist in
mammalian ERAD, as a non-glycosylated mutant of α1-antitrypsin (NHK-QQQ) and
non-glycosylated, unassembled immunoglobulin κ light chains were efficiently degraded
and were dependent on BiP, the Kar2 homolog (Hosokawa et al., 2008; Okuda-Shimizu
and Hendershot, 2007). Interestingly, non-glycosylated CPY* from S. cerevisiae is ef-
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ficiently degraded in the fission yeast S. pombe, and its degradation is not dependent
on Htm1 and Yos9 (Mukaiyama et al., 2011). Thus, multiple recognition pathways for
ER luminal misfolded proteins exist. It is not clear to which extent they overlap or
how substrates are triaged into these different pathways.
1.4.3 Insertion of luminal substrates into the Hrd1 complex for
retrotranslocation
Misfolded, Man7-glycosylated luminal proteins are delivered to the Hrd1 complex by
Yos9 through its interaction with Hrd3, an integral component of the Hrd1 complex
(Figure 1.5). Extensive studies using genetic and biochemical methods have identified
most, if not all, of the components of the Hrd1 complex required for degradation
of an ERAD-L substrate. All proteins shown in Figure 1.5 are required for efficient
degradation of misfolded, glycosylated luminal ER proteins.
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Figure 1.5: The Hrd1 complex in ERAD-L
The necessary components for efficient degradation of misfolded glycosylated proteins
are illustrated (ERAD-L pathway). Hrd1, the central component of the complex, is
linked to substrates by its interaction with Hrd3. Hrd3 binds to Yos9 and Kar2,
capturing the misfolded substrate in the lumen and routing it to Hrd1. Usa1 interacts
with Hrd1 to facilitate oligomerization and to link Hrd1 to Der1, which may have a role
in inserting substrates into the retrotranslocon. Der1 was shown to have 4 TMs (Hitt
and Wolf, 2004), but sequence homology to the mammalian orthologs, the Derlins,
indicates that it likely contains 6 TMs (Greenblatt et al., 2011) (indicated by dashed
lines). Cue1 recruits the E2 Ubc7, which polyubiquitinates substrates on the cytosolic
side of the membrane in conjunction with the Hrd1 RING domain. Ubx2 recruits
Cdc48 to the ER membrane, which extracts poylubiquitinated substrates. See text for
further details. Figure modified from Zattas and Hochstrasser (2014).
Hrd3
Hrd3 contains a C-terminal transmembrane domain flanked by a small cytosolic do-
main and a large luminal domain consisting of 12 Sel1-like repeats (SLRs), which are
scaffolding motifs that mediate specific protein-protein interactions (Schoebel et al.,
2017; Mittl and Schneider-Brachert, 2007). The most C-terminal SLR of Hrd3 binds
to the loop between transmembrane domains (TMs) 1-2 of Hrd1 (Schoebel et al., 2017)
(Figure 1.5). Hrd3 is crucial for Hrd1 stability, as Hrd1 rapidly self-degrades due to
autoubiquitination in the absence of Hrd3 (Plemper et al., 1999; Gardner et al., 2000;
Horn et al., 2009; Vashistha et al., 2016), indicating that Hrd3 influences Hrd1 ubiq-
uitination activity. In addition to its interaction with Yos9, Hrd3 can interact with
misfolded proteins independently of Yos9 and likely also with Kar2 and its cochaperone
Scj1 (Denic et al., 2006; Gauss et al., 2006; Mehnert et al., 2015), indicating that one
of the functions of Hrd3 is a substrate receptor for the Hrd1 complex. In line with this
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hypothesis, overexpression of Hrd3 inhibits substrate degradation, likely because ex-
cess Hrd3 sequesters substrates into dead-end complexes lacking Hrd1 (Plemper et al.,
1999). Substrate degradation is restored when Hrd1 is co-overexpressed (Vashistha
et al., 2016).
Hrd1
The Hrd1 ubiquitin ligase is the central component of the Hrd1 complex (Hampton
et al., 1996; Bordallo et al., 1998; Gardner et al., 2000). Originally shown to have 6 TMs
(Deak and Wolf, 2001), a recent cryo-EM structure of Hrd1 in complex with Hrd3 indi-
cates that it contains 8 TMs, with both N and C-termini facing the cytosol (Schoebel
et al., 2017) (see Figure 1.6). Hrd1 has been suggested to form the retrotranslocation
channel in ERAD-L (see section 1.9 for a detailed overview). The C-terminal cyto-
plasmic region of Hrd1 contains a RING H2 domain, which imparts E3 ligase activity,
and a long C-terminal extension which is predicted to be largely unstructured (Bor-
dallo and Wolf, 1999; Bays et al., 2001; Deak and Wolf, 2001). The RING domain of
Hrd1 catalyzes attachment of K48-linked polyubiquitin chains onto substrates on the
cytoplasmic side of the ER, which leads to their extraction from the membrane by the
Cdc48 complex and degradation by the proteasome (Bays et al., 2001; Bazirgan and
Hampton, 2008). Additionally, Hrd1 autoubiquitinates itself, a function also observed
with other E3 ligases (de Bie and Ciechanover, 2011). Autoubiquitination seems to
have two functions. First, Hrd1 autoubiquitination in its RING domain is suggested to
open the retrotranslocation channel (Baldridge and Rapoport, 2016). Second, it serves
as a regulatory mechanism, resulting in Hrd1 degradation by the proteasome (Gardner
et al., 2000). Hrd1 functions primarily in conjunction with the cytosolic E2 enzyme
Ubc7, and to a much lesser extent with the E2 Ubc1 (Bays et al., 2001; Friedlander
et al., 2000). The ER membrane-anchored Ubc6 may also function as an E2 for certain
Hrd1 substrates (Hiller et al., 1996).
Usa1
The C-terminal region of Hrd1 interacts with the N-terminal region of Usa1, a dual
membrane spanning protein with N and C-termini facing the cytosol (Figure 1.5). The
N-terminal portion of Usa1 also binds to another Usa1 molecule, thereby facilitating
Hrd1 oligomerization, most likely with 2:2 stoichiometry (Carvalho et al., 2006; Horn
et al., 2009). Usa1 is required for degradation of ERAD-L substrates and for some
ERAD-M substrates (Carvalho et al., 2006; Horn et al., 2009; Carroll and Hampton,
2010). The C-terminal region of Usa1 binds to the C-terminus of Der1, another integral
membrane protein of the Hrd1 complex, thereby linking Hrd1 to Der1 (Carvalho et al.,
2006; Horn et al., 2009; Mehnert et al., 2013). Usa1 is required in ERAD-L primarily
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due to its role in recruiting Der1 to the Hrd1 complex. Usa1 contains a ubiquitin-like
(UBL) domain in its N-terminal region, which seems to play a role in Hrd1 degradation.
The UBL domain is required for Hrd1 degradation in the absence of Hrd3, but is not
essential for substrate degradation in ERAD-L or ERAD-M (Carroll and Hampton,
2010; Vashistha et al., 2016).
Der1
Der1 contains 4-6 TMs, with both N and C-termini facing the cytosol (Hitt and Wolf,
2004) (see section 1.9 for further discussion about the role of Der1 in retrotransloca-
tion). It is exclusively required for ERAD-L but not for ERAD-M (Knop et al., 1996;
Vashist and Ng, 2004; Carvalho et al., 2006). As mentioned above, it is linked to the
Hrd1 complex through its interaction with Usa1, and is unstable in the absence of
Usa1 (Horn et al., 2009). Der1 and its mammalian orthologs, the Derlins (Lilley and
Ploegh, 2004; Ye et al., 2004; Oda et al., 2006), share homology to the rhomboid family
of intramembrane proteases, but lack the active site residues present in active rhom-
boid proteases, and likely do not possess intramembrane protease activity (Greenblatt
et al., 2011; Freeman, 2014). Although Der1 was found in a previous study to contain
4 TMs (Hitt and Wolf, 2004), its similarity to the 6 TM-containing GlpG and Derlin-1
proteins indicates that it may also contain 6 TMs (Greenblatt et al., 2011; Wang et al.,
2006). Der1 interacts with substrates downstream of Hrd3 and Yos9 and has been sug-
gested to insert luminal substrates into the the retrotranslocation machinery (Mehnert
et al., 2013) (see section 1.9).
Cue1/Ubc7
Although technically not part of the Hrd1 complex, Ubc7 is anchored to the ER mem-
brane by Cue1, a single-spanning membrane protein with its soluble region facing the
cytosol (Biederer et al., 1997) (Figure 1.5). Cue1 was originally thought to function
mainly by increasing the local concentration of Ubc7 at the ER membrane. However,
it later became clear that Cue1 is not only a tethering factor of Ubc7, but also signifi-
cantly stimulates Ubc7-dependent polyubiquitination (Bazirgan et al., 2006; Bazirgan
and Hampton, 2008). In fact, tethering Ubc7 to the membrane in the absence of Cue1
is not sufficient for substrate degradation in ERAD-M (Bazirgan and Hampton, 2008).
Cue1 contains a Ubc7 binding domain (U7BR) and a ubiquitin binding domain termed
a CUE domain (Kostova et al., 2009). The U7BR of Cue1 binds to the backside of
Ubc7 while the CUE domain binds preferentially to the distal K48-linked ubiquitin on
the substrate. Binding of U7BR to Ubc7 appears to activate Ubc7 for ubiquitin trans-
fer and increases its affinity for the Hrd1 RING domain, while binding of the CUE
domain to the distal ubiquitin aligns Ubc7 to efficiently elongate the polyubiquitin
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chain (Bagola et al., 2013; Metzger et al., 2013; von Delbrueck et al., 2016). Therefore,
polyubiquitination by Hrd1 and Ubc7 is tightly regulated by Cue1.
1.5 Extraction of ERAD-L substrates from the ER
membrane by the Cdc48 complex
Once substrates are retrotranslocated through the Hrd1 complex and polyubiquiti-
nated on the cytosolic side of the ER membrane, they are extracted by the Cdc48
AAA ATPase complex (Ye et al., 2001; Jarosch et al., 2002; Rabinovich et al., 2002).
The Cdc48 complex consists of the hexameric AAA ATPase Cdc48 and its cofactors
Ufd1 and Npl4. AAA ATPases (ATPases associated with a variety of cellular activ-
ities) are highly-conserved hexameric protein complexes that harness rounds of ATP
hydrolysis to unfold proteins or disentagle protein complexes, a function which is vital
in many cell biological processes (Hanson and Whiteheart, 2005). Cdc48 is special-
ized in extracting ubiquitinated proteins. In addition to ERAD, Cdc48 is involved in
the transcriptional regulation of membrane fluidity (Rape et al., 2001; Ballweg and
Ernst, 2017), ribosomal quality control (Brandman et al., 2012; Verma et al., 2013),
mitochondrial protein quality control (Taylor and Rutter, 2011), and the segregation
of proteins from chromatin during mitosis (Ramadan et al., 2007). Cdc48 is a ho-
mohexamer consisting of an N-terminal (N) domain and two AAA ATPase domains
termed D1 and D2, separated by a small linker. D1 and D2 form two stacked hex-
americ rings surrounding a narrow pore. The Ufd1/Npl4 (UN) complex binds to the
N domain of Cdc48 and to K48-linked polyubiquitin chains, thereby linking Cdc48 to
polyubiquitinated substrates (Bodnar and Rapoport, 2017a).
Cdc48 is recruited to the Hrd1 complex by Ubx2, an integral membrane protein with
two TMs, localized to the ER membrane (Neuber et al., 2005; Schuberth and Buch-
berger, 2005) (Figure 1.5). Ubx2 contains an N-terminal ubiquitin-associated (UBA)
domain and C-terminal UBX domain, both localized in the cytosol. The UBX domain
binds to the N domain of Cdc48 while the UBA domain binds to ubiquitinated proteins
(Schuberth et al., 2004). Interestingly, both Ubx2 and Ufd1 are required for recruiting
Cdc48 to substrates, suggesting a bipartite mechanism of Cdc48 recruitment to the
Hrd1 complex (Schuberth and Buchberger, 2005). Ubx2 may act by specifically re-
cruiting the Cdc48 complex to the Hrd1 complex only when Hrd1 is autoubiquitinated
or when ubiquitinated substrate is exposed on the cytoplasmic side.
Because the structure of mammalian Cdc48 (p97) shows a very narrow central pore
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(Banerjee et al., 2016), it was unclear if Cdc48 actively unfolds and translocates sub-
strates into the central pore during processing. Recently, the mechanism of Cdc48 ex-
traction was demonstrated for a cytosolic ubiquitinated substrate (Bodnar and Rapoport,
2017b). First, the UN complex binds to the Cdc48 N domain. This binding occurs
when the N domain is in an “up” conformation, which is triggered by ATP binding in
the D1 ring. Next, UN binds polyubiquitin chains in the substrate, which stimulates
ATP hydrolysis in the D2 ring. The substrate is inserted into the central pore and is
unfolded during translocation through the pore, which is powered by ATP hydrolysis
in the D2 ring. Polyubiquitin chains on the substrate would sterically obstruct translo-
cation through the central pore. They are removed during translocation by the DUB
Otu1 (YOD1 in mammals), which binds to the N domain of Cdc48 through its UBX-
like domain (Ernst et al., 2009; Bodnar and Rapoport, 2017b). Some oligoubiquitin
moieties are retained on the substrate, which are co-translocated through the pore.
After translocation, the ubiquitin moieties likely refold and serve as recognition signals
for downstream factors, which shuttle the substrate to the proteasome for degradation
(Bodnar and Rapoport, 2017a).
In addition to its role in substrate extraction, Cdc48 also acts as a chaperone, main-
taining the solubility of extracted proteins in the cytoplasm (Neal et al., 2017). This
is especially important for ERAD-M substrates, which are integral membrane proteins
containing numerous transmembrane domains.
1.6 End of the road: from Cdc48 to the proteasome
After Cdc48 extraction, substrates are recognized by the E4 enzyme Ufd2, an E3 ligase
specialized for extending ubiquitin chains (Koegl et al., 1999; Richly et al., 2005).
Ufd2 extends the the polyubiquitin chains on the substrate and shuttles the substrate
to the adapter proteins Rad23 and Dsk2. Rad23 and Dsk2 interact with Ufd2 and
the proteasome through their ubiquitin-like (UBL) domain, and with ubiquitinated
substrates through their UBA domains, thereby linking the substrate to the proteasome
(Richly et al., 2005; Medicherla et al., 2004; Kim et al., 2004; Wilkinson et al., 2001).
Delivery of the substrate to the proteasome by Rad23 and Dsk2 results in its proteolytic
degradation.
The enzyme peptide:N-glycanase (Png1, NGLY1 in mammals) removes remaining N-
glycans from some substrates before proteasomal degradation. Png1/NGLY1 interacts
with Cdc48, Rad23 and the proteasome (Suzuki et al., 2016). The overall importance
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of glycan removal before proteasomal degradation is unclear, as the proteasome is able
to degrade N-glycosylated proteins (Kario et al., 2007).
1.7 Mechanism of ERAD-M in S. cerevisiae
In ERAD-M, proteins containing misfolded domains in the ER membrane are degraded
by the Hrd1 complex. However, the requirements for Hrd1 cofactors differs between
ERAD-M and ERAD-L. Most notably, ERAD-M substrates do not require Der1 for
their degradation (Vashist and Ng, 2004; Carvalho et al., 2006). Hrd3 is required in
ERAD-M due to its role in stabilizing Hrd1, and it also may be important for effi-
cient substrate ubiquitination (Vashistha et al., 2016). Usa1 appears to be dispensable
for the degradation of some ERAD-M substrates but important for others (Carvalho
et al., 2006; Horn et al., 2009; Carroll and Hampton, 2010). It is not clear why some
substrates require Usa1 and others do not. One possibility is that different Hrd1 sub-
complexes consisting of Hrd1/Hrd3 or Hrd1/Hrd3/Usa1 exist in the cell, and both are
involved in ERAD-M. Some ERAD-M substrates may require Hrd1 oligomerization
for their degradation, and therefore require Usa1. Those that do not require Hrd1
oligomerization would be degraded by Hrd1/Hrd3 subcomplexes. Downstream of the
Hrd1 complex, ERAD-M requires the same ubiquitination and extraction machinery
as ERAD-L.
Substrate recognition in ERAD-M is not completely understood, but is thought to be
mediated by direct recognition of misfolded membrane segments by the Hrd1 trans-
membrane domains (Gardner et al., 2001; Sato et al., 2009). Hrd1 might constantly
scan the folding status of transmembrane domains in the ER and degrade proteins
that contain exposed hydrophilic residues in the membrane, which could be a common
feature in membrane misfolding. Consistent with this hypothesis, when conserved hy-
drophilic residues in the transmembrane domains of Hrd1 were mutated to alanine,
degradation of the yeast HMG-CoA reductase enzyme (Hmg2) was abolished (Sato
et al., 2009). Mutation of separate, hydrophobic Hrd1 TM residues inhibited degrada-
tion of a misfolded plasma membrane transporter (Pdr5*) and a misfolded variant of
Sec61 (Sec61-2) (Sato et al., 2009). The conformational changes that expose misfolded
transmembrane domains can be externally regulated. For example, degradation of
Hmg2 is mediated by the cofactors Nsg1 and Nsg2 (INSIG-1 and 2 in mammals), which
bind to Hmg2 in high sterol conditions and stabilize it (Flury et al., 2005; Theesfeld and
Hampton, 2013). Conversely, high levels of geranylgeranyl pyrophosphate (GGPP), an
isoprenoid intermediate in the sterol synthesis pathway, induce Hmg2 misfolding and
22
1.8 Role of the Hrd1 complex in mammalian ERAD
degradation (Wangeline and Hampton, 2018).
Recently, Dfm1, a Der1 homolog, a was implicated in the retrotranslocation of ERAD-
M substrates (Neal et al., 2018). Dfm1, like Der1, is related to the Derlin family of
rhomboid pseudoproteases (Greenblatt et al., 2011). Like Der1, it was predicted to
contain 4 TMs (Hitt and Wolf, 2004). However, owing to its similarity to the Derlins,
it also likely contains 6 TMs (Greenblatt et al., 2011). Dfm1 contains an SHP box,
which binds to Cdc48 and recruits it to the ER membrane (Sato and Hampton, 2006;
Goder et al., 2008; Stolz et al., 2010; Neal et al., 2018). Dfm1 also interacts with Doa10
and has been shown to be required for degradation of Ste6*, an ERAD-C substrate
(Stolz et al., 2010). Although previous studies showed no effect of Dfm1 deletion on
ERAD-L or -M, (Hitt and Wolf, 2004; Sato and Hampton, 2006; Goder et al., 2008;
Stolz et al., 2010), Neal et al. showed that Dfm1 was absolutely required for ERAD-M
and ERAD-C, but not for ERAD-L. Interestingly, upon substrate overexpression in a
Dfm1 deletion background, Hrd1 levels were upregulated by chromosomal duplication,
which suppressed the Dfm1 deletion phenotype after multiple generations. This is likely
the reason why previous studies overlooked the role of Dfm1 (Sato and Hampton, 2006;
Goder et al., 2008). The GxxxG motif and the WR motif, which are essential motifs
in rhomboid proteases and pseudoproteases (Greenblatt et al., 2011; Freeman, 2014),
were required for substrate degradation. Cdc48 recruitment by the SHP box was also
required. The GxxxG motif facilitates membrane protein dimerization (Teese and
Langosch, 2015). In line with this, Dfm1 and Der1 form dimers in vivo (Goder et al.,
2008; Mehnert et al., 2013). Dfm1 has been hypothesized to form a retrotranslocon or
an insertase into the channel for ERAD-M substrates (Neal et al., 2018). Its homology
to rhomboid proteases suggests that it contains a hydrophilic cavity and has the ability
to perturb the lipid bilayer. Additionally, its ability to dimerize supports the idea that
it forms part of a retrotranslocation channel for ERAD-M substrates.
In addition to Dfm1, Hrd1 has also been postulated to form the retrotranslocation
channel for ERAD-M. This is further discussed in section 1.9, which deals with the
identity of the retrotranslocon in ERAD.
1.8 Role of the Hrd1 complex in mammalian ERAD
ERAD is a highly-conserved process across all eukaryotes, which is evident by the
presence of mammalian homologs of all components of the S. cerevisiae Hrd1 complex
(Table 1.1). Because of the conservation of these components, ERAD likely func-
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tions with similar mechanisms in higher eukaryotes, including mammals. Nevertheless,
mammalian ERAD is strikingly more complex than that observed in S. cerevisiae.
For one, many more E3 ligases are involved in mammalian ERAD than in S. cere-
visiae. In addition to the direct homologs of yeast Hrd1 and Doa10: Hrd1/Synviolin
and TEB4/MARCH6, the E3 ligases gp78, TRC8 and RNF145 are also involved in the
degradation of different substrates (Christianson and Ye, 2014; Menzies et al., 2018).
Interestingly, gp78, TRC8 and RNF145 all show homology to the transmembrane do-
mains of S. cerevisiae Hrd1 (scHrd1) (Schoebel et al., 2017). TRC8 and RNF145 show
homology primarily to TMs 3-8 of scHrd1, which are suggested to form the aqueous
pore of the retrotranslocon (Schoebel et al., 2017) (see section 1.9 and Figure 1.6).
The homology of the mammalian E3 ligases to scHrd1 indicates that they function
similarly and probably also form parts of the retrotranslocation machinery. Besides
containing regions similar to scHrd1, mammalian ERAD ligases contain additional el-
ements to deal with the increased substrate complexity. Human TRC8 and RNF145
contain sterol-sensing domains, while human gp78 contains a CUE domain and a p97-
interacting motif, thus combining the function of multiple factors found in S. cerevisiae
(Christianson and Ye, 2014; Schoebel et al., 2017). Besides the aforementioned E3 lig-
ases, new uncharacterized E3 ligases continue to be discovered in mammalian ERAD
(Khouri et al., 2013; van den Boomen et al., 2014; van de Weijer et al., 2014)
In addition to the greater number and complexity of E3 ligases involved in mammalian
ERAD, the substrate specificities of different E3 ligases often overlap (Morito et al.,
2008; Menzies et al., 2018; Stefanovic-Barrett et al., 2018). Mammalian ERAD ap-
pears to be very modular, with various subcomplexes cooperating to degrade specific
substrates (Christianson et al., 2011). The substrate overlap and modularity provides
more redundancy in the process, which reflects the greater complexity of protein qual-
ity control in higher eukaryotes. Nevertheless, although more complex, mammalian
ERAD appears to utilize similar molecular mechanisms as observed in S. cerevisiae.
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Table 1.1: Components of the Hrd1 complex in S. cerevisiae and their cor-
responding mammalian counterparts
S. cerevisiae Mammals Reference
Hrd1 Hrd1/Synviolin Kikkert et al. (2004)
Hrd3 Sel1L Lilley and Ploegh (2005);
Mueller et al. (2006)
Der1 Derlin-1, Derlin-2,
Derlin-3
Lilley and Ploegh (2004);
Ye et al. (2004); Lilley
and Ploegh (2005); Oda
et al. (2006)
Usa1 Herp Schulze et al. (2005);
Carvalho et al. (2006)
Yos9 OS-9, XTP3-B Christianson et al.
(2008); Hosokawa et al.
(2008)
Kar2 BiP Christianson et al.
(2008); Hosokawa et al.
(2008)
Cue1 AUP1 Mueller et al. (2008)
Ubc7 UBE2G2, UBE2G1 Kikkert et al. (2004);
Christianson et al. (2011)
Ubx2 UbxD8 Mueller et al. (2008)
Cdc48 p97/VCP Ye et al. (2001)
Ufd1 UFD1 Ye et al. (2003)
Npl4 NPL4 Ye et al. (2003)
1.9 The elusive retrotranslocon
The most intriguing question in ERAD is how luminal substrates get retrotranslocated
across the ER-membrane in ERAD-L, and what proteins form the retrotranslocon
(Hampton and Sommer, 2012). Although detailed genetic and biochemical analysis has
provided a clear picture of the components involved, the identity of the retrotranslocon
has remained elusive. In the last ten years, evidence has accumulated that suggests that
the Hrd1 ubiquitin ligase forms the retrotranslocon in ERAD-L. Other retrotranslocon
candidates have been proposed throughout the years, none of which are as compelling
as Hrd1. They are briefly summarized below.
Sec61
Because Sec61 is the forward translocon for protein import into the ER, it was pro-
posed that it may also retrotranslocate substrates into the cytosol during ERAD.
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Studies showed that the ERAD-L substrate CPY* accumulated in Sec61-2 mutant
cells (Plemper et al., 1997) and immunoprecipitation experiments demonstrated that
Sec61 interacts with components of the Hrd1 complex and with soluble and membrane-
bound ERAD substrates (Wiertz et al., 1996; Schaefer and Wolf, 2009). However, other
studies clearly showed no association of components of the Hrd1 and Doa10 complexes
with Sec61 in immunoprecipitation and photocrosslinking experiments (Carvalho et al.,
2006; Denic et al., 2006; Carvalho et al., 2010; Mehnert et al., 2013).
Sec61 is an essential gene, and therefore studies have relied on temperature-sensitive
conditional mutants to study its role in ERAD. These mutants typically have ER
import defects, which may have pleiotropic and indirect effects that are difficult to
exclude. Retrotranslocation experiments using ER microsomes showed an inhibitory
effect of Sec61 cold-sensitive mutants on the degradation of the unglycosylated yeast
pro-α factor (Δgpαf) (Pilon, 1997). However, another study investigating Δgpαf retro-
translocation in mammalian microsomes showed that retrotranslocation was unaffected
when the Sec61 channel was blocked with ribosome-nascent chain complexes (Wahlman
et al., 2007). In this study, retrotranslocation was nearly completely blocked when an-
tibodies against Derlin-1 were added to the cytosol (Wahlman et al., 2007). In any
case, Δgpαf is an unusual ERAD-L substrate because it is not ubiquitinated and the
Cdc48 complex is dispensable for its retrotranslocation (Werner et al., 1996; Wahlman
et al., 2007). Another study using yeast microsomes found no effect of the Sec61-2
temperature-sensitive mutant on Hmg2 retrotranslocation (Garza et al., 2009). One
study showed an effect of the Sec61-3 cold-sensitive mutant on CPY* degradation
(Willer et al., 2008). However, the Sec61-3 mutant had severe import defects at low
temperatures, so a plethora of indirect effects may have contributed to this phenotype.
To summarize, it is unclear if Sec61 is directly involved in retrotranslocation. The evi-
dence of Sec61 interaction with the Hrd1 complex is contradictory. Because Sec61 is an
essential gene and is also required for ER import, experiments using Sec61 conditional
mutants are very difficult to interpret. Only reconstitutions with purified components
can conclusively demonstrate whether Sec61 can form a retrotranslocon. As will be
shown, together with evidence presented below for Der1 and Hrd1, it is highly unlikely
that Sec61 forms the retrotranslocon.
Der1
Der1, a component of the Hrd1 complex essential for ERAD-L, has been suggested to
form part of the retrotranslocation machinery. Photocrosslinking experiments demon-
strated that an ERAD-L substrate interacts with both luminal and membrane-embedded
residues of Der1 during retrotranslocation, and point mutations in Der1 transmembrane
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domains inhibited substrate degradation (Carvalho et al., 2010; Stanley et al., 2011;
Mehnert et al., 2013). It was also shown that Der1 interacts with substrates down-
stream of Hrd3 and Yos9, and when ubiquitination of Hrd1 was inhibited, substrate
accumulated at the Der1 luminal interface (Mehnert et al., 2013). In mammalian
ERAD, Derlin-1 is necessary for the retrotranslocation of the luminal substrate NHK
α-1 antitrypsin and for the membrane substrate MHC class I heavy chain (Greenblatt
et al., 2011; Lilley and Ploegh, 2004; Ye et al., 2004). Furthermore, in a mammalian
microsome system, retrotranslocation of yeast Δgpαf could be blocked with antibodies
against Derlin-1 (Wahlman et al., 2007). Therefore, Der1 likely is directly involved in
retrotranslocation.
Although Der1 is clearly involved in the retrotranslocation process, several factors argue
against it forming the retrotranslocon exclusively. First, although Der1 oligomerizes
(Horn et al., 2009; Mehnert et al., 2013), overexpression of Der1 is not sufficient to
overcome the deletion of other factors of the Hrd1 complex (Horn et al., 2009; Car-
valho et al., 2010), which would be expected if Der1 was the primary component of
the retrotranslocon. Second, Der1 becomes dispensable when Hrd1 is overexpressed
(discussed in the following paragraph). Third, analysis of crystal structures of the re-
lated bacterial rhomboid protease GlpG indicate that rhomboid proteases are unlikely
to form a conduit through the membrane (Wang et al., 2006; Wu et al., 2006). Nev-
ertheless, the structures show a hydrophilic cavity containing the active site dyad, as
well as a lateral gate, which allows substrates to enter the cavity from the membrane.
It is thus attractive to speculate that Der1 functions as a lateral insertase for the retro-
translocon, perhaps also unfolding substrates before threading them into the channel.
Further structural studies and reconstitutions with purified components are needed to
determine the exact role of Der1 in retrotranslocation.
Hrd1
The Hrd1 ubiquitin ligase has emerged as the strongest candidate for the retrotranslo-
con in ERAD-L. Overexpression of Hrd1 overcomes the simultaneous deletion of Hrd3,
Usa1 and Der1 in CPY* degradation (Carvalho et al., 2010). The downstream com-
ponents including the Cdc48 complex and ubiquitination machinery are still required,
indicating that Hrd1 is the only membrane-bound component required for ERAD-
L. In Hrd1 overexpression conditions, substrate N-glycosylation is dispensable (Denic
et al., 2006). Additionally, photocrosslinking experiments demonstrated that a lumi-
nal ERAD-L substrate interacts with Hrd1 en route to degradation (Carvalho et al.,
2010). This interaction is dependent on Hrd1 ubiquitination activity. Interestingly, the
N-terminal regions of the substrate interacts with Hrd3 and Der1 while the C-terminal
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region interacts with Hrd1, indicating that the substrate is shuttled from Hrd3 and
Der1 to Hrd1 (Carvalho et al., 2010). When ubiquitination of Hrd1 is blocked, sub-
strate accumulates at Hrd3 and Der1 (Mehnert et al., 2013), consistent with the idea
that these components act upstream of Hrd1.
Experiments using purified components demonstrated that Hrd1 binds to misfolded
proteins through its transmembrane domains, and that oligomerization of Hrd1 in-
creases its affinity towards substrates (Stein et al., 2014). Furthermore, Hrd1 autoubiq-
uitinates, and preferentially polyubiquitinates misfolded proteins in detergent and in
proteoliposomes. Polyubiquitination of Hrd1 and substrate recruits the Cdc48 com-
plex, which extracts ubiquitinated Hrd1 and substrate out of the membrane. However,
in this study the substrate was fully cleaved by outside proteases after reconstitution,
so retrotranslocation could not be concluded (Stein et al., 2014).
A later study utilized proteoliposomes containing purified Hrd1 and a membrane-
anchored version of CPY*, which allowed for insertion of CPY* into the liposomal
lumen (Baldridge and Rapoport, 2016) (Figure 1.8A). Upon addition of ubiquitina-
tion machinery, luminally-oriented CPY* was retrotranslocated and ubiquitinated by
Hrd1. Autoubiquitination of Hrd1 at three critical lysine residues in its RING domain
was required for retrotranslocation in the reconstituted system and for degradation of
substrates in vivo. Strikingly, ubiquitination of CPY* was not required for its retro-
translocation, as CPY* lacking lysines was efficiently retrotranslocated in vitro and
degraded in vivo, although it was not ubiquitinated (Baldridge and Rapoport, 2016).
However, the study did not demonstrate that Hrd1 and CPY* did not interact in de-
tergent during reconstitution into liposomes. Therefore, it remains a possibility that
a non-native retrotranslocation intermediate was inserted into liposomes, which was
then released upon Hrd1 autoubiquitination (see section 1.10.1).
A recent cryo-EM structure of the Hrd1/Hrd3 complex illustrates that Hrd1 and Hrd3
form a heterodimer, with two Hrd1 molecules interacting through their transmembrane
domains (Schoebel et al., 2017) (Figure 1.6). One molecule of Hrd3 binds to each
molecule of Hrd1 in the loop between TMs 1 and 2 in Hrd1, extending as an arch
into the luminal side (Schoebel et al., 2017). Hrd1 has eight TMs, instead of the six
TMs that were concluded previously (Deak and Wolf, 2001). TMs 3,4 and 6-8 of one
Hrd1 molecule form a hydrophilic funnel that is sealed by TM 1 of the adjacent Hrd1
molecule. The luminal side of the funnel is sealed by layers of hydrophobic residues.
TM1 could form a lateral gate for substrate entry from the membrane during ERAD-M
(Schoebel et al., 2017).
Hrd1 shares similarities to the protein translocases Sec61 and bacterial SecY, which
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also contain a hydrophilic cavity, lateral gate and hydrophobic seal (van den Berg
et al., 2004; Wu et al., 2019; Schoebel et al., 2017). Hrd1 also shows similarity to
the bacterial membrane protein insertase YidC, which contains a similar hydrophilic
cavity (Kumazaki et al., 2014). The structure represents the closed state of the chan-
nel, as Hrd1 autoubiquitination is likely required to open the channel (Baldridge and
Rapoport, 2016). In addition, ERAD-L requires the full complex consisting of Hrd1,
Hrd3, Usa1 and Der1, and it is unclear how these additional cofactors influence the
structure of Hrd1. The transmembrane domains of Hrd1 are highly conserved across
all eukaryotes. Importantly, other E3 ubiquitin ligases involved in ERAD in higher
eukaryotes, such as gp78 and TRC8, share sequence similarity to Hrd1 TMs 3-8, indi-
cating that they can probably also form channels (Schoebel et al., 2017).
In conclusion, a considerable amount of evidence points to Hrd1 forming the retro-
translocon. However, despite all of the evidence presented to date, questions about




Figure 1.6: Cryo-EM structure of the Hrd1/Hrd3 complex
A: Side view of the Hrd1/Hrd3 complex from within the membrane. Approximate
boundaries of the ER membrane are indicated. Hrd1 and Hrd3 form a dimer with 2:2
stoichiometry. Modified from Schoebel et al. (2017). Generated with PyMOL, PDB
ID: 5V6P (Hrd1 dimer), 5V7V (Hrd3). B: View of the Hrd1 dimer from the cytosol.
The location of the hydrophilic funnel in each Hrd1 molecule, along with the position
of the TMs, is indicated. The hydrophilic funnel is formed by TMs 3,4, 6, 7 and 8 of
one Hrd1 molecule and TM 1 from the other Hrd1 molecule. Modified from Schoebel
et al. (2017). Generated with PyMOL, PDB ID: 5V6P.
1.10 Proposed model of retrotranslocation by Hrd1
Based on the in vitro reconstitutions of Hrd1 with a membrane-anchored ERAD-L sub-
strate, combined with data from previous reconstitutions (Stein et al., 2014), Baldridge
and Rapoport proposed the following model for retrotranslocation by Hrd1 (Baldridge
and Rapoport, 2016) (Figure 1.7). First, the substrate (CPY*-TM), containing a mis-
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folded luminal domain, interacts with the luminal side of Hrd1 (steps 1-2). Hrd1 then
autoubiquitinates, which opens the channel. The substrate inserts as a loop and slides
back and forth in the channel (step 3). The substrate is ubiquitinated by Hrd1 once
it reaches the cytoplasmic side, which likely helps to prevent back-sliding into the lu-
men (step 4). Finally, the Cdc48 complex is recruited, which pulls the ubiquitinated
substrate out of the membrane through multiple rounds of ATP hydrolysis (step 5).
Figure 1.7: Proposed mechanism of Hrd1 retrotranslocation by Baldridge
and Rapoport
See text in section 1.10 for details. Modified from Baldridge and Rapoport (2016).
1.10.1 Drawbacks of the proposed retrotranslocation model
The proposed model has some drawbacks which have not yet been resolved. First, the
detergent-mediated reconstitution of CPY*-TM and Hrd1 into liposomes employed in
the Baldridge (Figure 1.8A) study raises the possibility that Hrd1 interacts with the
CPY* domain through its transmembrane domains, as was previously shown for Hrd1
and CPY* in detergent (Stein et al., 2014). In such a situation, the substrate may be
partially inserted into the membrane after detergent removal (Figure 1.8B). This lower
energy inserted state may be released into the cytosol upon Hrd1 autoubiquitination.
Second, due to the transmembrane domain present in the substrate, it cannot be ex-
cluded that lateral entry into the channel occurs. A lateral entry mechanism may be
distinct from the retrotranslocation mechanism of a fully-luminal substrate, which is
reflected by the fact that ERAD-M substrates do not require Der1 and only partially
require Usa1 (Carvalho et al., 2006; Horn et al., 2009; Carroll and Hampton, 2010) (see
section 1.7). Indeed, CPY*-TM degradation was only partially Der1-dependent in vivo
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(Baldridge and Rapoport, 2016). In addition, the CPY* appeared to be cleaved from
its TM in the ER before degradation, demonstrating that the degradation of a single
TM-anchored ERAD-L substrate may be more complex than previously appreciated
(Baldridge and Rapoport, 2016).
In order to investigate the mechanism of Hrd1-mediated retrotranslocation in ERAD-L
in greater detail, it is therefore essential to reconstitute the process with a fully-luminal
misfolded substrate, and to avoid detergent-mediated interactions during reconstitu-
tion.
Figure 1.8: Reconstitution strategy in the study from Baldridge and
Rapoport (2016)
A: Proposed mechanism of Hrd1 and CPY*-TM coreconstitution as asserted in the
study from Baldridge and Rapoport (2016). Step 1: Phospholipids (gray) are solubi-
lized in detergent along with CPY*-TM (red). Step 2: upon detergent removal, CPY*-
TM is inserted bidirectionally into liposomes. Step 3: The liposomes are partially sol-
ubilized with limiting amounts of detergent and Hrd1 (black). Hrd1 and CPY*-TM do
not interact in detergent. Step 4: Hrd1 is inserted into CPY*-TM liposomes, priming
a retrotranslocation reaction of the luminal CPY* domain. Modified from Baldridge
and Rapoport (2016), Figure 2A. B: Alternative mechanism of Hrd1 insertion using
the strategy employed above. Steps 1 and 2: same as in A. In step 3, the transmem-
brane domains of Hrd1 interact with luminal and cytosolic-facing CPY*, mediated by
detergent. Step 4: upon detergent removal, luminal CPY* is partially inserted into
the Hrd1 TMs, which may represent an intermediate stage of retrotranslocation. The
transmembrane domain of CPY*-TM may also laterally enter into the Hrd1 channel,
as indicated.
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1.11 Open questions about retrotranslocation in
ERAD-L
Based on the evidence presented in section 1.9, my working hypothesis is that Hrd1
forms the retrotranslocon in ERAD-L, while the other components in the Hrd1 complex
serve regulatory roles, such as substrate selection, channel gating, and insertion of
substrates into the channel. Taking into consideration the model from Baldridge and
Rapoport, several open questions remain about the mechanism of retrotranslocation
by Hrd1:
1. Is Hrd1 sufficient to fully retrotranslocate a luminal substrate across the mem-
brane?
2. Which lysine residues in Hrd1 become autoubiquitinated? How does this autoubiq-
uitination correlate to channel activity?
3. How is directionality provided during retrotranslocation?
4. How does Hrd1 recognize substrates on the luminal side? Which regions of Hrd1
interact with substrates during retrotranslocation?
5. Can Hrd1 accommodate large folded domains or is Cdc48 action required to
unfold substrates during retrotranslocation?
In my PhD, I attempted to answer these questions through reconstitution of Hrd1-
mediated retrotranslocation with purified components. The specific aims and outline
of my thesis are presented in the following section.
1.12 Aims and thesis outline
Over the last 20 years, most, if not all, of the components involved in ERAD have been
unraveled, and a mechanistic understanding of the process is beginning to take shape.
Yet, the most glaring gap in our understanding of ERAD lies in one of the most im-
portant steps in the process: retrotranslocation of substrates across the ER membrane.
Unlike the well-characterized process of forward translocation into the ER, in which
newly-synthesized proteins are imported in an unfolded state, retrotranslocation must
deal with a diverse range of substrates with partially-folded domains. Therefore, the




Genetic and biochemical experiments have implicated the Hrd1 ubiquitin ligase as
the retrotranslocon in ERAD-L (Carvalho et al., 2010). Further in vitro reconstitu-
tions using purified components provided strong evidence that Hrd1 can function as a
retrotranslocon (Stein et al., 2014; Baldridge and Rapoport, 2016). Yet, as discussed
in sections 1.9-1.10, it has not been conclusively demonstrated that Hrd1 can retro-
translocate luminal misfolded proteins across the membrane.
In my PhD, I aimed to reconstitute retrotranslocation by Hrd1 with purified com-
ponents in various model membranes to determine if Hrd1 is truly sufficient for the
retrotranslocation of a fully-luminal substrate. Furthermore, I aimed to characterize
the molecular mechanism of retrotranslocation in greater detail. Importantly, reconsti-
tution of protein translocation with purified components is the only method that allows
the researcher to answer the question of sufficiency: i.e. what is the minimal machinery
required? It is also allows conclusions to be drawn about mechanistic details, because
it excludes the multitude of confounding variables present in the cell. Reconstitution
with purified components has been used to extensively characterize other transloca-
tion events such as forward translocation into the ER (Gorlich and Rapoport, 1993),
translocation across the inner bacterial membrane (Brundage et al., 1990; Akimaru
et al., 1991), and insertion of membrane proteins into the bacterial outer membrane
(Hagan et al., 2010).
The first part of the thesis describes my efforts in developing a novel reconstituted
system in proteoliposomes to study retrotranslocation by Hrd1. In order to avoid non-
native detergent-mediated interactions between Hrd1 and substrate, I reconstituted
Hrd1 and the soluble misfolded substrate CPY* in separate populations of liposomes,
together with complementary SNARE proteins, which are membrane proteins found
in the secretory pathway that catalyze membrane fusion (Jahn and Scheller, 2006).
Substrates were delivered to the luminal side of Hrd1 by SNARE-mediated fusion,
which faithfully recapitulates the ground state of a retrotranslocation reaction without
the presence of detergent. The system is designed to test the sufficiency of Hrd1 in
retrotranslocating a fully-luminal substrate across a membrane. The thesis primarily
focuses on the development of the system, as the encapsulation of a misfolded protein
together with SNAREs, along with the corresponding Hrd1 reconstitutions, was quite
challenging and required substantial optimization.
In the next part of my thesis, I collaborated with Prof. Michael Meinecke and Dr.
Niels Denkert from the University Medical Center in Göttingen to assay Hrd1 retro-
translocase activity using the planar lipid bilayer (PLB) electrophysiological technique
(Harsman et al., 2011). This method provides an alternative readout for activity of
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protein translocases. It takes advantage of the fact that many protein translocases
form water-filled pores during translocation, which results in a voltage-dependent ion
conductance that can be measured as a readout for channel activity (Harsman et al.,
2011). The ion conductance can be used to calculate the pore diameter of the channel.
The PLB technique also allowed us to measure channel opening and closing in real time
on a single-molecule level. Importantly, this method allowed us to manipulate both
sides of the channel, which was not possible in liposomes. We found that Hrd1 formed
an aqueous channel upon autoubiquitination. We also characterized substrate interac-
tions with the channel and found that addition of CPY* to the luminal side stimulated
channel activity and expanded the pore to diameters large enough to accommodate
secondary structures. Finally, we observed closure of the channel upon deubiquitina-
tion of Hrd1. Our results demonstrate the first ever ubiquitin-activated channel and
illustrate that ubiquitination can act as an allosteric modification in addition to its
usual functions.
The final part of the thesis deals with the autoubiquitination sites in Hrd1 and the
interaction of substrates with Hrd1. Previous reconstitutions utilized lysine to arginine
mutants to determine which residues of Hrd1 are autoubiquitinated (Stein et al., 2014;
Baldridge and Rapoport, 2016). However, the mutants showed very small differences in
autoubiquitination efficiency in detergent. I reasoned that the difference would become
apparent when Hrd1 is reconstituted in a lipid bilayer. I used Hrd1 lysine to arginine
mutants reconstituted in liposomes to determine the primary ubiquitination sites.
Previous studies had determined that Hrd1 interacts with misfolded proteins with its
transmembrane domains in detergent and that its affinity towards substrate increases
upon autoubiqutination (Stein et al., 2014; Baldridge and Rapoport, 2016). However,
the transmembrane domains of Hrd1 are occluded by the lipid bilayer in vivo, and
the relevant binding sites are on the luminal and cytoplasmic side of the membrane.
To study cytoplasmic binding, I reconstituted Hrd1 into liposomes, taking advantage
of the unidirectional orientation, with the cytoplasmic domain facing the outside. I
determined that a high-affinity substrate cytoplasmic binding site is formed in Hrd1
upon autoubiquitination. In order to study binding on the luminal side of Hrd1, I
reconstituted Hrd1 into lipid nanodiscs and determined that Hrd1 binds substrate on
the luminal side, but with a lower affinity than the cytoplasmic side. By combining
the observations from electrophysiology, autoubiquitination mutants, and side-specific
binding experiments, I developed an updated model for retrotranslocation by Hrd1.




2 Materials and Methods
2.1 Materials
2.1.1 Lipids
All lipids were purchased as a lyophilized powder from Avanti Polar Lipids. Prior to
reconstitution, the lipids were dissolved in chloroform. Chloroform stocks were stored
at -20°C for up to one month.
Table 2.1: Lipids used in reconstitutions
Name Company Catalog Number
POPC: 1-palmitoyl-2-oleoyl-glycero-3-
phosphocholine
Avanti Polar Lipids 850457P
DOPE: 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine
Avanti Polar Lipids 850725P
DOPS: 1,2-dioleoyl-sn-glycero-3-
phospho-L-serine
Avanti Polar Lipids 840035P













Avanti Polar Lipids 790404P
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2.1.2 Detergents and miscellaneous materials
Table 2.2: Detergents used in this thesis
Name Company
DMNG: Decyl Maltose Neopentyl Glycol Anatrace
DM: n-Decyl β-maltoside Glycon Biochemicals
Fos-Choline-13, Anagrade Anatrace
Triton X-100: Anapoe-X-100 Anatrace
OG: n-Octyl β-D-glucopyranoside Glycon Biochemicals
UDM: n-Undecyl β-maltoside Glycon Biochemicals
DDM: n-Dodecyl α-maltoside Glycon Biochemicals
Sodium cholate hydrate, ≥99% Sigma-Aldrich
LDAO: n-Dodecyl-N,N-Dimethylamine-N-Oxide Anatrace
NG: n-Nonyl-β-D-Glucopyranoside Glycon Biochemicals
Table 2.3: Miscellaneous materials
Component Company Catalog number
Antifoam emulsion C Sigma Aldrich A8011
ATP PanReac AppliChem A1348
BSA: Bovine serum albumin PanReac AppliChem A1391
Coomassie Brilliant blue G-250 PanReac AppliChem A3480
DyLight 680 maleimide Thermo Fisher 46618
DyLight 800 maleimide Thermo Fisher 46621
D(+)-Galactose PanReac AppliChem A1131
HEPES Carl Roth 6763
HisPur NiNTA resin Thermo Fisher 88223
Imidazole Sigma Aldrich I202
IPTG, Dioxane free Formedium IPTG025
D-mannitol Sigma Aldrich M9647
Nycodenz Abbott Diagnostics 1002424
Pepstatin A Peptide Institute 4397
Proteinase K Jena Bioscience EN-178S
PMSF: Phenylmethyl sulphonyl fluoride Carl Roth 6367
Pierce Detergent removal spin columns Thermo Fisher 87777
Pierce High capacity streptavidin agarose Thermo Fisher 20361
Pierce Streptavidin magnetic beads Thermo Fisher 88817
TCEP Sigma Aldrich C4706
Ubiquitin (WT) Boston Biochem U-100Sc
Ubiquitin (K48R) LifeSensors SI217
YEP broth Formedium CCM0410
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2.1.3 S. cerevisiae strains
Hrd1 and all Hrd1 lysine mutants were expressed in a ubc7 deletion strain derived
from BY4742 (OpenBiosystems) (MATα ura3Δ0 his3Δ1 leu2Δ0 lys2Δ0 ubc7::KANR)
(Stein et al., 2014). The ERAD substrates CPY*, PrA*, and their WT forms were ex-
pressed in a hrd3, alg3 double deletion strain, derived from BY4741 (OpenBiosystems)
(MATa ura3Δ0 his3Δ1 leu2Δ0 lys2Δ0 hrd3::KANR alg3::HIS3) (Stein et al., 2014).
The E1 enzyme Uba1 was expressed in the InvSc1 strain (Invitrogen).
2.1.4 Bacterial strains
The human Usp2 catalytic domain, ApoE422k, and the following proteins from S. cere-
visiae: sCPY*, sCPY*-GFP, Ubc7, Ubc6, the cytoplasmic domain of Cue1 (Cue1-c),
Ulp1, and the Doa10 RING domain, were all expressed in the E. coli strain BL21-
CodonPlus (DE3)-RIPL (Agilent). The neuronal SNARE synaptobrevin 2, the soluble
domain of synaptobrevin 2, and the acceptor SNARE complexes ΔN49 and ΔN53 (all
from Rattus norvegicus) were also expressed in BL21-CodonPlus (DE3)-RIPL (Agi-
lent).
2.1.5 Yeast and bacterial media
For normal maintenance and growth, E. coli cultures were grown in LB medium sup-
plemented with the appropriate antibiotics (final concentrations: 40 µg/ml kanamycin,
100 µg/ ml ampicillin, 37 µg/ml chloramphenicol) (Miller, 1992). For protein expres-
sion, E. coli strains were grown in terrific broth (TB) supplemented with the appropri-
ate antibiotics (Tartoff and Hobbs, 1987). S. cerevisiae strains containing transformed
plasmids were grown in synthetic complete (SC) medium containing 2% (w/v) glucose
and the corresponding amino acid/uracil dropouts (Burke et al., 2005). S. cerevisiae
deletion strains were grown in YPD medium (Burke et al., 2005).
2.2 Constructs and cloning
2.2.1 Cloning
All cloning was performed by either Gibson assembly or site-directed mutagenesis.
Gibson assembly was used for inserting fragments into vectors and swapping fragments
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between vectors. Overlapping primers for Gibson assembly were designed using the
NEBuilder assembly tool and the cloning was performed with the NEB HiFi assembly
mix, according to manufacturer’s instructions (New England BioLabs). For mutagen-
esis, inserting sequences less than 100 base pairs, and deleting sequences from existing
vectors, the Q5 site-directed mutagenesis kit was used (New England BioLabs), accord-
ing to manufacturer’s instructions. Primers for site-directed mutagenesis were designed
using the NEBaseChanger tool (New England BioLabs).
2.2.2 Plasmids
Proteins expressed in S. cerevisiae were cloned into galactose-inducible expression vec-
tors of the pRS series (Mumberg et al., 1994), as in Stein et al. (2014). Hrd1 was
expressed in pRS426-PGal1, and contained a C-terminal streptavidin-binding peptide
tag lacking lysines (SBP), a tobacco etch virus (TEV) cleavage site before the SBP
tag, and a C-terminal LPETGG tag for sortase-mediated labeling with fluorescent
dyes (Stein et al., 2014; Popp and Ploegh, 2011). CPY* contained the N-terminal sig-
nal sequence from S. cerevisiae prepro-α-factor and the G255R point mutation (Finger
et al., 1993). It was cloned into pRS425-pGal1, with a C-terminal His14-LPETGG
tag preceded by an HA tag for detection by western blotting. Finally the construct
contained an HDEL sequence for ER retention (Pelham et al., 1988). Alternatively, a
CPY* construct containing an N-terminal His14-tag followed by a 3C protease cleavage
site was cloned into the same vector. CPY WT, in pRS425-PGal1, contained an N-
terminal prepro-α-factor signal sequence followed by an N-terminal His14-3C tag and a
C-terminal LPETGG-HDEL tag. The gene encoding PrA (pep4), was amplified from
genomic DNA and cloned by Gibson assembly into pRS426-PGal1 with C-terminal
His14 and LPETGG tags. To create PrA*, the sequence encoding amino acids 54-92
was removed by site directed mutagenesis (Spear and Ng, 2005). The plasmids en-
coding CPY*-TM and CPY*-TM2, both in pRS426-PGal1, were kindly provided by
Dr. Ryan Baldridge (Baldridge and Rapoport, 2016). The plasmid encoding the E1
enzyme Uba1 was as described in Stein et al. (2014).
The proteins Ubc7 and Cue1-c were expressed in the vectors pET28b and pET21b,
respectively, as previously described (Stein et al., 2014). Ubc6, Ubc6-SBP, sCPY*-
GFP and the Doa10 RING domain (amino acids 1-129) were expressed in the K27
SUMO vector, which contains an N-terminal His14-SUMO tag (Stein et al., 2014).
Ubc6 constructs were kindly provided by Claudia C. Schmidt (Max Planck Insti-
tute for Biophysical Chemistry). The expression vector containing Usp2 was a gift
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from Cheryl Arrowsmith (Addgene plasmid # 36894 ; http://n2t.net/addgene:36894 ;
RRID:Addgene_36894). Ulp1, with an N-terminal His14-TEV sequence, was expressed
in a vector derived from pQE-80L (Qiagen), provided kindly by Prof. Dirk Görlich,
Max Planck Institute for Biophysical Chemistry. Synaptobrevin was expressed in the
pET28a vector as previously described (Pobbati et al., 2006), whereas the soluble do-
main of synaptobrevin (Sybsol, amino acids 1-95) was expressed in K27SUMO. The
ΔN49 and ΔN53 complexes were expressed in the pETDuet-1 vector, as previously
described (Stein et al., 2007; Pobbati et al., 2006). sCPY*, containing an N-terminal
His14-SUMO tag and a C-terminal LPETGG tag, was expressed in a pBAD/HisC vec-
tor (Invitrogen). The plasmid encoding ApoE422K was a gift from Oscar Bello and
James Rothman (Bello et al., 2016). The sequence encoding ApoE422K was cloned
into the K27SUMO vector.
2.2.3 Yeast and bacterial transformation
Yeast transformation was carried out as described in Burke et al. (2005) under “High-
efficiency Transformation of Yeast”. Transformed yeast were grown on SC agar plates
with the appropriate dropout for three days at 30°C and colonies were restreaked on
fresh SC plates. Yeast strains were stored in 25% (w/v) glycerol at -80°C. Bacterial
transformation was performed as described in Miller (1992). Transformed bacteria were
grown on LB plates with appropriate antibiotics (concentrations listed in section 2.1.5).
For protein expression, bacteria were transformed freshly before each expression.
2.3 Protein expression
2.3.1 Protein expression in S. cerevisiae
Protein expression in S. cerevisiae by galactose induction was performed essentially as
described in Stein et al. (2014), with some minor modifications. Briefly, a starter culture
of the transformed yeast strain was innoculated in SC medium with the appropriate
dropout. The starter culture was grown at 30°C for 24 h and was diluted 1:50 into 6
L of fresh medium. This was grown for an additional 24 h at 30°C and expression was
induced by adding a 4X stock of induction medium (8% galactose (w/v) in 12% YEP
(w/v) broth with 1% (v/v) antifoam C emulsion (Sigma)), giving a final concentration
of 2% (w/v) galactose. The cultures were grown for 16 h at 30°C and harvested by
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centrifugation at 3000 x g. The cells were washed with MilliQ water, resuspended in a
minimal amount of MilliQ water, and stored at -80°C until further use.
2.3.2 Protein expression in E. coli
Protein expression in E. coli was performed as in Stein et al. (2014). Briefly, a streak
of colonies was innoculated into LB medium supplemented with the appropriate an-
tibiotics (including chloramphenicol for the BL21-CodonPlus RIPL strains), and the
preculture was grown for 16 h at 37°C. The preculture was diluted 1:50 into TB medium
containing the appropriate antibiotics, but without chloramphenicol. The cultures were
grown to an OD600 of 0.8-1 and expression was induced with 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). After induction, the cultures were grown at for 16 h at
18°C and were havested by centrifugation at 3000 x g. The pellet was resuspended in
a minimal volume of nickel wash buffer (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 40
mM imidazole (for His14-tagged proteins)). The imidazole concentration was reduced
to 8 mM for His6-tagged proteins. The resuspended pellet was stored at -20°C.
2.4 Protein purification
All protein purification steps were performed at 4°C or on ice, except where indicated
otherwise.
Hrd1 : Hrd1 and Hrd1 mutants were purified as in Stein et al. (2014), with the following
modifications in the membrane fraction preparation. Hrd1 expression was induced at
25°C instead of 30°C. Approximately 100-150 g of cells were resuspended in 900 ml
of cold MilliQ water. 2 mM DTT was added the cells were incubated on ice for 15
min. After centrifugation at 3000 x g for 10 min, the pellet was resuspended in buffer
MF (20 mM HEPES-KOH pH 7.5, 5 mM KoAc, 600 mM mannitol, 0.5 mM EDTA). 1
mM phenylmethanesulfonyl fluoride (PMSF) and 2 mM pepstatin A were added fresh.
Lysis was performed in a bead beater (BioSpec) with zirconia glass beads, with the
following cycles: 15 s on, 1 min off, for a total of 50 min. The beads were separated by
filtration and the lysate was centrifuged for at 1500 x g for 10 min to pellet unbroken
cells. The supernatant was then centrifuged at 40,000 x g for 45 min in a Ti45 rotor
(Beckman). The resulting supernatant was recovered and was centrifuged at 40,000
rpm for 30 min in a Ti45 rotor. The resulting pellet was dounced and resuspended in
a minimal volume of buffer MF. This is referred to as the crude membrane fraction.
42
2.4 Protein purification
Membrane fractions were flash frozen and stored at -80°C. Hrd1 was purified from the
crude membrane fraction as previously described (Stein et al., 2014).
CPY* : CPY* was purified as follows. A crude membrane fraction was prepared as
previously described (Baldridge and Rapoport, 2016), with the exception that 2 µM
pepstatin A was used and the centrifugation steps were performed at 40,000 rpm in
a Ti45 rotor. CPY* was purified from the membrane fraction as follows, modified
from the purification of CPY*-TM in Baldridge and Rapoport (2016). The membrane
fraction was washed with buffer MC (50 mM HEPES-KOH pH 7.4, 300 mM KCl)
and was pelleted by centrifugation at 40,000 rpm for 30 min in a Ti45 rotor. The
resulting pellet was resuspended in 250 ml of buffer SC (50 mM HEPES-KOH pH 7.4,
300 mM KCl, 1 mM MgAc, 1 mM TCEP, 40 mM imidazole, 6 M urea) and CPY* was
solubilized by stirring for 1 h at 4°C. The lysate was cleared by centrifugation at 40,000
rpm for 30 min in a Ti45 rotor. The cleared lysate was loaded onto a HisTrap HP 5
ml column (GE Healthcare), which was pre-equilibrated with buffer SC. After binding,
the column was washed with 30 CVs of buffer WC (25 mM HEPES-KOH pH 7.4,
300 mM KCl, 1 mM MgAc, 0.5 mM TCEP, 40 mM imidazole, 2 mM Fos-choline-13),
which replaced urea for the harsh detergent Fos-choline. Elution was carried out with
buffer IC (25 mM HEPES-KOH pH 7.4, 300 mM KCl, 1 mM MgAc, 0.5 mM TCEP,
400 mM imidazole, 2 mM Fos-choline-13). The eluted CPY* was analyzed by SDS-
PAGE, and peak fractions were pooled and concentrated with an Amicon filtration
unit (30 kDa, MilliPore). CPY* was sortase labeled with a fluorescent dye and was
further purified by gel filtration on a Superdex 200 increase 10/300 GL column (GE
Healthcare) equilibrated with buffer LC (20 mM HEPES-KOH pH 7.4, 300 mM KCl,
1 mM magnesium chloride, 1 mM DTT, 2.5 M urea).
CPY WT : CPY WT was purified directly from the lysate without the preparation of
a membrane fraction. Briefly, the cell pellet was resuspended in buffer MY (50 mM
HEPES-KOH pH 7.4, 300 mM KCl, 30 mM imidazole). PMSF (1 mM) and pepstatin
A (2 µM) were added fresh, and lysis was performed using a bead beater, as described
in the Hrd1 purification. To remove unbroken cells, the lysate was centrifuged at 2000
x g for 10 min. The resulting supernatant was centrifuged at 40,000 rpm for 30 min in
a Ti45 rotor. To further clarify the lysate, the resulting supernatant was centrifuged
again at 40,000 rpm for 30 min. A white film of lipids was found in the supernatant,
which could be removed by filtration through a 0.45 µm filter. The clarified lysate was
incubated with 6 ml of HisPur resin (Thermo Scientific) for 3 h at 4°C, with rotation.
The lysate was transferred to a column and was washed with 65 column volumes (CVs)
of buffer MY. The protein was eluted with buffer IY (50 mM HEPES-KOH pH 7.4,
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300 mM KCl, 400 mM imidazole) and peak fractions were pooled and concentrated in
an Amicon filter (30 kDa cutoff). Further purification was achieved by gel filtration
on a HiLoad Superdex 200 16/60 column (GE Healthcare) equilibrated with buffer LY
(20 mM HEPES-KOH pH 7.4, 150 mM KCl, 5 mM β-mercaptoethanol). Purified CPY
WT was sortase-labeled and further purified on a Superdex 200 increase 10/300 GL
column with buffer LY.
PrA* : PrA* was purified essentially as CPY*, with the following exceptions. Fol-
lowing solubilization and binding to the HisTrap column in 6 M urea buffer, the urea
concentration was reduced to 2 M for the elution step: buffer IP (50 mM HEPES-KOH
pH 7.4, 300 mM KCl, 40 mM imidazole, 0.5 mM TCEP, 2 M urea). PrA* was further
purified by gel filtration on a HiLoad Superdex 200 16/60 column equilibrated with
buffer LP(50 mM HEPES-KOH pH 7.4, 300 mM KCl, 0.5 mM TCEP, 2 M urea). Af-
terwards, it was sortase-labeled and further purified on a Superdex 200 increase 10/300
GL column equilibrated with buffer LP.
PrA WT : PrA WT was purified exactly as CPY WT. Sortase labeling and further
purification was done as with CPY WT.
sCPY*-GFP: The substrate His14-SUMO-sCPY*-GFP was purified from E. coli in the
following manner. The cell pellet was resuspended in approximately 200 ml of nickel
wash (50 mM Tris-HCl pH 7.4 at RT, 500 mM NaCl, 40 mM imidazole). PMSF (1 mM)
and pepstatin A (2 µM) were added freshly and the cells were lysed with two passes
through a microfluidizer at 17,000 PSI (M-110L, Microfluidics). Urea was added in
powder form to the lysate to a final concentration of 2 M, which prevented the protein
from aggregating on the nickel beads. After stirring for 30 min, the lysate was cleared
by centrifugation at 14,000 rpm in a F14S-6x250y rotor (Thermo Scientific) for 30
min. The supernatant was incubated with 8 ml of HisPur resin for 3 h with rotation.
The beads were washed with 40 CVs of buffer WS(50 mM Tris-HCl pH 8.0, 500 mM
NaCl, 40 mM imidazole, 2 M urea, 5 mM β-mercaptoethanol). The protein was eluted
with buffer IS (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 400 mM imidazole, 2 M urea,
5 mM beta-mercaptoethanol) and was further purified by gel filtration on a HiLoad
Superdex 200 26/60 column in buffer IS without imidazole. Finally, the protein was
sortase-labeled and further purified on a Superdex 200 increase 10/300 GL column.
sCPY* : His14-SUMO-sCPY*-LPETGG, without the GFP tag, was purified in a dif-
ferent manner, optimized by Claudia C. Schmidt (Max Planck Institute for Biophys-
ical Chemistry). Expression from the pBAD vector was induced with 0.2% (w/v)
L-arabinose for 16 h at 23°C. The cell pellet was resuspended in buffer MS(50 mM
Tris-HCl pH 8.0, 500 mM NaCl, 20 mM imidazole) and lysis was performed with a mi-
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crofluidizer (2 cycles, 17,000 PSI). To purify inclusion bodies containing sCPY*, Triton
X-100 was added to a final concentration of 1% (w/v) and the lysate was centrifuged
at 12,000 rpm in an SS-34 rotor (Thermo Scientific). The supernatant was discarded
and the pellet was resuspended in buffer MS containing 1% (w/v) LDAO. After sol-
ubilization for 30 min, the sample was centrifuged at 10,000 rpm in an SS-34 rotor
for 30 min. HisPur resin was added and the sample was nutated for 3 h. The beads
were washed with buffer MS containing 0.023% (w/v) LDAO and 150 mM NaCl. The
protein was eluted by overnight incubation of the beads with the SUMO protease Ulp1
(1 µM). DTT (1 mM) was added to the eluted sCPY* and the LDAO was exchanged to
the detergent n-Nonyl β-D-glucopyranoside (NG) by anion exchange chromatography.
Briefly, sCPY* was loaded onto a MonoQ 5/50 GL column (GE Healthcare) in buffer
SX (20 mM Tris-HCl pH 7.4, 75 mM NaCl, 1 mM DTT, 2% NG) and was eluted with
a linear gradient up to 600 mM NaCl in 6 CVs. The protein was sortase-labeled and
further purified on a Superdex 200 increase 10/300 GL column.
Ulp1 : His14-TEV-Ulp1 was purified as follows. The cell pellet was resuspended in
nickel wash containing 30 mM imidazole. The cells were lysed in a microfluidizer (2
passages, 17,000 PSI) and the lysate was clarified by centrifugation at 40,000 rpm in
a Ti45 rotor for 30 min. HisPur resin (8 ml) was added to the lysate and the sample
was incubated for 3 h with rotation. The beads were washed with 50 CVs of nickel
wash and were eluted with buffer IU (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 500 mM
imidazole, 10% (w/v) glycerol, 4 mM magnesium acetate). DTT (2 mM) was added to
the elution fractions. The protein was either directly loaded onto a HiLoad Superdex
200 16/60 column equilibrated with buffer LU(20 mM HEPES-KOH pH 7.4, 150 mM
NaCl, 10% (w/v) glycerol, 1 mM DTT), or the His tag was removed. For His tag
removal, the protein was dialyzed overnight against buffer NU (20 mM HEPES-KOH
pH 7.4, 150mM NaCl, 10% (w/v) glycerol, 15 mM imidazole) in the presence of a 1:10
molar ratio of His-tagged TEV protease. The TEV protease was removed by reverse
nickel-affinity chromatography and the flow-through was purified by gel filtration as
described above.
Ubc6 and Ubc6-SBP: This protocol was kindly provided by Claudia C. Schmidt (Max
Planck Institute for Biophysical Chemistry). After expression, the cell pellet was re-
suspended in nickel wash with 2 mM EDTA and 2 mM DTT. PMSF (1 mM) was
added and the cells were lysed in a microfluidizer, as described above. After lysis, the
unbroken cells were pelleted by centrifugation at 5,100 rpm in a F14-6x250y rotor for
10 min. The supernatant was centrifuged at 42,000 rpm in a Ti45 rotor for 1 h. The
pellet was resuspended in nickel wash with 1% (w/v) DDM and was solubilized for 1
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h with stirring. Insoluble material was removed by centrifugation at 42,000 rpm in a
Ti45 rotor for 30 min. HisPur resin (6 ml) was added and incubated with the lysate for
2.5 h. The beads were washed with nickel wash buffer containing 0.03% (w/v) DDM
and Ubc6 was eluted by cleavage with 0.5 µM Ulp1 for 1 h. Further purification was
performed by gel filtration on a HiLoad Superdex 200 16/60 column equilibrated with
buffer LU (20 mM HEPES-KOH pH 7.5, 200 mM NaCl, 1 mM DTT, 0.03% (w/v)
DDM).
Doa10 RING domain: This protocol was kindly provided by Claudia C. Schmidt (Max
Planck Institute for Biophysical Chemistry). The cell pellet was resuspended in nickel
wash and lysis was performed as with Ubc6. The crude lysate was clarified by cen-
trifugation at 42,000 rpm in a Ti45 rotor for 45 min. HisPur resin (6 ml) was added
and was incubated with the lysate for 2.5 h. The beads were washed with nickel wash
buffer and eluted with nickel wash containing 500 mM imidazole. DTT (0.5 mM) was
added and the protein was incubated with Ulp1 (0.5 µM) to cleave off the His14-SUMO
tag. The protein was dialyzed against buffer DR (20 mM Tris-HCl pH 7.5, 100 mM
NaCl) and was purified further on a MonoQ column, followed by gel filtration using a
Superdex 75 10/300 GL column (GE Healthcare).
ApoE 422K : Expression was induced with 0.5 mM IPTG for 3 h at 25°C. The cell pellet
was resuspended in nickel wash and lysed as with Ubc6. The lysate was centrifuged
at 42,000 rpm in a Ti45 rotor for 45 min and 8 ml of HisPur resin was added to
the supernatant. The sample was nutated for 2.5 h and the beads were washed with
nickel wash buffer. The protein was eluted by incubation with 0.5 µM Ulp1 for 1 h.
The eluted protein was dialyzed against buffer DR, as with the Doa10 RING domain.
Further purification was achieved by anion exchange chromatography on a MonoQ
10/100 GL column (GE Healthcare), eluting with a linear gradient of 0.1 M to 1 M
NaCl over 15 CVs. The peak fractions were pooled and the protein was dialyzed against
buffer DA (20 mM HEPES-KOH pH 7.5, 150 mM NaCl), followed by concentration in
an Amicon 10 kDa cutoff centrifugal filter.
Synaptobrevin and ΔN complex : Synaptobrevin was purified as previously described
(Fasshauer et al., 1997; Stein et al., 2007), except that the detergent DM (final concen-
tration 5 mM) was used instead of CHAPS. The ΔN49 and 53 complex were purified
as previously described (Stein et al., 2007), with the exception that 2% (w/v) OG and
200 mM sucrose were used in place of CHAPS.




CPY*-TM and CPY*-TM2 : These proteins were purified as described in (Baldridge
and Rapoport, 2016).
Doa10: Doa10, from S. cerevisiae, was kindly provided by Claudia C. Schmidt (Max
Planck Institute for Biophysical Chemistry).
2.5 Sortase labeling
Sortase labeling of proteins with fluorescent dyes was performed as previously described
(Stein et al., 2014), with a few modifications. A short peptide with the sequence GGGC
(Thermo Scientific) was labeled with a maleimide-conjugated fluorescent dye (DyLight
680, DyLight 800 or Alexa Fluor 488, all from Thermo Scientific) in the following
manner. The peptide was dissolved in 100 mM HEPES-KOH pH 7.4, and a 1.5-molar
excess was added to the lyophilized dye. The reaction was incubated in the dark for
1 h at RT and was quenched by adding 10 mM DTT. The LPETGG-tagged protein
was incubated with a 5-fold molar excess of the labeled peptide along with 15 µM of
the sortase A pentamutant (Chen et al., 2011) and 10 mM CaCl2. The reaction was
incubated for 16 h at 4°C, protected from light. The labeled protein was purified by size-
exclusion chromatography and was visualized by SDS-PAGE and fluorescence scanning
in an Odyssey scanner (LiCOR) or an FLA 7000 scanner (Fujifilm). Labeling was
determined by absorbance measurements, according to the manufacturer’s instructions.
The efficiency varied between 20-60%, depending on the protein.
2.6 SDS-PAGE and western blotting
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using Criterion
TGX Stain-Free gels (4-20% gradient gels) and the Criterion system (Bio-Rad), ac-
cording to the manufacturer’s instructions. The SDS sample buffer recipe is described
in Schaegger (2006). Colloidal coomassie staining was performed as described (Dy-
balla and Metzger, 2009). Western blotting was performed using the Trans-Blot Turbo
transfer system (Bio-Rad) for transfer onto nitrocellulose membranes, according to the
manufacturer’s instructions. The blots were blocked with 5% milk (w/v) in TBS buffer
with 0.5% (v/v) Tween-20 (TBS-T). The primary antibody (1:2500 dilution for mouse
anti SBP, MAB10764 MilliPore) was diluted in 5% milk TBS-T and incubated was for
1 h at RT. The blots were washed and incubated with DL680 or DL800-conjugated
secondary antibodies (1:15000 dilution, LiCOR) in 5% milk TBS-T for 1 h at RT.
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After washing, the blots were imaged by fluorescence scanning in an Odyssey scanner
(LiCOR). Alternatively, the blot was incubated with an HRP-conjugated secondary
antibody for 1 h at RT (1:2000 dilution, Bio-Rad), and was imaged using the ECL
select western blotting detection kit (Perkin Elmer) and the LAS-1000 CCD detector
(Fujifilm).
2.7 Protein reconstitution into liposomes
All protein reconstitutions into liposomes were performed using a method modified from
Hernandez et al. (2012), which was modified from Rigaud and Lévy (2003). Preformed
empty liposomes of 100 nm diameter (referred to as template from here on) were formed
using the reverse-phase evaporation method described in Hernandez et al. (2012). The
template contained a molar ratio of 6:2:1:1 POPC:DOPE:DOPS:Cholesterol, and the
final lipid concentration was 20 mM. Proteoliposome reconstitutions were performed
using liposome template as the starting lipid material. To this, detergent at a con-
centration termed the R value was added (Rigaud and Lévy, 2003), followed by the
proteins to be reconstituted. The R value is defined by the following expression, from
Rigaud and Lévy (2003):
R =[Dtotal − Dcmc][lipid]
where Dtotal is the total detergent concentration and Dcmc is the critical micellar con-
centration (cmc) of the detergent. It was established that SNAREs reconstitute well
at R values of above 1 (Hernandez et al., 2012). Each membrane protein will have an
optimal range of R values, which needs to be experimentally determined. In general,
the greater the R value, the more complete the solubilization of the liposome template.
2.7.1 Substrate encapsulation into liposomes using the NiNTA
method
To encapsulate substrates into liposomes, template was formed with 2% (mol%) NiNTA
lipids. 4 mM of template liposomes were mixed with OG at an R value of 3, along with
10 µMΔN49 complex and 1 µM substrate, all in buffer L (20 mM HEPES-KOH pH 7.4,
150 mM KCl, 5 mM MgAc, 1 mM TCEP). Additionally, urea at a final concentration
of 1 M was included. After incubation for 1 h at RT, the detergent was removed by
overnight dialysis against buffer L in a 2 kDa Slide-A-Lyzer cassette (Pierce). 1 g of
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Bio-Beads SM-2 (Bio-Rad) were added to each 300 ml of buffer. Dialysis was performed
at RT. To remove outside-bound substrate, the liposomes were floated in a Nycodenz
step gradient containing 4 M urea and 400 mM imidazole in the bottom layers, and 1
M urea in the top layers (see section 2.7.4). The liposomes floated in fractions 1 and
2, and were harvested from the gradient and analyzed by a protease protection assay
(see section 2.7.5). In Figure 3.15, 1 µM His14-Ulp1 was included in the encapsulation
with and 2 µM ΔN49. In Figure 3.19, 1 µM His14-Ulp1 was included in the Hrd1/Syb
coreconstitution, with 2% NiNTA template (see section 2.7.2). To reconstitute Ubc6
with ΔN49 (Figure 3.14), the same protocol was performed as in the NiNTA method,
but without NiNTA lipids. 2 µM Ubc6 was added with an R value of 1.5, and the
liposome were not floated.
In Figures 3.3 and 3.4, encapsulation was performed without the use of NiNTA lipids.
Briefly, 8 mM of template was mixed with OG at an R value of 2.5, along with 8 µM
Syb and 8 µM sCPY*-A488, in buffer L. Detergent was removed by dialysis as above,
with and without 2 M urea. Liposomes were floated in a Nycodenz gradient and
fraction 2 was harvested for protease protection assays. Direct reconstitution of Hrd1
into CPY* liposomes: In Figure 3.25, Hrd1 was directly incorporated into liposomes
containing encapsulated CPY*, modified from Baldridge and Rapoport (2016). CPY*
was encapsulated as described above, and the floated liposomes were incubated with
DMNG at an R value of 0.35, for 30 min on ice. Lipid concentration of CPY* liposomes
was estimated as approximately 2 mM, accounting for dilution after flotation. 1 µM
Hrd1 was added and the liposomes were incubated on ice for 1 h. Detergent was
removed with three sequential incubations in detergent removal spin columns (Pierce),
with each incubation for 30 min at RT. The liposomes were analyzed by flotation in a
Nycodenz gradient.
2.7.2 Hrd1 coreconstitution with Syb into liposomes
To coreconstitute Hrd1 with Syb, 4 mM of template liposomes were mixed with DM at
an R value of 1.5, along with 2 µM Hrd1 and 10 µM Syb, all in buffer L. Detergent was
removed by sequential addition of detergent-removal spin column resin (referred to as
SCR) (Pierce). Briefly, SCR was washed with buffer L, and 3 x 50 mg were added per
200 µl of liposome mix. Incubations were carried out for 20 min at RT. The liposome
solution was centrifuged through a spin column at 1500 x g after each incubation with
SCR. Optimizations of Syb reconstitution without Hrd1 (Figure 3.9) were performed as
above. R values of 1.5 were used for OG, DM and UDM. As a control, OG was removed
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by dialysis, as in section 3.9. When testing DMNG R values with Syb reconstitution
(Figure 3.8), detergent was removed by application to two successive detergent removal
spin columns (Pierce), according to manufacturer’s instructions.
2.7.3 Reconstitutions of Hrd1, Hrd1/Ubc6 and Ubc6 into
liposomes
When Hrd1 or Hrd1 mutants were reconstituted into liposomes alone or with Ubc6,
DMNG was the solubilization detergent used. For Hrd1 reconstitution, 4 mM template
liposomes were mixed with DMNG at an R value of 1.5, along with 2 µM Hrd1, in
buffer L (see section 2.7.1). The mixture was incubated for 1 h at RT and detergent was
removed by applying the solution to two consecutive detergent removal spin columns
(Pierce). Each incubation was performed for 15 min at RT, and liposomes were eluted
by centrifugation at 1200 x g. A maximum volume of 150 µl was added to each
spin column. In Hrd1 reconstitution for planar lipid bilayer experiments, the protocol
was the same with the exception that 8 mM lipids and 8 µM Hrd1 were used, with
three consecutive spin columns for detergent removal instead of two. Hrd1 and Ubc6
were coreconstituted into liposomes in the following manner (Figure 3.38). 4 mM
template liposomes were mixed with DMNG at an R value of 1.5, along with 2 µM
Hrd1 and 2 µM Ubc6, in buffer L. After 1 h of incubation at RT, detergent was removed
by incubating the solution in two consecutive detergent removal spin columns. The
protocol for reconstituting Ubc6-SBP into liposomes (Figure 3.39) was kindly provided
by Claudia C. Schmidt (Max Planck Institute for Biophysical Chemistry). Briefly, 4
mM of template was mixed with OG at an R value of 2, along with 2 µM Ubc6-SBP,
in buffer L. The mixture was incubated for 1 h at RT and detergent was removed
by three sequential incubations with SCR (10 mg, 30 mg, 30 mg of SCR per 100 µl
of liposomes). Each incubation with SCR was performed for 20 min at RT and the
liposomes were collected by spin elution at 1200 x g after each incubation.
2.7.4 Nycodenz flotations
Liposomes were floated in Nycodenz step gradients to assess protein incorporation and
also as a purification technique to remove outside-bound substrate during encapsula-
tion. Nycodenz stocks were prepared in buffer L. In scale flotations, 50 µl of 80% (w/v)
Nycodenz was mixed with 50 µl of liposomes. This was overlaid with 40 µl of 30%,
15% and 0% Nycodenz solutions. In large scale flotations, 250 µl of 80% Nycodenz was
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mixed with 250 µl of liposomes, and this was overlaid with 500 µl of 30%, 15% and
0% Nycodenz each. The gradients were centrifuged at 50,000 rpm in an S55-S rotor
(Thermo Scientific) for 1 h (small scale) and 2.5 h (large scale) flotations. Six equal
fractions were harvested from the top of the gradient and were analyzed by SDS-PAGE.
2.7.5 Protease protection assays
Protease protections were performed to assess encapsulation efficiency and orientation
of membrane proteins in liposomes. Encapsulation was judged by accessibility to pro-
teinase K (PK). Briefly, 3 µl of liposomes were incubated with 0.01 mg/ml PK in a
final volume of 15 µl in buffer L. As a positive control, 0.67% (v/v) of Triton X-100
was included. The reaction was incubated for 20 min at RT and was quenched by ad-
dition of 0.5 µl of a 200 mM stock of PMSF (6.5 mM final concentration). The PMSF
was incubated for 10 min and then SDS-sample buffer was added. The reactions were
analyzed by SDS-PAGE and fluorescence scanning. Quantification was performed us-
ing ImageStudio Lite software (Li-COR). Protections with TEV protease with Hrd1
liposomes were performed as with PK protections, except 0.2 mg/ml TEV protease
was added and reactions were incubated for 30 min at RT. As a positive control, 6
mM DMNG was included. Reactions were quenched by adding SDS-sample buffer.
Protections with 3C protease were performed as protections with TEV protease, with
a final concentration of 14 µM of 3C protease.
2.8 Hrd1 reconstitution into nanodiscs
Hrd1 reconstitution into nanodiscs was modified from a previously-described protocol
for SNARE incorporation into nanodiscs using the scaffold protein ApoE422K (Bello
et al., 2016). In the initial optimizations of Hrd1 reconstitution into nanodiscs, POPC
template liposomes with 100 nm diameter were used as the starting lipid material,
which were prepared as previously described (Hernandez et al., 2012). The reasoning
was that DMNG was poor in solubilizing lipids directly from a lipid film, whereas
DMNG solubilization of liposome template was efficient. Briefly, POPC template lipo-
somes (lipid concentrations indicated in the results section) were mixed with DMNG
at an R value of 2.5, in buffer L. ApoE422K and Hrd1 were added at the indicated
ApoE:Hrd1:POPC ratios. The mixture was incubated for 16 h at 4°C and detergent
was removed by application of the mixture to three consecutive detergent removal spin
columns, as in section 2.7.3, with incubation times of 30 min at RT per spin column.
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The nanodiscs were characterized by size exclusion chromatography on a Superose 6
5/15 GL column (GE Healthcare) in buffer L. It was later concluded that preparation
of Hrd1 nanodiscs with DM and a lipid film was preferential. For this, POPC was
dissolved in chloroform and the chloroform was removed with a rotary evaporator (Ro-
tovapor R-124, Büchi) at 20 mbar. The lipid film was resuspended in buffer NS (20
mM HEPES-KOH pH 7.4, 150 mM NaCl, 2% (w/v) DM) to a final lipid concentration
of 10 mM. For reconstitution, 500 µl of POPC/DM micelles were mixed with 10 µM
Hrd1 and 31.25 µM ApoE422K in a total volume of 1 ml, in buffer L. The resulting
ApoE:Hrd1:POPC ratio was 1:0.26:160. The mixture was incubated for 16 h at 4°C
and detergent was removed by four sequential incubations with 200 mg of SCR (see
section 2.7.2), with each incubation lasting 20 min at RT. The solution was eluted
through a spin column after each incubation step and transferred to a fresh tube. To
further purify the nanodiscs, they were centrifuged through a 10-30% (w/v) glycerol
gradient, prepared in buffer N using a Gradient Master (BioComp Instruments). Cen-
trifugation was performed for 20 h at 4°C in a SW 32 rotor (Beckman). 20 equal size
fractions of approximately 1.5 ml were collected from the top of the gradient and were
analyzed by SDS-PAGE and coomassie staining. The peak Hrd1-containing fractions
were pooled and concentrated in an Amicon 100 kDa cutoff centrifugal filter, after
which glycerol was removed by dialysis against buffer ND (20 mM HEPES-KOH pH
7.4, 150 mM NaCl). The Hrd1 concentration was determined by SDS-PAGE and col-
loidal coomassie staining (InstantBlue, Expedeon), using a Hrd1 standard curve. The
gel was scanned using an Odyssey scanner (Li-COR) and quantification was performed
using ImageStudio Lite software (Li-COR).
2.8.1 Electron microscopy of Hrd1 nanodiscs
Electron microscopy was performed by Dr. Dietmar Riedel, Max Planck Institute
for Biophysical Chemistry. Briefly, the samples were applied to a glow-discharged
carbon foil grid, washed with 0.1% glutaraldehyde, and stained with 1% uranyl acetate.
Imaging was performed using a Talos L120C transmission electron microscope with a
Ceta 16M camera (ThermoFisher- FEI, Netherlands). The size distribution of Hrd1
nanodiscs was calculated with iTEM software (Olympus Soft Imaging Solutions).
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2.9 Fluorescence dequenching assay
Membrane mixing was monitored with a fluorescence dequenching assay using NBD-PE
and Rhodamine-PE, as previously described (Hernandez et al., 2012). Syb liposomes
contained 1.5% NBD-PE and 1.5% Rhodamine-PE (molar percentage) and ΔN49 lipo-
somes were unlabeled. 15 µl of Syb liposomes were mixed with 20 µl of ΔN49 liposomes
in a total volume of 1200 µl, in buffer L. Reactions were measured in a quartz cuvette
at 30°C and excitation and emission wavelengths were 460 and 538 nm, respectively.
In inhibition controls, 15 µM of Sybsol was pre-incubated with ΔN49 liposomes, which
contained 10 µM ΔN49. After incubation for 5 min at RT, these liposomes were added
to the fusion reaction.
2.10 Fusion and ubiquitination assays
20 µl of floated substrate liposomes were mixed with 15 µl of Hrd1 liposomes in a
total volume of 100 µl in buffer U (20 mM HEPES-KOH pH 7.4, 150 mM KCl, 5 mM
MgAc, 0.5 mM TCEP). The reaction was incubated for 45 min at 30°C. In the inhibited
fusion controls, 2 µM Sybsol was mixed with substrate liposomes before adding Hrd1
liposomes. In reactions with unfloated substrate liposomes, 10 µl were added instead
of 20 µl. 40 µl of fused liposomes were mixed with ubiquitination machinery in a total
volume of 50 µl in buffer U. The final concentrations of the ubiquitination machinery
were: 0.2 µM Uba1, 2 µM Ubc7, 2 µM Cue1-c and 100 µM ubiquitin. BSA (0.2 mg/ml)
was included to reduce sticking to the tube. The reaction was started by adding 2.5 mM
ATP on ice. After taking the 0 min timepoint into SDS-sample buffer, the reactions
were shifted to 30°C and timepoints were collected in SDS-sample buffer. Reactions
were analyzed by SDS-PAGE and fluorescence scanning. The fusion assay with Hrd1
and Ubc6 liposomes was performed in the same manner, (Figure 3.14), except Ubc7
and Cue1-c were omitted from the ubiquitination mix.
2.11 Ubiquitination assays with Hrd1 and substrates
For Hrd1 ubiquitination assays in liposomes and nanodiscs, with or without cytoso-
lic substrates, the following protocol was followed, modified from Stein et al. (2014).
Ubiquitination reactions were performed in 50 µl total volume, in buffer U (as in sec-
tion 2.10), with 1 mg/ml BSA. The liposomes were diluted 1:10, so that the final Hrd1
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concentration was approximately 200 nM. Ubiquitination machinery was added with
final concentrations as in section 2.10. Where indicated, substrates were added at 100
nM final concentration. Because the substrates were stored in urea, they were diluted
into the reaction mixture immediately before starting the reaction. The reaction was
pipetted on ice and 2.5 mM ATP was added to start the reaction. The 0 min timepoint
was taken into SDS-sample buffer and the reaction was shifted to 30°C in a thermocy-
cler. Timepoints were taken into SDS-sample buffer and were analyzed by SDS-PAGE
and fluorescence scanning. The ubiquitination of PrA* by Hrd1 in detergent (Figure
3.22) was performed as above, with 120 µM DMNG instead of liposomes. The Hrd1
and PrA* concentrations were 200 nM each.
2.12 Pulldown binding assays
Binding assays with Hrd1 liposomes and Hrd1 nanodiscs were performed in the fol-
lowing manner, adapted from Stein et al. (2014). Hrd1 liposomes or nanodiscs were
diluted to desired concentrations in buffer BB (20 mM HEPES-KOH pH 7.4, 150 mM
potassium chloride, 5 mM magnesium acetate, 0.5 mM TCEP, 0.2 mg/ml BSA) and
were immobilized onto streptavidin magnetic beads (Pierce), which were prewashed
with buffer BA (20 mM HEPES-KOH pH 7.4, 150 mM potassium chloride, 5 mM
magnesium acetate, 0.5 mM TCEP, 2 mg/ml BSA). Washing the beads with high con-
centrations of BSA was very important to prevent non-specific binding of substrates to
the beads. Binding was performed for 1 h at RT and the beads were washed with buffer
BB. To verify binding of Hrd1, inputs and supernatants were analyzed by SDS-PAGE.
Hrd1 binding to the beads was quantitative. 20 µl of beads were used per 20 µl of li-
posomes or nanodiscs. Ubiquitination was performed on beads by resuspending beads
in ubiquitination mix, as described in section 2.10. Ubiquitination was performed for
1 h at 30°C, and ATP was omitted in control reactions. The beads were washed with
buffer BAand substrates (diluted freshly in buffer BA ) were incubated with the im-
mobilized liposomes or nanodiscs for 30 min at RT. The supernatant containing the
unbound fraction was collected and beads were washed with buffer BB. The beads
were eluted by incubation in buffer BB supplemented with 2 mM biotin for 45 min
at RT. In single concentration binding experiments, the inputs and supernatants were
analyzed by SDS-PAGE and fluorescence scanning in an Odyssey scanner. In titration
experiments, input and unbound fractions were analyzed by fluorescence scanning in a
384 well plate (Corning 3655) using the Odyssey scanner. The fluorescence was quan-
tified using ImageStudio Lite software (Li-COR) and fraction bound was determined
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as 1-unbound fraction, normalizing to the unbound fraction in the beads only con-
trol. Fitting was performed using Origin 2018 software, with a one-site binding model,
assuming 1:1 stoichiometry. PrA WT binding to Hrd1 liposomes was analyzed with
SDS-PAGE and fluorescence scanning, followed by quantification using ImageStudio
Lite software. Quantifications were from three binding experiments and error bars
indicate standard deviation. Binding of CPY* to polyubiquitinated Ubc6-SBP in lipo-
somes (Figure 3.39) was performed as above, with the exception that the ubiquitination
mix was supplemented with 10 µM of the Doa10 RING domain.
2.13 Deubiquitination assays
Deubiquitination of Hrd1 in liposomes (Figure 3.32C) was performed after purifying
ubiquitinated Hrd1 liposomes on streptavidin magnetic beads. Briefly, Hrd1 liposomes
were diluted to 0.5 µM Hrd1 in buffer BB and were immobilized on prewashed strepta-
vidin magnetic beads. The liposomes were incubated with the standard ubiquitination
machinery (as in section 2.10) for 1 h at 30°C. The beads were washed with buffer
BB to remove the ubiquitination machinery and ubiquitinated Hrd1 was eluted with
buffer BB supplemented with 2 mM biotin. Usp2 was added at increasing concentra-
tions and timepoints were taken into SDS-sample buffer. The reactions were analyzed
by SDS-PAGE and fluorescence scanning. To quantify the fraction of released CPY*
from Hrd1 after deubiquitination (Figure 3.40), Hrd1 liposomes (250 nM Hrd1) were
immobilized onto streptavidin magnetic beads as described in section 2.12. CPY* (50
nM) was incubated for 30 min at RT and the unbound fraction was collected. The
beads were washed and incubated with 2 µM Usp2 (or with buffer) for 30 min at RT.
The supernatants containing released CPY* were collected. The beads were washed
and eluted with 2 mM biotin in buffer BB. The input, unbound, supernatants and
elutions were analyzed by SDS PAGE and fluorescence scanning. To determine the
fraction of CPY* released, the elution fractions were quantified. CPY* release without
Usp2 was normalized to 1. Quantification was performed from three experiments and
error bars indicate standard deviation.
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2.14 Electrophysiological experiments in planar lipid
bilayers
Electrophysiological measurements of Hrd1 using the planar lipid bilayer technique
were performed by Dr. Niels Denkert (University Medical Center Göttingen and Max
Planck Institute for Biophysical Chemistry), in the lab of Prof. Michael Meinecke (Uni-
versity Medical Center Göttingen). Further details about the technique are provided
in section 3.8 and in Harsman et al. (2011). Experiments were performed as previously
described (Denkert et al., 2017; Reinhold et al., 2012; Harsman et al., 2011), with all
quantifications derived from three independent experiments, except where indicated.
Error bars indicate standard error of the mean. To characterize channel activity, Hrd1
liposomes were incubated with ubiquitination machinery at 30°C for 1 h, and were then
added to the cis side of the chamber. In fusion conditions, the buffer contained 250
mM KCl, 10 mM MOPS pH 7.0 on the cis side and 20 mM KCl, 10 mM MOPS pH
7.0 on the trans side. Upon fusion, the chambers were perfused with buffer containing
250 mM KCl on both sides of the membrane. Current traces were recorded at different
holding potentials in symmetrical buffer conditions. The conductance histograms show
conductance states from constant voltage conditions. To calculate channel diameter,
the channel was treated as a cylindrical pore with a restriction zone of 2 nm, assum-
ing a fivefold greater resistivity than the resistivity of the bulk buffer, as previously
prescribed (Smart et al., 1997). In substrate activation experiments, 100 nM CPY*
was added to the indicated sides of the chamber after incorporation of Hrd1 channels.
The solution was mixed with a magnetic stirrer for 2 min, let to rest for 2 min, and
then recordings were continued. Fusion rates of Hrd1 channels were calculated by mea-
suring the amount of fusions to the PLB over a 20 h time period. This was repeated
three times, for a total of 60 h per condition. For calculation of channel lifetimes, the




3.1 Developing a fusion system to study
retrotranslocation by Hrd1
3.1.1 Overview
Two previous Hrd1 reconstitutions paved the way for investigating mechanistic details
of Hrd1-mediated retrotranslocation (Stein et al., 2014; Baldridge and Rapoport, 2016).
However, these reconstitutions had limitations which precluded the study of direct
retrotranslocation by Hrd1. In the reconstitution by Stein and colleagues, Hrd1 and
the model substrate CPY* were either reconstituted in detergent or coreconstituted as
a preformed complex in liposomes. Importantly, CPY* was not protected from outside
proteases, indicating that it was already exposed to the outside of the liposomes. In the
study by Baldridge et al, a membrane-anchored version of CPY* was coreconstituted
into liposomes and then Hrd1 was added to the same population of liposomes using
detergent (Figure 1.8). This coreconstitution method leaves open the possibility that
detergent-mediated complexes of Hrd1 and CPY* were formed, which may represent
intermediate states of retrotranslocation or non-native, detergent-mediated complexes.
In order to keep Hrd1 and substrate separate before the retrotranslocation reaction,
they must not be allowed to interact during the reconstitution. The fusion system solves
this problem by reconstituting Hrd1 and CPY* in separate populations of liposomes
and bringing them together by SNARE-mediated fusion (Figure 3.1). In this manner,
the substrate is delivered to the luminal side of Hrd1 in a detergent-free manner.
The resulting fused liposomes are primed for a retrotranslocation reaction. Since the
substrate is encapsulated in the lumen of the liposomes, subsequent movement or
exposure of the substrate to the outside indicates retrotranslocation by Hrd1.
As Hrd1 autoubiquitination has been postulated to prime or open the channel (Baldridge
and Rapoport, 2016), I initiated retrotranslocation by adding ubiquitination machinery
and ATP. Because the model substrates CPY* and sCPY* are efficiently ubiquitinated
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by Hrd1 (Stein et al., 2014; Baldridge and Rapoport, 2016), the substrate should be-
come ubiquitinated as it emerges from the lumen (Figure 3.1). As the encapsulated
substrate is not accessible to the Hrd1 RING domain and ubiquitination machinery
in the lumen of the liposomes, it can only be ubiquitinated if it moves through the
membrane. Therefore, I analyzed substrate ubiquitination status as a readout for
retrotranslocation efficiency.
Figure 3.1: Overview of the fusion system
Hrd1 and an ERAD-L substrate are coreconstituted separately into liposomes and
are brought together by SNARE-mediated fusion. Upon addition of ubiquitination
machinery, Hrd1 autoubiquitinates, which is hypothesized to open the channel. Retro-
translocated substrate is ubiquitinated by Hrd1, which is monitored as a readout for
retrotranslocation.
3.2 Encapsulation of ERAD-L substrates
In order to study retrotranslocation of a substrate by Hrd1, the substrate must first be
encapsulated into the lumen of liposomes. The following section details the optimiza-
tion of substrate encapsulation into liposomes.
3.2.1 Substrate encapsulation using the traditional method
One of the most challenging aspects of the fusion system is the encapsulation of a
misfolded protein into the lumen of liposomes. Encapsulation of proteins into lipo-
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somes is not a well-established technique, but encapsulation of small molecules such as
fluorescent dyes and oligonucleotides has been demonstrated (Nickel et al., 1999; Liu
et al., 2017). The traditional method used to encapsulate a molecule into liposomes
is to provide a high concentration of the molecule during liposome formation. In this
manner, some of the molecules become entrapped in the lumen during bilayer forma-
tion. Thereafter, the non-encapsulated molecule is removed by various methods such
as size exclusion chromatography, flotation, centrifugation or dialysis (Figure 3.2).
Figure 3.2: General strategy for encapsulation of a molecule into liposomes
An excess of substrate is provided during detergent solubilization of lipids. Upon
detergent removal and bilayer formation, a fraction of the substrate becomes entrapped
in the lumen of the liposomes. Removal of the non-encapsulated substrate is achieved
by further purification of the liposomes (in this case, by flotation in a density gradient).
I first attempted to apply this traditional method to encapsulate the model substrate
sCPY*. To this end, sCPY* labeled with AlexaFluor 488 (sCPY*-488) was mixed
with performed liposomes, the detergent OG (R-value 2.5) and the v-SNARE synap-
tobrevin, labeled with AlexaFluor 633 (Syb-633). Upon detergent removal by dialysis,
the liposomes were floated in a nycodenz gradient with or without 2 M urea (Figure
3.3). The presence of urea in the flotation helped to wash off some of the outside-bound
sCPY* (compare lanes 4, 5 and 6 in no urea vs. 2M urea samples). However, Syb was




Figure 3.3: Flotation of sCPY*/Syb liposomes
Liposomes containing reconstituted sCPY* and Syb were subjected to flotation in a
Nycodenz gradient with or without 2 M urea in the bottom layer of the gradient. Six
fractions were collected from the top of the gradient and were analyzed by SDS-PAGE
and fluorescence scanning. The x denotes a skipped lane.
To test for encapsulation of sCPY*, the floated liposomes were harvested (fraction 2)
and a protease protection was performed with trypsin and proteinase K. All of the
sCPY* was cleaved by proteinase K and trypsin, and therefore neither sample showed
any encapsulated sCPY* (Figure 3.4).
Figure 3.4: Protease protection of floated sCPY*/Syb liposomes
Floated liposomes were treated with trypsin (T) or proteinase K (PK) with or without
DMNG (det). Samples were analyzed by SDS-PAGE and fluorescence scanning. In:
Input.
Encapsulation of sCPY* using the traditional method proved to be challenging for mul-
tiple reasons. First, the model substrate sCPY* is misfolded and therefore aggregation-
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prone. To avoid aggregation, it needs to be purified in detergent or denaturing agents
such as urea. When detergent and/or urea are removed during reconstitution, the
substrate needs to be present at low concentrations to avoid aggregation. As encap-
sulation efficiency depends on the starting concentration of the substrate, this makes
encapsulation using the traditional method inefficient.
3.2.2 Substrate encapsulation using the NiNTA method
In order to improve the efficiency of substrate encapsulation, I modified the tradi-
tional method by introducing an affinity step. The purpose of the affinity step is to
concentrate the substrate onto the phospholipids, thereby increasing the likelihood of
encapsulation during lipid bilayer formation. To this end, I made preformed liposomes
with phospholipids labeled on their head group with NiNTA, which have been shown
to significantly increase the encapsulation efficiency of a His-tagged protein (Colletier
et al., 2002). His14-CPY*, phospholipids and ∆N49, a t-SNARE complex engineered
for efficient in vitro fusion (Pobbati et al., 2006), were mixed with OG with an R value
of 3. Detergent was removed by dialysis and outside-bound CPY* was removed by
flotation in a Nycodenz gradient containing imidazole and urea in the bottom layers
(Figure 3.5). Urea was included in the flotation because the CPY* aggregates when
detergent is removed and becomes otherwise insensitive to imidazole (data not shown).
The OG-dialysis protocol was modified from a previously-established protocol for re-
constitution of SNARE proteins (Hernandez et al., 2012).
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Figure 3.5: Strategy of substrate encapsulation using the NiNTA affinity
method
A His-tagged substrate is solubilized in detergent with NiNTA-labeled phospholipids.
Upon detergent removal, the substrate is bound to NiNTA-phospholipids to both sides
of the membrane. Subsequent flotation in a Nycodenz gradient with imidazole and
urea removes the outside-bound substrate.
Overall encapsulation efficiency was first tested by subjecting the unfloated liposomes
to a protease protection assay (Figure 3.6). Increasing concentrations of urea were
included during the solubilization and detergent removal steps in order to increase the
encapsulation efficiency. Urea at concentrations of 1M and above significantly improved
the encapsulation efficiency of CPY*, presumably by preventing aggregation during the
detergent removal process (Figure 3.6). Therefore, at least 1M urea was included in all
subsequent substrate encapsulations. The encapsulation efficiency with 2 M urea was
30%.
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Figure 3.6: Encapsulation efficiency of His14-CPY* with increasing concen-
trations of urea
His14-CPY* labeled with DL800 was reconstituted into liposomes containing 2%
NiNTA. Increasing concentrations of urea were included during the solubilization and
detergent removal. The liposomes were subjected to protease protection with pro-
teinase K (PK), with or without Triton X-100 (Det). The samples were analyzed by
SDS-PAGE and fluorescence scanning.
CPY*/∆N49 liposomes from the 1 M urea reconstitution were floated in a Nycodenz
gradient with imidazole. After flotation, CPY* was localized both in the top of the
gradient as well as in the bottom fractions (Figure 3.7A). The CPY* in the bottom of
the gradient represents the fraction that was washed off. Notably, the ∆N49 remained
in the top fractions, indicating that it was well reconstituted, and demonstrating that
this encapsulation method is compatible with SNARE reconstitution. The floated
liposomes were harvested and encapsulation efficiency was analyzed by a protease pro-




Figure 3.7: Imidazole flotation and protease protection of His14-
CPY*/∆N49 liposomes
A: His14-CPY*/∆N49 liposomes were subjected to flotation in a Nycodenz step gra-
dient containing 400 mM imidazole and 4 M urea in the bottom layers. Six fractions
were collected from the top of the gradient (left to right on gel) and were analyzed by
SDS-PAGE, fluorescence scanning (top) and coomassie staining (bottom). SNAP-25
and Stx 183-288 are components of the ∆N49 complex. B: The top two fractions were
harvested from the gradient and were analyzed by protease protection with proteinase
K (PK). Det: Triton X-100. Numbers below the lanes indicate the fraction protected
from PK.
In the retrotranslocation assay, it is important to have most of the substrate encap-
sulated in the liposomal lumen because any outside-bound substrate contributes to
background signal in the ubiquitination assay. Having an encapsulated fraction of
about 85% was an acceptable starting point for the retrotranslocation assay. Although
it would have been preferential to have close to 100% of the substrate encapsulated,
some fraction of the outside-bound substrate was invariably resistant to imidazole and
urea treatment.
3.3 Coreconstitution of Hrd1 and Synaptobrevin
3.3.1 Optimization of reconstitution conditions for Hrd1 and
Synaptobrevin
In order to fuse substrate liposomes with Hrd1 liposomes, Hrd1 needed to be reconsti-
tuted with synaptobrevin (Syb), the v-SNARE complementary to the ∆N49 complex
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used in the substrate liposomes (Pobbati et al., 2006). In principle, the SNAREs are
interchangeable, that is, it does not matter if Syb is reconstituted in the substrate
liposomes or in the Hrd1 liposomes. However, practical limitations made it simpler
to reconstitute Syb with Hrd1 instead of ∆N49. Hrd1 is stable in only a few select
detergents (Stein et al., 2014; Baldridge and Rapoport, 2016), whereas the activity of
∆N49 is greatest when reconstituted with the OG-dialysis method (Hernandez et al.,
2012) (Figure 3.9). Importantly, Hrd1 cannot be reconstituted with the OG-dialysis
method because OG interferes with Hrd1 autoubiquitination activity (data not shown).
I attempted to reconstitute ∆N49 with the detergents compatible with Hrd1 reconsti-
tution, but this resulted in poor fusion efficiency (data not shown). Syb is amenable
to a wide variety of detergents and reconstitution conditions (personal observation),
making it the better option for coreconstitution with Hrd1. When developing the
reconstitution protocol for Hrd1 and Syb, I considered two main factors. First, the
solubilization detergent had to be compatible with Hrd1. Second, the chosen detergent
had to preserve fusion efficiency.
To screen for reconstitution conditions, I used an established lipid mixing assay as
a readout for fusion (Struck et al., 1981; Hernandez et al., 2012) (see materials and
methods). Upon fusion, unlabeled lipids from one population of liposomes mix with
and dilute the NBD/Rhodamine FRET pair in another population of liposomes. De-
quenching of the NBD FRET donor is monitored as the readout for fusion. Based on
previous studies, I defined an efficient fusion reaction as a reaction having a relative
two-fold increase in donor fluorescence in the first 5-10 min (Hernandez et al., 2012).
I first tested how the Hrd1-compatible detergent DMNG influenced Syb reconstitution
(Stein et al., 2014). To this end, I made ∆N49 liposomes with the OG-dialysis method
(as described in Hernandez et al. (2012)) and tested fusion to liposomes where Syb was
reconstituted with either the OG-dialysis method (as described in Hernandez et al.
(2012)), or with the detergent DMNG at a range of different R values (Figure 3.8).
I checked whether I could determine an R value where the fusion rate was similar to
the OG-dialysis method. As evident in Figure 3.8, DMNG-mediated reconstitution of
Syb significantly inhibited fusion (compare the black trace to all other traces). At very
low R values, fusion was nonexistent and matched the inhibited OG-dialysis reaction,
where soluble Syb (Sybsol) to was added to ∆N49 liposomes before fusion. There was
some fusion activity between R values of 0.35 and 1, but significantly less than the
OG-dialysis control. Above R values of 1, fusion was completely inhibited. Therefore,
I concluded that DMNG was incompatible with Syb reconstitution.
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Figure 3.8: Effect of DMNG on Syb reconstitution and fusion
∆N49 was reconstituted in unlabeled liposomes using the OG-dialysis method and
was fused with Syb reconstituted in NBD/Rh liposomes. Fusion was monitored as a
function of the change in NBD fluorescence. Syb was reconstituted using OG-dialysis
(black, red) or different R values of DMNG, as indicated. Inhib: fusion was inhibited by
incubating ∆N49 liposomes with the soluble domain of Syb (Sybsol) prior to addition
of Syb liposomes.
I next screened for detergents in Syb reconstitution that would result in better fusion
efficiency than DMNG. I tested the detergents OG, DM, UDM and DDM. The deter-
gents were removed with a cyclodextrin-based resin (SCR), which has a high affinity
for a wide range of detergents (Antharavally et al., 2011). The rationale behind this
removal method is that low-CMC detergents like DM, DDM and UDM are not effi-
ciently removed by dialysis. This is especially important during Hrd1 reconstitution
because trace amounts of the low-CMC detergent DMNG are introduced. Of all de-
tergents tested, DM resulted in the best fusion efficiency compared to the OG-dialysis
method (Figure 3.9, blue vs black traces). OG removed with SCR was the worst, while
UDM had an intermediate effect on fusion efficiency (Figure 3.9, red and green traces).
DDM-mediated Syb reconstitution was not viable because the lipids precipitated. Re-
constitution of ∆N49 with OG removed by SCR significantly decreased fusion efficiency
compared to OG removal by dialysis (Figure 3.9, yellow vs black traces), indicating
that ∆N49 activity is sensitive to the detergent removal method. As SCR removes
detergent more rapidly than dialysis, it appears that slow detergent removal favors
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proper ∆N49 reconstitution. Overall, I concluded that DM was the best detergent for
Syb reconstitution apart from OG-dialysis.
I then tested whether fusion efficiency was affected in the DM reconstitution when
Hrd1 was coreconstituted. As seen in Figure 3.9, Hrd1/Syb coreconstitution slightly
reduced fusion efficiency compared to Syb DM liposomes (cyan vs blue traces), but the
overall efficiency was similar. Fusion efficiency was not affected when an additional tail-
anchored membrane protein, Ubc6, was coreconstituted in the ∆N liposomes (Figure
3.9, brown vs cyan traces). Therefore, Hrd1/Syb coreconstitution using DM and SCR
results in efficiently-fusing liposomes.
Figure 3.9: Effect of various detergents on SNARE and Hrd1 reconstitution
Syb or Hrd1/Syb were reconstituted into NBD/Rh liposomes using the indicated de-
tergents, and were fused with unlabeled lipsomes containing ∆N49, prepared by OG-
dialysis. Fusion was monitored as a function of the change in NBD fluorescence. SCR
indicates that detergent was removed with a cyclodextrin-based resin. Black trace:
both Syb and ∆N49 were reconstituted with the OG-dialysis method. Inhib: fusion
was inhibited by incubating ∆N49 liposomes with Sybsol. ∆N53 is similar to ∆N49,
except the stabilizing Syb fragment contains residues 53-96 instead of 49-96 (Hernandez
et al., 2012).
3.3.2 Biochemical characterization of Hrd1/Syb liposomes
Having established a method to coreconstitute Hrd1 and Syb while maintaining fu-
sion efficiency, I then characterized these liposomes biochemically. The four important
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factors to consider were the incorporation efficiency, coreconstitution efficiency, orien-
tation and activity of the proteins. Incorporation efficiency was assayed by a flotation
assay. Hrd1/Syb liposomes were floated in a Nycodenz step gradient and fractions
were analyzed by SDS-PAGE (Figure 3.10A). Hrd1 floated primarily in fraction 2 and
no Hrd1 was observed in the bottom fractions, indicating complete incorporation into
liposomes. Likewise, Syb cofloated primarily in fraction 2 and no Syb was observed
in the bottom fractions. Thus, both proteins were efficiently inserted into liposomes.
In order to determine the orientation of Hrd1 in the liposomes, liposomes were incu-
bated with TEV protease, which cleaves off the SBP tag and fluorescent dye on the
C-terminus. In the correct orientation, Hrd1 is oriented with its N and C-termini fac-
ing the cytosol (outside) (Gardner et al., 2000). About 90% of the Hrd1 is accessible
to TEV protease, indicating that Hrd1 is primarily oriented with its N and C-termini
facing the outside (Figure 3.10B).
Figure 3.10: Flotation and orientation of Hrd1/Syb liposomes
A: Hrd1/Syb liposomes were subjected to flotation in a Nycodenz step gradient. Frac-
tions were analyzed by SDS-PAGE and coomassie staining. B: Hrd1/Syb liposomes
were treated with TEV protease in the presence or absence of DMNG (Det.). Samples
were analyzed by SDS-PAGE and fluorescence scanning. Numbers under the lanes
indicate the fraction of Hrd1 remaining normalized to the input sample.
I next checked the coreconstitution efficiency of Hrd/Syb. When coreconstituting two
membrane proteins, it is important to determine the fraction of liposomes that contain
both proteins. The majority of Hrd1 liposomes should contain Syb, because liposomes
containing only Hrd1 would be unable to fuse and participate in retrotranslocation. To
check the coreconstitution efficiency of Syb in Hrd1 liposomes, I performed a pull-down
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experiment. Hrd1/Syb liposomes were immobilized onto magnetic streptavidin beads
through the SBP tag of Hrd1, and input, unbound and biotin elutions were analyzed
(Figure 3.11). The biotin elution was inefficient and was therefore not included in the
quantification. Quantification of the input and unbound fractions showed that 92% of
Hrd1 and 75% of Syb bound to the beads (Figure 3.11, -Biotin). This indicated that
the majority of Syb was localized in Hrd1-containing liposomes. As a control, beads
were treated with biotin before the pull-down experiment (Figure 3.11, +Biotin). In
that case, only 12% of Hrd1 and 10% of Syb bound to the beads, indicating that
non-specific binding was low.
Figure 3.11: Coreconstitution efficiency of Hrd1/Syb in liposomes
Hrd1/Syb liposomes were immobilized onto magnetic streptavidin beads. Input (In),
unbound (U) and biotin elutions (E) were analyzed by SDS-PAGE and fluorescence
scanning (Hrd1) and immunoblotting (α-Syb, Synaptic Systems 69.1). As a control,
beads were treated with biotin before use (+Biotin). Fraction of Hrd1 and Syb re-
maining were quantified and normalized to the input sample.
Hrd1 autoubiquitination is essential for its ability to degrade ERAD substrates in vivo
and has been proposed to trigger a conformational change that opens the channel
(Bordallo and Wolf, 1999; Baldridge and Rapoport, 2016). Therefore, Hrd1 must re-
tain the ability to autoubiquitinate when coreconstituted with Syb. I checked Hrd1
autoubiquitination by adding components of the standard Hrd1 ubiquitination machin-
ery (Uba1, Ubc7, Cue1-c, and ubiquitin) to Hrd1/Syb liposomes. Approximately 60%
of Hrd1 autoubiquitinated after 1 h (Figure 3.12A, B), which is in the range of what
was observed in previous reconstitutions, albeit slightly less efficient (Stein et al., 2014;
Baldridge and Rapoport, 2016). The presence of Syb did not affect autoubiquitina-
tion as Hrd1-only liposomes prepared with DM showed identical autoubiquitination
(Figure 3.12B). Hrd1 autoubiquitination is more efficient when reconstituted into li-
posomes with DMNG than with DM, indicating that DMNG is better in maintaining
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Hrd1 activity (compare Figure 3.12 to Figure 3.42). Nevertheless, DM was the best op-
tion in terms of preserving fusion efficiency while maintaining Hrd1 autoubiquitination
activity (Figures 3.8, 3.9, 3.12).
Figure 3.12: Hrd1 coreconstitution with Syb does not affect autoubiquiti-
nation activity
A : Hrd1/Syb or Hrd1 were reconstituted into liposomes with DM and were incubated
with ubiquitination machinery with or without ATP for 1 h at 30°C. Timepoints were
taken into sample buffer and were analyzed by SDS-PAGE and fluorescence scanning.
The -ATP sample was collected after 60 min. B: Quantification of Hrd1 autoubiquiti-
nation normalized to the 0 min timepoint.
3.4 Characterizing fusion between substrate and Hrd1
liposomes
Having established that Hrd1/Syb liposomes fuse efficiently to ∆N49 liposomes, I pro-
ceeded to encapsulate CPY* into the ∆N49 liposomes and checked how fusion efficiency
was affected (as in Figure 3.7). SNARE-mediated fusion proceeds via a series of well-
characterized intermediates. This includes tight docking of the liposomes where the
bilayers are in close proximity but do not mix, a hemifused state where only the outer
leaflets mix, and finally the completely-fused state where the fusion pore expands and
luminal contents mix (Hernandez et al., 2012). A prerequisite of the fusion system is
that fusion must go to completion, with membrane and luminal contents completely
mixing. Because liposomes can be trapped in an extended hemifused state during
fusion (Hernandez et al., 2012), I aimed to characterize the extent of fusion between
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substrate and Hrd1 liposomes with assays that monitored both membrane mixing as
well as luminal content mixing.
3.4.1 Fusion of Hrd1 and substrate liposomes results in efficient
membrane mixing
I first assayed fusion between Hrd1/Syb and CPY*/∆N49 liposomes by a lipid mixing
assay. As shown in Figure 3.13, fusion was as efficient with unfloated CPY*/∆N49
liposomes as with ∆N49 liposomes (compare Figure 3.13A, black trace to Figure 3.9,
cyan trace). Thus, the use of NiNTA lipids in the liposomes and encapsulation of
CPY* does not inhibit lipid mixing. In the next step of the encapsulation protocol,
the outside-bound CPY* is removed by flotation in a Nycodenz gradient with imidazole
and urea (Figure 3.5). These floated liposomes exhibited less efficient lipid mixing than
the unfloated liposomes (Figure 3.13A, blue trace). This was not due to dilution of
CPY*/∆N49 liposomes after flotation, as the dilution factor was accounted for in
the lipid mixing assay. Flotation in imidazole and urea might affect the activity of
the ∆N49 complex or the integrity of the liposomes. Both fusion reactions could be
inhibited by incubation with Sybsol, although there was some spontaneous lipid mixing
in both unfloated and floated samples (Figure 3.13A, red and green traces).
The lipid mixing assay is a bulk biophysical assay which is useful for general charac-
terization of fusion, but it does not provide insight into the fusion of specific liposome
populations. It is possible that populations of liposomes that contain only ∆N49 or
Syb fuse more efficiently than liposomes containing both SNAREs and Hrd1 or CPY*.
I employed an alternative biochemical assay to check for delivery of CPY* to Hrd1
liposomes. After fusion, Hrd1-containing liposomes were immobilized on streptavidin
magnetic beads (Figure 3.13B). Most of the CPY* was pulled down along with Hrd1
after fusion. When fusion was inhibited, less CPY* was pulled down, indicating that
CPY* was transferred to Hrd1 liposomes in a SNARE-specific manner. However, a
significant fraction of CPY* was pulled down in the inhibited reaction and could be
eluted with biotin, meaning that a fraction of CPY*-containing liposomes sticks non-
specifically to Hrd1 liposomes. A disadvantage of the pull-down assay is that it does
not discriminate between docked, fused or hemifused liposomes. Any of these three
possibilities would result CPY* pulldown along with Hrd1. Therefore, I continued to
characterize fusion with additional assays.
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Figure 3.13: Transfer of CPY* to Hrd1 liposomes after fusion
A: Lipid mixing assay of Hrd1/Syb and CPY*/∆N49 liposomes before and after
flotation in a Nycodenz step gradient. Inhib: fusion was inhibited by incubation of
CPY*/∆N49 liposomes with Sybsol prior to fusion. B: Hrd1/Syb liposomes were im-
mobilized onto magnetic streptavidin resin after fusion with CPY*/∆N49 liposomes,
or after fusion was inhibited with Sybsol. Input (In), unbound (Sup) and biotin elutions
(Elut) were analyzed by SDS-PAGE and fluorescence scanning.
Having observed efficient lipid mixing, I then asked how well the fusion system could
transfer membrane proteins between populations of liposomes. I developed a bio-
chemical assay involving Hrd1 autoubiquitination as a readout (Figure 3.14A). Briefly,
Hrd1/Syb liposomes were fused with ∆N49 liposomes coreconstituted with the E2
ubiquitin conjugating enzyme Ubc6. Ubc6 is a tail-anchored E2 enzyme localized to
the ER membrane and functions in conjunction with the E3 ligase Doa10 (Sommer
and Jentsch, 1993; Swanson et al., 2001). It has been shown to prime Doa10 substrates
by monoubiquitination (Weber et al., 2016). Genetic experiments have also implicated
Ubc6 in Hrd1-mediated degradation of CPY* (Hiller et al., 1996).
In order to catalyze autoubiquitination, the RING domain of Hrd1 requires an E2
enzyme loaded with ubiquitin in close proximity. Ubc6 is the only E2 enzyme in this
reaction, and is localized in the membrane of a separate population of liposomes. There-
fore, Hrd1 autoubiquitination can only occur if Ubc6 is delivered to Hrd1 liposomes
by fusion. Liposomes were fused and autoubiquitination was initiated by adding E1
enzyme and ATP. Hrd1 autoubiquitinated efficiently upon fusion with Ubc6 liposomes,
reaching 80% ubiquitination efficiency after 60 min, with about 50% ubiquitinated af-
ter 10 min (Figure 3.14B, C). By comparison, when fusion was inhibited with Sybsol,
Hrd1 autoubiquitination was noticeably less efficient. Hrd1 also ubiquitinated Ubc6,
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and this was more efficient in the fused sample compared to the inhibited fusion sample
(Figure 3.14B, C). No ubiquitination of Hrd1 or Ubc6 was observed in the absence of
ATP. These results indicated that the fusion system successfully delivers membrane
components to Hrd1, and that Hrd1 retains ubiquitination activity after fusion. There
was a fraction of Hrd1 and Ubc6 that was ubiquitinated in the inhibited fusion control.
This could be explained by Ubc6 having some activity in trans, where it might catalyze
ubiquitination from an opposing membrane.
This result also established that Ubc6 can act as an E2 enzyme for Hrd1 in a recon-
stituted system, which has been implied in previous studies but never directly shown
(Hiller et al., 1996). Of note, Ubc6 primarily catalyzed monoubiquitination of Hrd1,
which is evident by the main size shift corresponding to the size of a single ubiqui-
tin. This is in agreement with previous observations that the function of Ubc6 is to
prime substrates by monoubiquitination, which is followed by chain elongation by Ubc7
(Weber et al., 2016).
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Figure 3.14: Hrd1 autoubiquitinates upon fusion with Ubc6 liposomes
A: Scheme of fusion assay using the E2 enyzme Ubc6 and Hrd1. Hrd1/Syb liposomes
were fused with Ubc6/∆N49 liposomes and ubiquitination was initiated by adding
E1 enzyme and ATP. B: Ubiquitination reaction after fusion. Samples were taken at
indicated timepoints and analyzed by SDS-PAGE and fluorescence scanning. Where
indicated, fusion was inhibited with Sybsol or ATP was omitted. Note that Hrd1
autoubiquitination is notably more efficient after fusion. C: Quantification of Hrd1
autoubiquitination normalized to the 0 min timepoint.
3.4.2 Fusion of Hrd1 and substrate liposomes leads to luminal
content mixing
After establishing that membrane mixing occurs efficiently in the fusion system, I
characterized the luminal content mixing. Failure to mix luminal contents sufficiently
would be a bottleneck in the subsequent retrotranslocation experiments. There are
many existing methods to monitor luminal content mixing. The standard methods
rely on encapsulation of fluorescent dyes at very high concentrations, which exhibit
dequenching upon fusion with liposomes containing no fluorescent dye (van den Bogaart
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et al., 2010). Other assays have used FRET between encapsulated dyes or even between
larger molecules like DNA oligonucleotides or GFP (Liu et al., 2017; Diao et al., 2010;
Heo et al., 2017). Assays using fluorescent dyes are prone to leakage, whereas assays
using encapsulated oligonucleotides do not establish that the fusion pore is large enough
to accommodate larger proteins. Content mixing assays using GFP are better because
the fusion pore must be large enough for a protein of at least 25 kDa to pass through
(Heo et al., 2017).However, the GFP assay developed by Heo et al, as well as all other
assays mentioned, rely on FRET or fluorescence dequenching as the readout. Like the
lipid mixing assay, these content mixing assays are suitable for assessing bulk fusion,
but they give no information about different subpopulations of liposomes or the activity
of the proteins encapsulated within them.
Therefore, I developed a biochemical content mixing assay that reports on content
mixing of liposomes containing an encapsulated substrate, as well as the activity and
solubility of the encapsulated proteins. As shown in Figure 3.15, the ERAD-L substrate
short CPY* (sCPY*), with an N-terminal His14-SUMO tag and a C-terminal GFP tag
labeled with DL800, was encapsulated into liposomes using the NiNTA technique (as
described in section 3.2.2). The substrate sCPY* is a truncated version of CPY*,
where the first 52 amino acids of CPY* are fused to its last 75 amino acids (Carvalho
et al., 2010; Stein et al., 2014). Importantly, sCPY* is a bona fide ERAD-L substrate
and behaves similarly to CPY*, both in vivo in degradation experiments and in vitro
in reconstitutions with Hrd1 (Carvalho et al., 2010; Stein et al., 2014). SUMO (small
ubiquitin-like modifier) is a ubiquitin-like protein which is added to lysine residues
of proteins post-translationally, and plays various roles in cell cycle progression and
nucleocytoplasmic transport (Wilkinson and Henley, 2010). The SUMO tag can be
efficiently cleaved by the SUMO protease Ulp1, which recognizes the SUMO fold and
cleaves after its C-terminal diglycine motif (Li and Hochstrasser, 1999). The SUMO
and GFP tags on sCPY* improved the solubility of the aggregation-prone sCPY* (Stein
et al., 2014).
His-tagged Ulp1 was encapsulated using the NiNTA method and was fused to liposomes
containing encapsulated His-SUMO-sCPY*-GFP. If fusion leads to content mixing, the
substrate will become accessible to Ulp1 cleavage (Figure 3.15A), which is monitored
by a size shift in SDS-PAGE. As evident in Figure 3.15B, SUMO-sCPY* was cleaved
during the course of fusion. The cleavage kinetics were similar to previously-observed
lipid mixing kinetics (Figure 3.13, blue trace). This indicates that Ulp1 cleavage, which
is normally extremely fast (Frey and Gorlich, 2014), was rate-limited by fusion. When
fusion was inhibited with soluble Syb, no cleavage was observed over 60 min (Figure
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3.15B). Cleavage was slightly faster at 30 and 37°C compared to 25°C, in agreement
with previous observations that lipid mixing is temperature-dependent (Hernandez
et al., 2012). Approximately 65-70% of sCPY* was cleaved after 60 min (Figure 3.15C),
indicating that about 30-35% of substrate-containing liposomes either did not fuse, or
fused with liposomes that did not contain Ulp1.
To conclude, the SUMO-cleavage content mixing assay demonstrated that fusion went
to completion in this system, with luminal contents efficiently mixed between two
populations of liposomes.
Figure 3.15: Fusion system mixes luminal contents efficiently
A: Scheme of the luminal content mixing assay. His-tagged Ulp1 was encapsulated
into liposomes with ∆N49 using the NiNTA method. These liposomes were fused
with liposomes containing encapsulated His-SUMO-sCPY*-GFP along with Syb, also
prepared with the NiNTA method. Upon fusion and content mixing, the substrate
bcomes accessible to Ulp1, which cleaves off the SUMO tag. B: Timepoints were taken
during fusion into SDS sample buffer to quench the reaction. Fusion was performed
at different temperatures. Where indicated, fusion was inhibited by incubating Ulp1
liposomes with Sybsol. The inhibited reaction was analyzed after 60 min. Samples
were analyzed by SDS-PAGE and fluorescence scanning. C: Quantification of His-
SUMO-sCPY*-GFP remaining (top band), normalized to the inhibited fusion after 60
min.
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3.5 Retrotranslocation experiments using the fusion
system
3.5.1 CPY* was not retrotranslocated by Hrd1 after fusion
Having established that the fusion system efficiently delivered luminal contents to Hrd1
liposomes, I asked whether Hrd1 could retrotranslocate encapsulated CPY*. To this
end, I fused CPY*/∆N49 liposomes with Hrd1/Syb liposomes, and added ubiquitina-
tion machinery along with ATP. Because luminal CPY* can only be ubiquitinated if it
becomes exposed to the outside, the ubiquitination status of the CPY* was monitored
as a readout for retrotranslocation. About 85% of CPY* was encapsulated (Figure 3.7),
meaning that retrotranslocation could be concluded only if more than 15% of CPY*
became ubiquitinated. Ubiquitination levels in the range of 0-15% could originate from
outside-bound CPY*.
Consistently, only 15% of CPY* was ubiquitinated after fusion (Figure 3.16A, B), which
corresponded with the fraction that was unprotected from proteinase K (Figure 3.7).
Therefore, it could not be concluded that CPY* was retrotranslocated by Hrd1. Hrd1
autoubiquitinated to approximately 50% efficiency after fusion, which was slightly less
efficient than observed in unfused liposomes (Figure 3.12). There are many possible
reasons why CPY* was not retrotranslocated by Hrd1 in this experiment. The next
sections deal with these problems individually.
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Figure 3.16: Encapsulated H14-CPY* does not get retrotranslocated by
Hrd1 after fusion
A: His14-CPY*/∆N49 and Hrd/Syb liposomes were fused and mixed with ubiquitina-
tion machinery. ATP was added to start the reaction. Time points taken during the
ubiquitination reaction were analyzed by SDS-PAGE and fluorescence scanning. The
-ATP sample was taken after 60 min. B: Quantification of CPY* and Hrd1 ubiquiti-
nation, normalized to 0 min timepoint.
3.5.2 C-terminal tethered CPY* was possibly retrotranslocated
In the NiNTA encapsulation method, the encapsulated substrate remains bound or
tethered to NiNTA lipids in the inner bilayer. Although this was a necessary step
in order to efficiently encapsulate substrates, the tethering could potentially cause
issues in retrotranslocation. It may be important in which orientation substrates are
presented to the luminal face of Hrd1, as there may be a preferred site for insertion into
the channel. It was previously demonstrated that attachment of a tightly-folded DHFR
domain to the C-terminus of CPY* delayed its degradation, whereas attachment to the
N-terminus did not (Bhamidipati et al., 2005), raising the possibility that there is a
preferred directionality of CPY* insertion into the retrotranslocon. However, this study
did not show whether CPY*-DHFR was actually imported into the ER. In the previous
retrotranslocation experiments, I used an N-terminal His-tagged CPY* (Figure 3.16).
If the N-terminal region of CPY* is preferred for insertion into the channel, this may
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be inhibited by N-terminal tethering. To test for this possibility, I swapped the His14
tag to the C-terminus of CPY* (CPY*-H14). CPY*-H14 behaved identically to N-
terminally-tagged His14-CPY* during reconstitution with ΔN49 (Figure 3.17A) and
was efficiently encapsulated into liposomes, with 82% protected from proteinase K
(Figure 3.17B).
Figure 3.17: C-terminally tagged CPY*-H14 is efficiently encapsulated into
liposomes
CPY* with a C-terminal His14 tag (CPY*-H14) was encapsulated along with ΔN49
using the NiNTA method. A: Flotation of CPY*-H14/ΔN49 liposomes in a Nycodenz
gradient with 400 mM imidazole. Outside-bound CPY*-H14 remained in the bottom
fractions, while encapsulated CPY*-H14 cofloated with the lipids. SNAP-25 and Stx
183-288 are components of the ΔN49 complex. B: Proteinase K protection of floated
liposomes (fraction 2). Det: Triton X-100 was added to solubilize the liposomes. Num-
bers below indicate the fraction of protected CPY*-H14.
Upon fusion and addition of ubiquitination machinery, roughly 25% of CPY*-H14 was
ubiquitinated (Figure 3.18A, B). Approximately 15% was ubiquitinated in the inhibited
fusion control. When accounting for the inhibited fusion control and the protease pro-
tection, which showed that 18% of CPY* was on the outside (Figure 3.17B), up to 10%
of CPY*-H14 may have been retrotranslocated. More repetitions of the experiment are
required to determine the significance of this result, as well as additional controls for
leakage during fusion. However, I decided to focus on improving the efficiency of retro-
translocation because I aimed to use the system to characterize mechanistic details,
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and 10% retrotranslocation was an inefficient starting point. Hrd1 remained active
after fusion, as 55% of Hrd1 autoubiquitinated after 1 hour, and this was independent
of fusion (Figure 3.18A, C).
Figure 3.18: CPY*-H14 is potentially inefficiently retrotranslocated after
fusion
A: CPY*-His14/∆N49 and Hrd/Syb liposomes were fused and mixed with ubiquitina-
tion machinery. ATP was added to start the reaction. Where indicated, fusion was
inhibited by incubating CPY*-H14/∆N49 with Sybsol. Time points taken during the
ubiquitination reaction were analyzed by SDS-PAGE and fluorescence scanning. B:
Quantification of ubiquitination of CPY*-H14 and Hrd1 (C), normalized to the 0 min
timepoint.
3.5.3 Untethered sCPY*-GFP was not retrotranslocated by Hrd1
Because N-terminally tethered CPY* did not get retrotranslocated by Hrd1 and C-
terminally tethered CPY* was potentially only inefficiently retrotranslocated, I asked
if an untethered substrate gets more efficiently retrotranslocated. To test an untethered
luminal substrate, I used the H14-SUMO-tagged sCPY*-GFP that could be cleaved
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upon fusion by encapsulated Ulp1 (described in section 3.4.2, Figure 3.15). Substrate
liposomes were fused with Hrd1 liposomes containing encapsulated Ulp1. After fu-
sion, liposomes were floated in a Nycodenz gradient with imidazole to remove outside-
bound substrate and substrate that might have leaked out of the liposomes during
fusion (Figure 3.19A). Liposomes were harvested from the flotation and incubated
with ubiquitination machinery (Figure 3.19B). The Ulp1 cleavage was efficient, gener-
ating sCPY*-GFP in the fused sample and not in the inhibited fusion control. However,
ubiquitination efficiency of the sCPY*-GFP was inefficient and was similar to the inhib-
ited fusion control (Figure 3.19C). Therefore, Hrd1 did not retrotranslocate untethered
sCPY*GFP.
Figure 3.19: Encapsulated sCPY*-GFP is not retrotranslocated after cleav-
age from membrane
A: scheme of fusion and ubiquitination using the substrate His-SUMO-sCPY*-GFP
and Ulp1. The substrate was encapsulated with ∆N49 using the NiNTA method. His-
Ulp1 was encapsulated into NiNTA-containg Hrd1 liposomes with Syb. Liposomes were
fused, floated in a Nycodenz gradient containing imidazole, and then ubiquitinated.
B: Ubiquitination time-course of fused liposomes. Fusion was inhibited by incubating
substrate liposomes with Syb. C: Quantification of ubiquitination the bottom band
(cleaved sCPY*-GFP, indicated by green arrow).
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3.5.4 Fusion causes leakage of substrate
It is important in the fusion system that the substrate remains encapsulated throughout
fusion. To check for leakage after fusion, I cloned a 3C protease cleavage site before the
C-terminal sortase tag in His-SUMO-sCPY*-GFP. Cleavage by 3C protease removes
the fluorescent dye and causes a loss of fluorescence when analyzed by SDS-PAGE.
His-SUMO-sCPY*-GFP/∆N49 liposomes were fused with Hrd1/Ulp1/Syb liposomes
and floated in a Nycodenz/imidazole gradient to remove outside-bound and leaked
substrate (Figure 3.20A). The liposomes were harvested and subjected to a 3C protease
protection. In the fused sample, all of the SUMO-cleaved sCPY*-GFP was accessible to
3C protease, matching the amount remaining in the detergent control (Figure 3.20B,
lower band). When fusion was inhibited, the full-length substrate was completely
protected from 3C protease. There was some SUMO-cleaved substrate present in the
inhibited fusion control, which was accessible to 3C protease. This was most likely
the fraction of outside-bound substrate remaining after encapsulation, which was then
cleaved by residual Ulp1 on the outside of Hrd1 liposomes.
Thus, fusion resulted in leakage of the encapsulated substrate. Although the sCPY*
leaked during fusion, it cofloated with the liposomes, showing that it was somehow still
associated with the liposomes. It is possible that the SUMO-cleaved substrate leaks
to the outside of the liposomes during fusion and then aggregates and sticks to the
liposome membrane. This would explain why it is not ubiquitinated by Hrd1 (Figure
3.19). The leakage was not caused by flotation in Nycodenz, because the substrate was
protected in the inhibited fusion control liposomes, which were also floated.
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Figure 3.20: Ulp1-cleaved sCPY*-GFP leaks out of liposomes during fusion
A: His-SUMO-sCPY*-GFP/∆N49 liposomes were fused with Hrd1/Ulp1/Syb lipo-
somes and floated in a Nycodenz/imidazole gradient. The sCPY* construct contained
a 3C cleavage site on its C-terminus before the sortase tag, which contains the DL800
fluorescent dye. B: Liposomes were harvested from the gradient and were treated with
3C protease either with or without DMNG (Det). In: input, where no protease was
added. The reactions were analyzed by SDS-PAGE and fluorescence scanning.
3.5.5 Leakage during fusion is dependent on protein:lipid ratio
To gain further insight into leakage during fusion, I asked whether leakage was specific
to Hrd1 or whether it was dependent on the protein concentration in the liposomes. For
this, I fused His-SUMO-sCPY*-GFP/Syb liposomes with either Hrd1/∆N53, Doa10/∆N53,
or ∆N53-only liposomes. ∆N53 is a variant of the ∆N49 acceptor SNARE complex,
which fuses efficiently with Syb liposomes in vitro (Hernandez et al., 2012). Doa10 is
also a membrane-embedded ubiquitin ligase involved in ERAD, but it is not involved
in CPY* degradation (Swanson et al., 2001). It served as a control for overall protein
concentration in the membrane.
Fusion was performed in the presence of excess Ulp1 added to the outside, so that
any leaked substrate would immediately be cleaved (Figure 3.21B). The substrate was
cleaved over time in the fused samples but not in the inhibited fusion controls (Figure
3.21A). The cleavage kinetics were similar to lipid mixing kinetics, indicating that
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leakage happened during the fusion process (Figure 3.21C). The observed effect was
indeed leakage and not retrotranslocation by Hrd1, as Doa10 liposomes also resulted in
similar cleavage during fusion. Interestingly, there was minimal leakage when substrate
liposomes were fused to ∆N53-only liposomes, indicating that fusion using Syb and the
∆N complex is not inherently leaky. Rather, the high protein:lipid ratio in the Hrd1
and Doa10 liposomes likely contributed to membrane instability during fusion. Here
they were reconstituted at protein:lipid ratios of 1:1000. Considering that Hrd1 and
Doa10 contain 8 and 14 transmembrane domains, respectively (Schoebel et al., 2017;
Kreft et al., 2005), they contribute significantly greater protein density in the membrane
than the single-TM SNAREs at a similar protein:lipid ratio.
Figure 3.21: Leakage occurs during fusion and is dependent on protein:lipid
ratio
A: His-SUMO-sCPY*-GFP/Syb liposomes were fused with Hrd1/∆N53, Doa10/∆N53,
or ∆N53-only liposomes in the presence of 2 µM Ulp1. Hrd1, Doa10 and ∆N53 were
reconstituted at protein:lipid ratios of 1:1000. Timepoints were taken into SDS sample
buffer and analyzed for cleavage by SDS-PAGE. B: Scheme of leakage assay: fusion in
the presence of SUMO protease (Ulp1). C: Quantification of His-SUMO-sCPY*-GFP
(top band) SNAREs only: Fusion of substrate liposomes with ∆N53-only liposomes.
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3.5.6 PrA* is a Hrd1-substrate in detergent
So far, all of the retrotranslocation experiments utilized variations of the canonical
ERAD-L substrate CPY*. In order to not limit the investigation to only one model
substrate, I asked if another ERAD-L substrate could be retrotranslocated by Hrd1 in
the fusion system. I chose the substrate PrA*, a misfolded vacuolar protease that is
degraded in a Hrd1-dependent manner in S. cerevisiae, requiring the same ERAD-L
components as CPY* (Finger et al., 1993; Spear and Ng, 2005; Kanehara et al., 2010).
PrA* has never been investigated in a reconstituted system. Therefore, I expressed
it in S. cerevisiae and purified it with a C-terminal His14 tag. PrA*, like CPY*, was
aggregation-prone and was purified in 2 M urea to maintain solubility. After sortase-
labeling, PrA* eluted as two peaks in size exclusion chromatography (Figure 3.22A),
with peak 1 being close to the exclusion limit of the column. When mixed with Hrd1
and ubiquitination machinery in detergent, peak 2 was ubiquitinated as efficiently as
CPY* (Figure 3.22B, C). Peak 1 was less efficiently ubiquitinated, consistent with the
fact that it eluted close to the void volume and was likely in an aggregated state.
PrA* contains two glycosylation sites and appeared to be purified as a mixture of non-
glycosylated and glycosylated forms (Figure 3.22B). However, this would need to be
confirmed by treatment with endoglycosidase H. Interestingly, peak 2 contained mainly
the fully glycosylated form, but all forms of PrA* were ubiquitinated independent of the




Figure 3.22: PrA* is efficiently ubiquitinated by Hrd1 in detergent
A: Size exclusion chromatography of PrA* in 2 M urea on a Superdex 200 10/300 GL
column, after sortase labeling . Peak 1 eluted close to the void volume of 8 ml. B:
Ubiquitination time-course of PrA* and CPY* by Hrd1 in detergent (120 µM DMNG).
C: Quantification of fraction PrA*/CPY* ubiquitination, normalized to the 0 min
timepoint.
3.5.7 PrA* does not get retrotranslocated by Hrd1 in the fusion
system
PrA* was subsequently encapsulated with ∆N49 using the NiNTA method. Most of
the PrA* floated in the top fractions, indicating that encapsulation efficiency was high
(Figure 3.23A). 88% of PrA* in the floated fraction was encapsulated, as determined
by protease protection (Figure 3.23B).
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Figure 3.23: Encapsulation of PrA* using the NiNTA method
A: PrA*-His14 was encapsulated into liposomes with ∆N49 using the NiNTA method
and was floated in a Nycodenz gradient with imidazole. Fractions were collected and
analyzed by SDS-PAGE and fluorescence scanning. B: Liposomes were harvested from
the gradient and subjected to protease protection with proteinase K. Det: Triton X-100.
Upon fusion with Hrd1/Syb liposomes and addition of ubiquitination machinery, ap-
proximately 12% of PrA* was ubiquitinated (Figure 3.24A, B). This corresponded
with the fraction of PrA* that was not protected from proteinase K, indicating that
the ubiquitinated fraction could have originated exclusively from the outside-bound
PrA*. Indeed, this was most likely the case, as the inhibited fusion control showed




Figure 3.24: PrA* does not get retrotranslocated by Hrd1
A: PrA*-His14/∆N49 and Hrd/Syb liposomes were fused and mixed with ubiquitina-
tion machinery. ATP was added to start the reaction. Where indicated, fusion was
inhibited by incubating PrA*-H14/∆N49 liposomes with Sybsol. B: Quantification of
ubiquitination of PrA* and Hrd1 (C), normalized to the 0 min timepoint.
3.5.8 Retrotranslocation of membrane-anchored ERAD-L
substrates
As a control for the fusion system, I attempted to use CPY*-TM and CPY*-TM2,
which contain a C-terminal transmembrane domain, allowing them to be reconstituted
without the NiNTA method (Baldridge and Rapoport, 2016). After insertion into
liposomes with a random orientation, the luminally-oriented substrate is relabeled to a
different fluorescent dye using the sortase technique (Baldridge and Rapoport, 2016).
Unfortunately, I was not able to reconstitute CPY*-TM or TM2 with CPY* facing the
lumen. This was assessed with protease protection with Lys-C protease, which cannot
cleave the C-terminus of the transmembrane domain. Despite my efforts to replicate the
protocol from Baldridge and Rapoport (2016), CPY* was always completely accessible
to Lys-C and did not float efficiently in Nycodenz flotation assays (data not shown).
This behavior was persistent across a range of salt, urea and glycerol concentrations,
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as well as various detergent removal methods. It appeared that CPY*-TM substrates
were aggregating instead of inserting with their TM into liposomes.
3.6 Bypassing fusion by sequential coreconstitution of
Hrd1 and substrate
In order to further characterize the lack of efficient retrotranslocation in the fusion
system, I decided to bypass the fusion step by reconstituting Hrd1 directly into lipo-
somes containing encapsulated CPY*. If retrotranslocation were to be observed using
this coreconstitution approach, this would point to the fusion being the bottleneck
in the system. Of course, the coreconstitution approach has disadvantages, namely
the possible detergent-mediated interaction between CPY* and Hrd1 (as discussed in
section 3.1.1). However, the purpose of this approach was to determine if, upstream
of fusion, Hrd1 was capable of retrotranslocating encapsulated CPY*. Even if this
were due to detergent-mediated interactions, it would provide a proof of concept that
retrotranslocation of CPY* can be observed in certain circumstances..
To this end, CPY*-H14 was encapsulated using the NiNTA method and these lipo-
somes were then partially solubilized with limiting amounts of DMNG (R value of
0.35, Figure 3.25A). Hrd1 was added to the partially solubilized liposomes, with the
expectation that encapsulated CPY* would not leak to the outside. Upon detergent
removal, Hrd1 inserted into CPY* liposomes, judged by its coflotation with CPY*
(Figure 3.25B). Additionally, no decrease in CPY* encapsulation was detected by pro-
teinase K protection after Hrd1 addition (Figure 3.25C). In fact, slightly more CPY*
was protected after Hrd1 addition.
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Figure 3.25: Sequential coreconstitution of Hrd1 into CPY* liposomes
A: Scheme of reconstitution strategy. Liposomes containing encapsulated CPY*-H14
were partially solubilized with DMNG at an R value of 0.35 and Hrd1 was added.
Upon removal of DMNG, Hrd1 inserted into CPY* liposomes. B: Nycodenz flotation
of Hrd1/CPY* liposomes. C: Protease protection of CPY* with proteinase K before
and after Hrd1 addition. Det: Triton X-100.
Upon addition of ubiquitination machinery and ATP, approximately 30% of CPY*
was ubiquitinated by Hrd1 (Figure 3.26A, B). Because 23% of CPY* was accessible
to proteinase K (Figure 3.25), this meant that up to 7% of CPY* was possibly retro-
translocated. However, this was quite inefficient and did not approach retrotranslo-
cation efficiencies observed in the Baldridge study. Therefore, bypassing fusion by
detergent-mediated Hrd1 incorporation did not significantly increase the retrotranslo-
cation efficiency of CPY*.
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Figure 3.26: CPY* ubiquitination after sequential Hrd1 coreconstitution
A: Hrd1/CPY* liposomes made by sequential Hrd1 coreconstitution were mixed with
ubiquitination machinery and ATP. The -ATP control was taken after 60 min. B:
Quantification of CPY* and Hrd1 ubiquitination, normalized to 0 min timepoint.
3.7 Problems with the retrotranslocation experiments
3.7.1 Aggregation of substrates
There are a variety of factors that could contribute to the lack of retrotranslocation
observed in the fusion system and in the sequential coreconstitution. Because fusion
efficiency and Hrd1 activity did not appear to be the limiting factors, the problem
most likely lied in the substrate itself. The ERAD-L substrates CPY* and PrA* are
aggregation-prone. In their purified state, they aggregate within a few hours without
the presence of detergent or urea (personal observation). In the cell, misfolded proteins
are kept in a soluble state in the ER lumen by chaperones. Abrogation of the chaper-
one system causes CPY* and other luminal substrates to aggregate and inhibits their
degradation by ERAD (Nishikawa et al., 2001).
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Upon encapsulation into liposomes, CPY* is in close proximity to the membrane,
and its exposed hydrophobic regions may partially insert into the lipid bilayer. Both
aggregation and sticking to the membrane would likely block retrotranslocation. As an
indirect readout of aggregation, I tested the ubiquitination of outside-bound CPY* after
reconstitution into liposomes (Figure 3.27A). As shown in Figure 3.27B, after the first
step of the NiNTA encapsulation protocol, 27% of CPY* was protected from proteinase
K, meaning that 73% of CPY* was located on the outside of the liposomes. However,
when fused with Hrd1 liposomes and incubated with ubiquitination machinery, only
30% of the CPY* was ubiquitinated (Figure 3.27C, D). Thus, despite the fact that
the majority of CPY* was on the outside of the liposomes and accessible to Hrd1 after
fusion, it was still inefficiently ubiquitinated. In contrast, when CPY* was diluted from
urea and added directly to the outside of Hrd1 liposomes, it was nearly completely
ubiquitinated (see section 3.9.1 and Figure 3.34), indicating that the reconstitution
into liposomes caused aggregation of CPY*.
Figure 3.27: CPY* reconstituted on outside of liposomes is inefficiently
ubiquitinated by Hrd1 after fusion
A: CPY*-H14 was encapsulated with ∆N49 using the NiNTA method. B: Unfloated
liposomes were analyzed by proteinase K protection. Fraction protected is indicated
below the lanes. C: Unfloated CPY*-H14/∆N49 liposomes were fused with Hrd1
liposomes and incubated with ubiquitination machinery. Timepoints were analyzed
by SDS-PAGE and fluorescence scanning. D: Quantification of ubiquitination in (C).
About 30% of CPY* was ubiquitinated, independent of fusion.
3.7.2 Improving solubility of encapsulated CPY* with urea
In order to increase the solubility of encapsulated CPY*, I treated the liposomes with
increasing concentrations of urea during the Nycodenz/imidazole flotation step. Urea is
a denaturing agent commonly used to unfold or stabilize membrane proteins and protein
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aggregates during purification. Because it is a small nonpolar molecule, it is membrane
permeable and diffuses through lipid bilayers (Lippe, 1969). The rationale was that
urea would diffuse into the lumen and solubilize aggregated CPY*. Because high
urea concentrations would likely interfere with subsequent fusion and ubiquitination
reactions, CPY* liposomes were diluted by a factor of 10 into the fusion reaction. The
idea was that there would be a time window before aggregation, where CPY* could
interact with Hrd1 and be retrotranslocated.
In the standard NiNTA encapsulation protocol, I included 1 M urea in the top layers of
the Nycodenz gradient. To modify this, increasing concentrations of urea starting from
1.5 M were added to the top layers of the Nycodenz gradient. Upon flotation, CPY*
liposomes were fused with Hrd1 liposomes and incubated with ubiquitination machin-
ery. Unfortunately, I did not observe an increase in CPY* ubiquitination efficiency
from 1.5 to 3 M urea (Figure 3.28A, B). Ubiquitination efficiency was about 15% in all
cases, corresponding again with the fraction of CPY* which was unprotected from pro-
teinase K (compare Figure 3.28B to Figure 3.16B). Dilution of CPY* liposomes into
the reaction introduced up to 180 mM urea. Nevertheless, Hrd1 autoubiquitination
was not impaired at these urea concentrations (Figure 3.28C).
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Figure 3.28: Urea titration of CPY*/∆N49 liposomes
A: Liposomes containing encapsulated H14-CPY* with ∆N49 were floated in a Ny-
codenz/imidazole step gradient with increasing concentrations of urea in the top lay-
ers. The liposomes were harvested from the top of the gradient, diluted, fused with
Hrd1/Syb liposomes, and incubated with ubiquitination machinery. Timepoints were
analyzed by SDS-PAGE and fluorescence scanning. B: Quantification of ubiquitination
of CPY* and Hrd1 (C) , normalized to the 0 min timepoint.
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3.8 Electrophysiological investigation of Hrd1
retrotranslocase activity
The fusion system posed difficulties in investigating retrotranslocation by Hrd1, pri-
marily due to aggregation problems with the substrate. As an alternative technique
to study Hrd1 retrotranslocation, I collaborated with Dr. Niels Denkert (University
Medical Center, University of Göttingen and Max Planck Institute for Biophysical
Chemistry) and Prof. Michael Meinecke (University Medical Center, University of
Göttingen) to reconstitute Hrd1 into planar lipid bilayers (PLBs) for electrophysiolog-
ical characterization. The PLB technique has been used to extensively characterize a
variety of translocation channels, such as mitochondrial Tim23 and Tom40, eukaryotic
Sec61, bacterial SecY, and Toc75 from chloroplasts (Truscott et al., 2001; Meinecke
et al., 2006; Hill et al., 1998; Wirth et al., 2003; Saparov et al., 2007; Hinnah et al.,
2002). The principle of the technique is that a bilayer is formed in a small aper-
ture flanked by two aqueous chambers which can be manipulated by the experimenter
(Harsman et al., 2011). It has been widely demonstrated that protein translocation
channels can form water-filled pores that have the capacity to conduct ions in a voltage-
dependent manner (Harsman et al., 2011). Using ion conductance as a readout, the
PLB technique allows for the investigation of pore diameter, substrate interactions,
and the mechanism of channel formation with single-molecule resolution.
3.8.1 Reconstitution of Hrd1 into liposomes for PLB experiments
We hypothesized that Hrd1 would form a water-filled channel in its autoubiquitinated
state and would thus be amenable to characterization with the PLB technique. In order
to insert a protein of interest into the PLB, it is first reconstituted into liposomes. Pro-
teoliposomes are then added to the PLB chamber, and liposomes that contain active
channels undergo osmotic swelling and fuse with the PLB (Cohen et al., 1980; Niles
et al., 1989). To this end, I reconstituted Hrd1 into liposomes with DMNG, as previ-
ously described (Stein et al., 2014). Hrd1 was efficiently incorporated into liposomes,
as it floated in a Nycodenz step gradient (Figure 3.29A). Treatment of the liposomes
with TEV protease showed that Hrd1 was incorporated in the correct orientation, with
its C-terminus and RING domain facing the outside (Figure 3.29B). Hrd1 liposomes
autoubiquitinated efficiently when incubated with ubiquitination machinery, with ap-
proximately 80% ubiquitinated after 1 hour (Figure 3.29C). We proceeded with these
Hrd1 liposomes in PLB experiments.
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Figure 3.29: Hrd1 reconstitution into liposomes for planar lipid bilayer ex-
periments
A: Hrd1 was reconstituted into liposomes with DMNG and floated in a Nycodenz step
gradient. Hrd1 was efficiently incorporated into liposomes, as all of it floated at the
top of the gradient. B: To assess orientation, Hrd1 liposomes were treated with TEV
protease with or without DMNG (Det.). TEV protease cleaves off the sortase tag and
fluorescent dye on the C-terminus of Hrd1. C: Hrd1 liposomes were incubated with
ubiquitination machinery and ATP was added to start the reaction. Timepoints were
analyzed by SDS-PAGE and fluorescence scanning.
3.8.2 Hrd1 forms a dormant channel upon autoubiquitination
All electrophysiology experiments described in the following sections (3.8.2-3.8.5, and
section 3.10.2, Figure 3.44) were performed by Dr. Niels Denkert (University Medical
Center, University of Göttingen and Max Planck Institute for Biophysical Chemistry),
who also kindly provided the figures. When nonubiquitinated Hrd1 liposomes were
added to PLBs, no current was detected at holding potentials of +40 or -40 mV (Fig-
ure 3.30A). In fact, we never observed fusion of nonubiquitinated Hrd1 liposomes with
PLBs (quantification in Figure 3.30C). Because fusion by osmotic swelling depends on
the presence of active channels (Niles et al., 1989), this indicates that nonubiquitinated
Hrd1 likely does not form a channel. Strikingly, when Hrd1 liposomes were incubated
with ubiquitination machinery and ATP, we observed fusions that led to small currents
and sporadic gating events at different holding potentials (Figure 3.30B, C). The gat-
ing events showed small conductance changes, indicative of a small pore or dormant
channel. Importantly, no fusions were observed when Hrd1 liposomes were incubated
96
3.8 Electrophysiological investigation of Hrd1 retrotranslocase activity
with ubiquitination machinery lacking ATP (Figure 3.30C).
Figure 3.30: Hrd1 forms an ion-conducting channel only when polyubiqui-
tinated
Current traces of nonubiquitinated (A) and polyubiquitinated Hrd1 liposomes (B) at
holding potentials of +40 and -40 mV. Dashed lines indicate the closed states and
different open states (c, o1, o2). Inset in B: expanded view of indicated region with
conductance changes of independent gating events shown. C: Quantification of fusion
rate per liposome preparation. Hrd1 refers to nonubiquitinated Hrd1. +Ub: Hrd1 lipo-
somes incubated with ubiquitination machinery. n=3 independent experiments, error
bars indicate SEM. Experiments and analysis were performed by Dr. Niels Denkert
(University Medical Center, University of Göttingen, Max Planck Institute for Bio-
physical Chemistry).
3.8.3 CPY* stimulates Hrd1 channel activity
Although we observed small currents and sporadic gating events in Figure 3.30, the
conductance changes observed were about 40-50 pS on average, with very few gating
events observed above 200 pS (Figure 3.31D). As a comparison, the S. cerevisiae Sec61
translocon was shown to undergo frequent gating events with conductance changes
ranging between 200-700 pS, from which pore sizes of up to 1-6 nm were calculated
(Wirth et al., 2003). We reasoned that if Hrd1 forms a retrotranslocon, it should also
undergo gating events with similar conductance changes. We postulated that the chan-
nel may have to be activated by substrate. To this end, we fused ubiquitinated Hrd1
channels to the PLB and added CPY* to both sides of the membrane. Remarkably,
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addition of CPY* stimulated considerably more frequent gating of Hrd1, with signif-
icantly greater conductance changes than observed without CPY* (Figure 3.31A, C,
D). The channel activation was specific to misfolded proteins, as WT CPY added at
a two-fold greater concentration did not induce any additional channel gating or con-
ductance changes (Figure 3.31B, C, D). CPY* added to the PLB alone did not result
in any detectable current, indicating that the channel stimulation was specific for the
CPY* interaction with Hrd1 and not due to nonspecific effects of a misfolded protein
interacting with the bilayer (Figure 3.31C).
Upon CPY* stimulation, Hrd1 gating events with conductance changes greater than
100 pS were significantly increased, with conductance changes in the range of 200-
800 pS observed (Figure 3.31C, D). These conductance states were similar to those
previously observed for Sec61 (Wirth et al., 2003), indicating that Hrd1 can open to
similar pore diameters upon interaction with substrate. Thus, CPY* stimulated Hrd1
channel activity, causing it to gate more frequently and leading to expansion of the
pore.
98
3.8 Electrophysiological investigation of Hrd1 retrotranslocase activity
Figure 3.31: CPY* addition to inserted Hrd1 channels stimulates gating
and opening of the channel
Current traces of ubiquitinated Hrd1 with and without CPY* (A) or CPY WT (B) at
holding potentials of +60 and -60 mV. Dashed lines indicate two different open states
of the channel (o1, o2). C: Quantification of gating events with conductance changes
greater than 100 pS, before and after CPY* or CPY WT addition. n=3 independent
experiments, error bars indicate SEM. D: Conductance histogram of gating events
from ubiquitinated Hrd1 channels with or without addition of 100 nM CPY* to the
chamber. Inset shows a zoom plot of a region with higher conductance states for
better visualization. Experiments and analysis were performed by Dr. Niels Denkert
(University Medical Center, University of Göttingen and Max Planck Institute for
Biophysical Chemistry).
3.8.4 Deubiquitination of Hrd1 closes the channel
Ubiquitination is a reversible post-translational modification. We therefore asked if
deubiquitination of Hrd1 closes the channel. This is important, as having a constitu-
tively open retrotranslocation channel in the ER would likely be detrimental to the
cell. To test this hypothesis, we fused ubiquitinated Hrd1 liposomes to the PLB and
added the catalytic domain of the human deubiquitinase Usp2 (Renatus et al., 2006).
In biochemical experiments with ubiquitinated Hrd1 in liposomes, addition of 1 µM
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Usp2 efficiently deubiquitinated Hrd1 within 10 minutes (Figure 3.32C). Remarkably,
addition the same concentration of Usp2 to the PLB containing ubiquitinated Hrd1
closed the channel, as current flow was abolished (Figure 3.32A). Channel closure was
only observed when Usp2 was added to the cis side of the chamber and was complete
within 5 minutes, whereas incubation with Usp2 on the trans side for 3x as long had no
effect (Figure 3.32B). Because the orientation of Hrd1 in liposomes was unidirectional
(Figure 3.29), with the RING domain facing the outside, polyubiquitin chains can only
be attached to the cytoplasmic side of Hrd1. Therefore, this experiment demonstrated
that Hrd1 maintained its orientation during fusion to the PLB, inserting unidirection-
ally, with the the cytoplasmic region containing the RING domain facing the cis side
of the chamber.
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Figure 3.32: Deubiquitination of Hrd1 leads to channel closure
A: Current traces of ubiquitinated Hrd1 before (left) and after Usp2 addition (right)
at a holding potential of +40 mV. Dashed lines indicate the closed state and open
states (c and o1). Note that addition of Usp2 abolishes current flow and closes the
channel. B: Relative open probability of Hrd1 channels before Usp2 addition, and
after side-specific addition of Usp2 to the cis and trans sides (n=3, error bars indicate
SEM). C: Deubiquitination of polyubiquitinated Hrd1 in liposomes by Usp2. Hrd1
liposomes were immobilized on magnetic streptavidin beads and incubated with ubiq-
uitination machinery. The liposomes were washed and eluted with biotin. Increasing
concentrations of Usp2 were added and timepoints were analyzed by SDS-PAGE and
fluorescence scanning. Experiments and analysis in (A) and (B) were performed by
Dr. Niels Denkert (University Medical Center, University of Göttingen and Max Planck
Institute for Biophysical Chemistry).
3.8.5 CPY* stimulates Hrd1 channel activity only from the
luminal side
In previous experiments, we observed that CPY* stimulated Hrd1 channel activity
when added to both sides of the chamber (Figure 3.31). Having established the ori-
entation of Hrd1 in the PLB (Figure 3.32), we asked whether CPY* stimulation was
side-specific. We hypothesized that CPY* would stimulate channel activity only from
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the luminal side, as this is where luminal substrates first interact and insert into the
channel. To this end, ubiquitinated Hrd1 liposomes were fused with the PLB and
CPY* was added either to the cytosolic (cis) or luminal (trans) side. Increased gating
frequency was observed only when CPY* was added to the luminal side of Hrd1 (Fig-
ure 3.33A,B). In this experiment, multiple Hrd1 channels inserted into the PLB, which
explains why the gating frequency and conductance states appear more heterogenous
than in Figure 3.31A. Therefore, substrate interaction with the luminal side of ubiq-
uitinated Hrd1 stimulates channel gating and opening to larger pore sizes (see section
3.8.3, and Figure 3.31). This result suggests that Hrd1 alone can recognize substrates
in the ER lumen, without the need for Hrd3, Der1 or Usa1. This may explain why the
overexpression of Hrd1 makes these other components dispensable in vivo (Carvalho
et al., 2010).
Figure 3.33: Addition of CPY* to the luminal side of ubiquitinated Hrd1
stimulates channel gating
Hrd1 liposomes were ubiquitinated and fused with PLBs. CPY* (100 nM) was added
to either the cis (cytosolic) or trans (luminal) side of the chamber. A: Current traces
of Hrd1 channels at +40 mV with side-specific CPY* addition. Note the increased
gating frequency upon addition of CPY* to the trans (luminal) side. B: Quantification
of relative gating frequency increase upon CPY* addition. Shown are means ± SEM
(n=3). Experiments and analysis were performed by Dr. Niels Denkert (University
Medical Center, University of Göttingen and Max Planck Institute for Biophysical
Chemistry).
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3.9 Interaction of the cytoplasmic region of Hrd1 with
substrates
Having observed that CPY* binding stimulated Hrd1 channel activity in the PLB ex-
periments (Figures 3.31, 3.33), I further investigated Hrd1 interaction with substrates
biochemically. Previous studies showed an interaction between Hrd1 and CPY* in de-
tergent (Stein et al., 2014; Baldridge and Rapoport, 2016), but this was likely mediated
by the transmembrane domains of Hrd1, as shown in Stein et al. (2014). It remained
unclear whether this interaction persisted with membrane-embedded Hrd1, where the
TMs are occluded by the lipid bilayer. The relevant binding sites in retrotranslocation
are the luminal and cytosolic sides of Hrd1, which contact the substrate before insertion
into and after emergence from the channel. I took advantage of the liposome system, in
which Hrd1 inserts into the bilayer unidirectionally with its cytoplasmic region facing
the outside (Figure 3.29), to investigate the interaction between Hrd1 and substrates
on the cytosolic side of the membrane.
3.9.1 Hrd1 polyubiquitinates cytosolic ERAD-L substrates
Because the RING domain of Hrd1 faces the outside, I asked whether Hrd1 could ubiq-
uitinate CPY* when added to the outside of Hrd1 liposomes (referred to as cytosolic
CPY* from here on). Indeed, when cytosolic CPY* was added to Hrd1 liposomes and
incubated with ubiquitination machinery, it was very efficiently ubiquitinated (Figure
3.34A, C). CPY WT was ubiquitinated less efficiently than CPY*, indicating that the
Hrd1 cytoplasmic region can discriminate between misfolded and correctly-folded pro-
teins, which was previously demonstrated for Hrd1 in detergent (Stein et al., 2014;
Baldridge and Rapoport, 2016). However, a fraction of CPY WT was also ubiqui-
tinated, but at a slower rate. The ERAD-L substrate PrA* (see section 3.5.6) was
ubiquitinated with identical kinetics as CPY*, and PrA WT showed almost no ubiq-
uitination (Figure 3.34B, C) The fact that cytosolic ERAD-L substrates were ubiqui-
tinated by Hrd1 was surprising, because a similar experiment in the Baldridge study
showed no ubiquitination of cytosolic CPY* when it was added to CPY*-TM/Hrd1
liposomes (Baldridge and Rapoport, 2016). In that experiment, CPY*-TM most likely
outcompeted cytosolic CPY* for Hrd1 binding. The result was also at odds with a
previous study which found that cytosolic CPY* did not cofloat with Hrd1 liposomes
in a flotation experiment (Stein et al., 2014).
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Figure 3.34: Hrd1 polyubiquitinates cytosolic CPY* and PrA* efficiently
but not CPY WT and PrA WT
A, B: Hrd1 (200 nM) reconstituted in liposomes was incubated with the misfolded
substrates CPY*, PrA* or their corresponding WT versions (100 nM). Ubiquitination
machinery was added and timepoints were analyzed by SDS-PAGE and fluorescence
scanning. C: Quantification of ubiquitination in (A) and (B) from three experiments
(mean ± standard deviation).
3.9.2 Polyubiquitinated Hrd1 binds cytosolic CPY* and PrA*
I inferred that the Hrd1 cytoplasmic region must bind to CPY* and PrA* in order to
catalyze ubiquitination. Because CPY* did not associate with nonubiquitinated Hrd1
liposomes in coflotation experiments (Stein et al., 2014), I hypothesized that binding
might occur only after Hrd1 autoubiquitination. Autoubiquitination of Hrd1 likely
results in a conformational change, which, in addition to opening the channel, may lead
to the creation of a cytoplasmic binding site. To test this hypothesis, I immobilized
Hrd1 liposomes onto streptavidin magnetic beads and ubiquitinated Hrd1 either in
the presence or absence of ATP. The beads were washed to remove ubiquitination
machinery and CPY* was added. I observed almost complete CPY* binding when
Hrd1 was was ubiquitinated, and no binding compared to background binding to the
beads when ATP was omitted (Figure 3.35, lanes 1, 2, 3 and 5). When Hrd1 was
deubiquitinated with Usp2 before CPY* addition, CPY* did not bind (compare lanes 3
and 4), indicating that the conformational change induced by Hrd1 autoubiquitination
was reversible. CPY* and ubiquitinated Hrd1 were eluted with biotin, indicating that
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CPY* binding was specific for Hrd1 and not due to nonspecific binding to the beads
upon Hrd1 ubiquitination (lane 8).
Figure 3.35: Cytoplasmic region of Hrd1 binds CPY* upon autoubiquitina-
tion
Hrd1 (250 nM) reconstituted in liposomes was immobilized onto magnetic streptavidin
beads and polyubiquitinated with ubiquitination machinery. Where indicated, ATP
was omitted. The beads were washed and the DUB Usp2 was added where indicated.
CPY* (50 nM) was then added and input, unbound (supernatant) and biotin elutions
were analyzed by SDS-PAGE and fluorescence scanning.
In order to determine the affinity of ubiquitinated Hrd1 for cytosolic CPY* and PrA*,
I performed titration experiments. Increasing concentrations of liposome-reconstituted
Hrd1 were immobilized on streptavidin magnetic beads, ubiquitinated, and incubated
with CPY*, PrA*, or their wild-type counterparts. Cytosolic CPY* bound to ubiquiti-
nated Hrd1 with a high affinity, whereas no binding of CPY* was observed when ATP
was omitted (Figure 3.36A). Assuming a 1:1 binding stoichiometry, the apparent KD
of ubiquitinated Hrd1 for cytosolic CPY* was approximately 7 nM. CPY WT bound
less efficiently to ubiquitinated Hrd1 than CPY*, although a fraction of CPY WT
did bind with similar binding kinetics as CPY*. This result explains why a fraction
of CPY WT was ubiquitinated by Hrd1 (Figure 3.34A, C). No binding of CPY WT
was observed when ATP was omitted from the ubiquitination reaction. Similar results
were observed for PrA*, with ubiquitinated Hrd1 displaying a KD of approximately
120 nM for PrA* (Figure 3.36B). No binding of PrA WT to ubiquitinated Hrd1 was
observed, which also explains the low ubiquitination efficiency observed (Figure 3.34B,
C). Like CPY*, no binding of PrA* or PrA WT was observed when ATP was omitted.
Therefore, autoubiquitination of Hrd1 creates a high affinity binding site for misfolded
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proteins on its cytosolic side.
Figure 3.36: Titration of ubiquitinated Hrd1 in liposomes against cytosolic
CPY*, PrA*
A: Increasing concentrations of Hrd1 reconstituted in liposomes were immobilized on
magnetic streptavidin beads and ubiquitinated. Beads were washed and CPY* or
CPY WT (20 nM) were added and incubated for 30 minutes. Input and unbound
samples were analyzed by fluorescence scanning in a 384 well plate. Fraction bound
was quantified from the unbound fraction, normalizing to the unbound fraction of the
beads only control. Shown are means ± standard deviations (n=4). To determine KD,
CPY* binding was fit with a single-exponential one-site binding model. B: Titration
of ubiquitinated Hrd1 against PrA* and PrA WT, as in (A). Shown are means ±
standard deviations (n=3).
3.9.3 Hrd1 monoubiquitination is not sufficient for cytosolic
substrate binding
Having observed that Hrd1 autoubiquitination leads to the creation of a cytosolic bind-
ing site for misfolded proteins, I asked whether polyubiquitination of Hrd1 is required
for this conformational change, or whether shorter ubiquitin chains would suffice. In
other words, is there a minimal ubiquitin chain length required for creation of the bind-
ing site? To determine this, I originally planned to ubiquitinate Hrd1 with K48-linked
ubiquitin chains of predetermined lengths, as was performed in a previous study with
Hrd1 in detergent (Baldridge and Rapoport, 2016). However, the loading of di, tri and
tetra-ubiquitin to the E1 enzyme Uba1 was inefficient, even at high concentrations of
Uba1 (data not shown). Therefore, I first tested whether monoubiquitination of Hrd1
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with K48R ubiquitin, which cannot form K48-linked chains, is sufficient for cytosolic
substrate binding. When reconstituted into liposomes and incubated with ubiquiti-
nation mix containing K48R ubiquitin, Hrd1 was monoubiquitinated primarily at one
or two positions, and a fraction was monoubiquitinated at multiple positions (Figure
3.37A, note the single modified band vs the smear). Hrd1 liposomes were immobi-
lized onto streptavidin magnetic beads and monoubiquitinated with K48R ubiquitin.
CPY* did not bind to monoubiquitinated Hrd1 above background binding to the beads,
whereas binding was efficient when WT ubiquitin was present in the ubiquitination mix
(Figure 3.37B, lanes 5 vs 3, lanes 10 vs 8). Thus, monoubiquitination of Hrd1 is not
sufficient to create the cytosolic substrate binding site.
Monoubiquitinated Hrd1 was also tested in the PLB assay. We did not observe any
fusions with the PLB when Hrd1 was ubiquitinated with K48R ubiquitin, indicating
that monoubiquitination of Hrd1 is also not sufficient for channel formation (Figure
3.44A).
Figure 3.37: Monoubiquitinated Hrd1 does not bind cytosolic CPY*
A: Liposomes containing Hrd1 (200 nM) were incubated with ubiquitination machinery
including K48R ubiquitin. Timepoints were analyzed by SDS-PAGE and fluorescence
scanning. B: Hrd1 liposomes (250 nM Hrd1) were immobilized and ubiquitinated as in
Figure 3.35, but with K48R ubiquitin. CPY* (40 nM) was added and input, unbound
(supernatants) and biotin elutions were analyzed by SDS-PAGE and fluorescence scan-
ning.
As another method to test CPY* binding to multi-monoubiquitinated Hrd1, I recon-
stituted Hrd1 into liposomes along with the E2 enzyme Ubc6, which catalyzes multi-
monoubiquitination of Hrd1 in the absence of Ubc7 and Cue1-c (Figure 3.14, Weber
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et al., 2016). Hrd1/Ubc6 liposomes were immobilized onto streptavidin magnetic beads
and incubated with ubiquitination machinery with or without Ubc7 and Cue1-c. Very
minimal binding of CPY* was observed when Ubc7 and Cue1-c were omitted (Figure
3.38A, lanes 6 and 15). In contrast, CPY* bound efficiently when Ubc7 and Cue1-c
were included in the ubiquitination mix (Figure 3.38A, lanes 3-5, 12-14). No CPY*
binding was observed in any condition when ATP was omitted, as expected (Figure
3.38A, lanes 7-10, 16-19). Ubiquitin chains attached to Hrd1 were considerably shorter
in the presence of Ubc6 alone compared to when Ubc7 and Cue1-c were present (Fig-
ure 3.38B, lane 5 compared to lanes 2-4). Interestingly, Hrd1 was more efficiently
ubiquitinated by Ubc6 and Ubc7/Cue1-c together than with Ubc7 and Cue1-c alone
(Figure 3.38B, lane 4 vs 2 and 3). However, no additional CPY* binding was observed
compared to when Hrd1 was ubiquitinated with only Ubc7 and Cue1-c (Figure 3.38A,
lanes 5 vs 3 and 4).
This result confirmed that multi-monoubiquitination of Hrd1 is not sufficient for cy-
tosolic CPY* binding. Polyubiquitination by Ubc7 and Cue1-c is clearly sufficient, but
the minimum chain size required for the creation of the binding site is still unknown.
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Figure 3.38: Hrd1 multi-monoubiquitination by Ubc6 does not a create cy-
tosolic binding site
A: Hrd1 was reconstituted into liposomes alone or along with Ubc6. Liposomes (250
nM Hrd1 and Ubc6, respectively) were immobilized onto streptavidin magnetic beads
and ubiquitinated with or without Ubc7 and Cue1-c. CPY* (500 nM) was then added
and input, unbound (supernatants) and biotin elutions were analyzed by SDS-PAGE
and fluorescence scanning to detect CPY* Lanes labeled Ubc7: Hrd1-only liposomes
ubiquitinated with Ubc7 and Cue1-c. Lanes labeled Ubc6: Hrd1/Ubc6 liposomes
ubiquitinated without Ubc7 and Cue1-c. Lanes labeled Ubc6+7: Hrd1/Ubc6 liposomes
ubiquitinated with Ubc7 and Cue1-c. Two replicates of Ubc7 are shown. B: Biotin
elutions from (A) were analyzed by western blotting against the SBP tag to detect
Hrd1.
3.9.4 CPY* does not bind to polyubiquitin chains alone
I next tested whether polyubiquitin chains alone, without the context of being attached
to Hrd1, were sufficient to bind CPY*. To this end, I reconstituted Ubc6 containing
a C-terminal SBP tag into liposomes and immobilized the liposomes onto streptavidin
magnetic beads. In order to attach K48-linked polyubiquitin chains onto Ubc6, the
liposomes were incubated on beads with the soluble RING domain of Doa10 along
with Ubc7 and Cue1-c. As a positive control, liposomes containing Hrd1 or Hrd1
and Ubc6 were included. CPY* did not bind efficiently to polyubiquitinated Ubc6
but bound efficiently to Hrd1 and Hrd1/Ubc6 liposomes, as expected (Figure 3.39,
lane 5 compared to lanes 3 and 4 and lane 12 compared to lanes 10 and 11). The
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polyubiquitin chains attached to Ubc6 appeared to be shorter than those attached to
Hrd1 (Figure 3.39, lane 12 compared to 10), although this could also be explained by
similar-sized ubiquitin chains attached to fewer lysine residues in Ubc6 compared to
Hrd1. Therefore, I concluded that CPY* does not bind to K48-linked polyubiquitin
chains alone. Rather, polyubiquitination of Hrd1 causes a conformational change which
may expose a hydrophobic binding pocket for misfolded proteins.
Figure 3.39: CPY* does not bind to polyubiquitin chains attached to Ubc6
Liposomes containing Ubc6-SBP (250 nM), Hrd1-SBP (250 nM), or Hrd1-SBP/Ubc6
(250 nM each) were immobilized onto streptavidin magnetic beads. Ubc6-SBP lipo-
somes were polyubiquitinated with the Doa10 RING domain in conjunction with Ubc7
and Cue1-c. Hrd1 and Hrd1/Ubc6 liposomes were ubiquitinated with the standard
ubiquitination mix containing Ubc7 and Cue1-c. CPY* (500 nM) was added and in-
put, unbound (Sup.) and biotin elutions (Elut.) were analyzed by SDS-PAGE and
fluorescence scanning. CPY* was labeled with DL800 and Hrd1 and Ubc6 were both
labeled with DL680. The gel was cropped to remove irrelevant lanes.
3.9.5 Deubiquitination of Hrd1 partially releases bound substrate
In addition to deubiquitination closing the Hrd1 channel, I asked if deubiquitination of
Hrd1 releases substrate bound on the cytoplasmic side. This release of substrate may
be an important step in the retrotranslocation of substrates which do not get ubiqui-
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tinated, such as cholera toxin and yeast pro-α-factor (Bernardi et al., 2010, 2013). In
fact, the overexpression of a catalytically inactive DUB impeded cholera toxin retro-
translocation (Bernardi et al., 2013). To test if the bound substrate is released upon
deubiquitination, I immobilized Hrd1 liposomes, incubated them with ubiquitination
machinery, and added CPY*. The immobilized complex was treated with the DUB
Usp2 and the supernatant and elution fractions were analyzed. CPY* was released
into the supernatant when Usp2 was added (Figure 3.40A, lane 4 vs 3), indicating
that cytosolic substrate binding was indeed reversible. Analysis of the elution fractions
confirmed that Hrd1 was completely deubiquitinated after Usp2 incubation (lane 6 vs
5). About 30% of bound CPY* was released after Usp2 treatment, although Hrd1 was
completely deubiquitinated (Figure 3.40B). This indicates that only a fraction of bound
CPY* was releasable, which could have been due to aggregation or CPY* sticking to
the beads after release from Hrd1.
Figure 3.40: CPY* partially dissociates from Hrd1 upon deubiquitination
of Hrd1
A: Hrd1 (250 nM) in liposomes was immobilized onto streptavidin magnetic resin
and incubated with ubiquitination machinery. CPY* (50 nM) was added to form a
Hrd1/CPY* complex. The input and unbound (lanes 1 and 2) shows that the majority
of CPY* bound to Hrd1. Beads were then treated with buffer or Usp2 (2 µM) and
supernatants were collected. The beads were subsequently washed and eluted with
biotin. Samples were analyzed by SDS-PAGE and fluorescence scanning. B: Fraction
of CPY* released was determined by quantification of the elution fractions, normalized
to the sample without Usp2. Shown is mean ± standard deviation (n=3).
111
Chapter 3 Results
3.10 Autoubiquitination of the Hrd1 RING domain is
essential for substrate binding and channel
stability
In order to determine which ubiquitination sites in Hrd1 are important for cytoso-
lic substrate binding, I utilized mutants in which lysine residues in different regions
of Hrd1 were mutated to arginine (KxR mutants, Figure 3.41A) (Stein et al., 2014).
Arginine residues have a similar structure to lysine residues but cannot be ubiquiti-
nated because they lack the primary ε-amine (Pickart, 2001). In detergent, some KxR
mutants showed reduced autoubiquitination, but this did not completely correlate with
CPY* ubiquitination (Stein et al., 2014). This may have been due to CPY* binding
to transmembrane domains that would otherwise be occluded in the membrane. The
Baldridge study later demonstrated that the KRK mutant was incapable of catalyzing
substrate retrotranslocation in vitro and was defective in CPY* degradation in vivo,
whereas the RKK and KKR mutants were unaffected (Baldridge and Rapoport, 2016).
This study also demonstrated that three lysine residues in the RING domain of Hrd1
(373, 387 and 407, referred to as the 3K mutant) were essential for CPY* degradation.
With this in mind, I asked how these KxR mutants, particularly KRK, behaved in
cytosolic substrate binding assays.
Because I observed that autoubiquitination of Hrd1 was critical for cytosolic substrate
binding, and because autoubiquitination of the KxR mutants has never been tested in a
membrane environment, I first reconstituted the KxR mutants in liposomes and checked
their autoubiquitination. The KxR mutants showed significantly reduced ubiquitina-
tion efficiency compared to WT Hrd1, with KRK and 3K mutants showing slightly
lower ubiquitination efficiency than KKR (Figure 3.41B and quantification in Figure
3.42A). Ubiquitination was almost completely abolished in the KRR mutant, which
has no lysine residues in the cytoplasmic region. Although the KKR mutant showed a
similar autoubiquitination efficiency to KRK and 3K mutants, the ubiquitin chains ap-
peared to be longer. The results show that the lysine residues in the RING domain are
the primary ubiquitination sites in Hrd1, particularly for long ubiquitin chains. The
C-terminal extension is also ubiquitinated, but with shorter chains. The 3K mutant
showed very similar autoubiquitination efficiency to the KRK mutant, indicating that
lysine residues 373, 387 and 407 are the primary ubiquitination sites within the RING
domain of Hrd1 (Figures 3.41B, 3.42A).
CPY* was also included in the reaction to check the effects of differential Hrd1 autoubiq-
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uitination on substrate ubiquitination. The ubiquitination efficiency of CPY* mostly
mirrored the trend in Hrd1 autoubiquitination efficiency, with KRR, KRK and 3K mu-
tants showing markedly less CPY* ubiquitination than WT Hrd1 (Figure 3.41B and
quantification in Figure 3.42B). Interestingly, The KKR mutant ubiquitinated CPY*
with similar efficiency to WT Hrd1, although its overall autoubiquitination efficiency
was impaired. This result indicated that autoubiquitination of the RING domain, not
overall autoubiquitination efficiency, is the primary factor in efficient substrate ubiqui-
tination. It is also worth noting that the effects on autoubiquitination and substrate
ubiquitination in the KxR mutants were significantly different in the membrane en-
vironment of liposomes than what was previously observed in detergent (Stein et al.,
2014).
Figure 3.41: Hrd1 lysine to arginine mutants show differential autoubiqui-
tination and CPY* ubiquitination efficiencies
A: Top: Scheme of Hrd1 KxR mutants, in which lysine residues (K) in different regions
of Hrd1 are mutated to arginine. Below: Ubiquitination reaction scheme. CPY* was
present during ubiquitination. B: Liposomes containing Hrd1 WT or KxR mutants
(200 nM) were incubated with ubiquitination machinery in the presence of CPY* (100
nM). Timepoints were analyzed by SDS-PAGE and fluorescence scanning.
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Figure 3.42: Quantification of Hrd1 autoubiquitination and CPY* ubiquiti-
nation by Hrd1 KxR mutants
Quantification of Hrd1 autoubiquitination (A) and CPY* ubiquitination (B) from Fig-
ure 3.41, normalized to the 0 min timepoint. Shown are means from three experiments.
Error bars indicate standard deviation.
3.10.1 Autoubiquitination of the Hrd1 RING domain is required
for efficient cytosolic substrate binding
I reasoned that because Hrd1 mutants lacking lysine residues in the RING domain
ubiquitinated CPY* inefficiently (Figure 3.42B), they would also have a lower affinity
for cytosolic CPY*. I performed titration experiments of autoubiquitinated Hrd1 KxR
mutants against CPY* and found that indeed, the KRR, KRK and 3K mutants had
substantially lower affinity for CPY* than WT Hrd1 (Figure 3.43).The KRK and 3K
mutants behaved identically in CPY* binding, matching what was observed for CPY*
ubiquitination (compare binding in Figure 3.43 to ubiquitination in Figure 3.42B), and
demonstrating that autoubiquitination in the RING domain is essential for efficient
cytosolic substrate binding. The KRR mutant had a lower affinity for CPY* than
KRK/3K, which indicated that Hrd1 autoubiquitination at C-terminal lysine residues
also has a positive effect in substrate binding. This was further supported by the obser-
vation that the KKR mutant displayed a higher affinity for CPY* than the KRK/3K
and KRR mutants, but still had a lower affinity than WT Hrd1.
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Figure 3.43: Titration of Hrd1 KxR mutants in liposomes against cytosolic
CPY*
Liposomes containing WT Hrd1 or Hrd1 KxR mutants were immobilized on strepta-
vidin magnetic resin at increasing concentrations, ubiquitinated, and incubated with
CPY* (20 nM). The input and unbound fractions were detected by fluorescence scan-
ning in a 384 well plate. Fraction bound was determined by quantification of the un-
bound fractions, normalized to the unbound fraction in the beads only control. Shown
are means ± standard deviations (n=3).
Overall, these results give insight into the role of autoubiquitination of the RING
domain vs cytoplasmic tail of Hrd1 and demonstrate that autoubiquitination of the
RING domain is the primary factor in creation of a high affinity substrate binding site
in the cytosol. This interaction on the cytoplasmic side of Hrd1 is required for efficient
substrate ubiquitination.
3.10.2 Autoubiquitination of the RING domain is essential for
channel stability and substrate activation
Autoubiquitination of the Hrd1 RING domain was shown to be essential for retro-
translocation of CPY*-TM in vitro as well as for CPY* degradation in vivo (Baldridge
and Rapoport, 2016; Neal et al., 2018). Having observed that autoubiquitination of
the RING domain was critical for cytosolic substrate binding and efficient substrate
polyubiquitination, we asked whether it was also important for channel activity. Using
the PLB system in collaboration with Dr. Niels Denkert, we reconstituted Hrd1 KRK
into liposomes, added ubiquitination machinery, and attempted to fuse these liposomes
with the PLB. Interestingly, ubiquitinated KRK liposomes fused with the PLB with a
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similar rate as WT Hrd1 (Figure 3.44A), although the autoubiquitination of this mu-
tant was significantly inhibited (Figure 3.41, 3.42). However, we observed that these
channels were highly unstable and conductance was suddenly reduced to 0 within min-
utes (Figure 3.44B, C). The channel closure was very sudden, occurring within seconds
(Figure 3.44B). The half-time of KRK channels was less than 2 minutes, whereas WT
channels were stable for upwards of 30 minutes (Figure 3.44C). The channel closure
appeared to be irreversible because we never observed any conductance after initial
closure. When CPY* was added to both sides of the membrane after channel closure,
it was unable to reactivate the closed channel (Figure 3.44D). Therefore, autoubiquiti-
nation of the RING domain is critical for channel stability. However, it is not explicitly
required for channel formation, because channels did still form without RING domain
autoubiquitination. It seems that residual ubiquitination in the C-terminal extension
is sufficient to form short-lived channels. Accordingly, the KRR mutant, which showed
almost no autoubiquitination (Figures 3.41, 3.42), was unable to fuse to the PLB, in-
dicating that it cannot form channels (Figure 3.44A). These results provide further
molecular insight into the ERAD-L defect observed in the KRK mutant (Baldridge
and Rapoport, 2016; Neal et al., 2018).
We also observed that monoubiquitination of Hrd1 with K48R ubiquitin was insufficient
for channel formation, as we observed no fusions to the PLB in this case (Figure
3.44A, see section 3.9.3). This mirrors the lack of cytosolic substrate binding observed
with monoubiquitinated Hrd1 (Figures 3.37 and 3.38), demonstrating that channel
formation and substrate binding appear to be coupled.
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Figure 3.44: Hrd1 KRK mutant forms highly unstable channels
A: Fusion rates of polyubiquitinated KRK Hrd1, KRR Hrd1 as well as WT Hrd1
monoubiquitinated with K48R ubiquitin, (relative rate compared to polyubiquitinated
WT Hrd1). Shown are means ± SEM (n=3). B: Representative current trace of a Hrd1
KRK channel, at a holding potential of -10 mV. Notice the sudden channel closure at
around 25 s. Dashed lines refer to closed (c) and open (o1) states of the channel. C:
Quantification of channel lifetime expressed as the fraction of open channels at each
timepoint compared to all channels observed for WT and KRK, respectively. n=6
independent experiments for WT and 11 for KRK. D: Current traces of closed KRK
channels at +60 and -60 mV, without CPY* (left) and with the addition of 100 nM
CPY* to both sides of the chamber (right). CPY* was unable to reactivate the closed
channels. Experiments and analysis were performed by Dr. Niels Denkert (University
Medical Center, University of Göttingen and Max Planck Institute for Biophysical
Chemistry).
3.10.3 Lysines in the RING domain are not required for Hrd1
ubiquitin ligase activity
I next asked whether the presence of lysines in the RING domain is required for Hrd1
ubiquitin ligase activity. It could be that mutation of lysine residues in the RING
domain, such as in the KRK mutant, inhibits the activity of the RING domain. Al-
ternatively, it might be that ubiquitin ligase activity is not affected by the presence of
these lysines, and only autoubiquitination sites are affected. To differentiate between
these two possibilities, I coreconstituted Hrd1 KRK with the E2 enyzme Ubc6. Be-
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cause Ubc6 has been shown to catalyze monoubiquitination of serine and threonine
residues, in addition to lysine residues (Weber et al., 2016), I hypothesized that it
would catalyze Hrd1 autoubiquitination even in the KRK mutant. As shown in Figure
3.45A and B, Hrd1 KRK autoubiquitination efficiency was comparable with WT Hrd1
and the KKR mutant in the presence of Ubc6 and Ubc7/Cue1-c. This indicates that
Hrd1 ubiquitin ligase activity is maintained in the KRK mutant. Interestingly, cytoso-
lic CPY* was also ubiquitinated with similar efficiency, although the ubiquitin chains
were shorter in the KRK mutant (Figure 3.45A, B). This result implies that the affin-
ity of the KRK mutant towards cytosolic substrates was rescued by Ubc6-catalyzed
autoubiquitination with Ubc7 and Cue1-c. It is not clear, however, which regions of
Hrd1 are monoubiquitinated by Ubc6.
Figure 3.45: Hrd1 ubiquitin ligase activity is maintained in the KRKmutant
A: Liposomes containing coreconstituted Hrd1 and Ubc6 (200 nM each) were mixed
with CPY* (100 nM) and ubiquitination machinery including Ubc7/Cue1-c. Time-
points were analyzed by SDS-PAGE and fluorescence scanning. B: Quantification of
Hrd1 and CPY* ubiquitination from (A).
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3.11 Binding of substrates to the luminal side of Hrd1
We observed in PLB experiments that addition of CPY* stimulated Hrd1 channel ac-
tivity only when added to the luminal side (Figure 3.33). This result implied that Hrd1
contains a luminal substrate binding site. Because the luminal side of Hrd1 is not easily
accessible in liposomes, I reconstituted Hrd1 into lipid nanodiscs to investigate luminal
binding of substrates to Hrd1. Nanodiscs are discoidal phospholipid bilayers enclosed
by amphipathic membrane scaffold proteins derived from apolipoproteins (Denisov and
Sligar, 2017). Nanodiscs have the advantage that both sides of the membrane are ac-
cessible. Furthermore, they keep membrane proteins close to their native state in a
phospholipid bilayer, while maintaining solubility in aqueous solutions. I reasoned that
because there was no cytosolic substrate binding observed when Hrd1 was in the nonu-
biquitinated state, if substrate binding were to be observed to Hrd1 in nanodiscs, it
would have to originate from the luminal side.
3.11.1 Overview of Hrd1 reconstitution into nanodiscs
Nanodiscs are formed by self-assembly of phospholipids, scaffold protein and the desired
membrane proteins to be incorporated (Denisov and Sligar, 2017). Phospholipids are
normally solubilized in detergent and mixed with the scaffold protein and the desired
membrane protein, also in detergent. Upon gradual removal of detergent, nanodiscs
self-assemble and incorporate the desired membrane protein into the phospholipid bi-
layer. There are a variety of factors that determine the size and shape of nanodiscs.
The diameter of the nanodiscs is primarily determined by the characteristics of the
scaffold protein used and the corresponding scaffold:lipid ratio. The major factors in
the homogeneity and overall efficiency of membrane protein incorporation into nan-
odiscs are the scaffold:target protein:lipid ratio, the solubilization detergent, speed of
detergent removal, lipid composition, and temperature (Denisov and Sligar, 2017).
Due to heterogeneity in the oligomeric state of Hrd1 after purification, higher molecular
weight oligomers would most likely require larger nanodiscs for efficient incorporation.
Of the widely-used scaffold proteins developed by the Sligar lab, the MSP2N constructs
form the largest nanodiscs, with diameters of up to 17 nm (Grinkova et al., 2010). More
recently however, studies emerged describing the use of the 22 kDa N-terminal domain
of ApoE (ApoE422K), which forms nanodiscs with diameters of up to 33 nm (Chromy
et al., 2007; Bello et al., 2016).
For this reason, ApoE422K was chosen as the scaffold protein for reconstitution of Hrd1
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into nanodiscs. I initially used DMNG as the solubilizing detergent, because this is
best compatible with Hrd1 reconstitution. To solubilize phospholipids, normally a lipid
film is rehydrated in buffer containing an excess of detergent. However, DMNG was
very poor in solubilizing a lipid film (personal communication from Alexander Stein).
Therefore, I made empty POPC liposomes as the starting lipid material and solubilized
them with an excess of DMNG (Figure 3.46). This was mixed with ApoE422K and
Hrd1 in DMNG and incubated overnight. Following detergent removal, nanodiscs were
characterized by size-exclusion chromatography.
Figure 3.46: Reconstitution scheme of Hrd1 into nanodiscs by solubilization
of empty liposomes with DMNG
Preformed POPC liposomes with an average diameter of 100 nm were solubilized with
a 2.5-fold molar excess of DMNG. Following solubilization, ApoE422K and Hrd1 were
added at an optimized ApoE:Hrd1:lipid ratio (see text in following section for details).
Upon DMNG removal, Hrd1 nanodiscs formed by self-assembly and were characterized
by size-exclusion chromatography.
3.11.2 Optimization of nanodisc assembly with Hrd1 and ApoE
using DMNG
One of the major variables in nanodisc reconstitution is the scaffold:lipid ratio. Before
incorporating Hrd1, I first screened for ratios that result in homogeneous nanodiscs. I
tested ApoE:POPC molar ratios of 1:120, 1:180 and 1:290, which were previously char-
acterized in an earlier reconstitution protocol using ApoE422K (Bello et al., 2016).
Nanodisc size and homogeneity were analyzed by size exclusion chromatography on a
Superose 6 5/15 GL column. Ratios of 1:180 and 1:120 produced relatively homoge-
neous nanodiscs, with 1:120 resulting in smaller nanodiscs than 1:180 (Figure 3.47A).
At a ratio of 1:290, most of the nanodiscs eluted in the void volume, indicating that they
were either very large or aggregated. Therefore, I concluded that a 1:180 ApoE:POPC
ratio was a good starting point for Hrd1 reconstitution.
I next incorporated Hrd1 into nanodiscs, using an ApoE:POPC ratio of 1:160. ApoE
concentration was slightly increased from 1:180 to 1:160 in order to account for the
extra nanodiscs formed from the phospholipids displaced by Hrd1 incorporation. Al-
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ternatively, lipid concentration could be decreased instead of increasing scaffold con-
centration. I varied the ApoE:Hrd1:lipid ratio by correspondingly increasing the con-
centration of POPC and ApoE, which thereby decreases the Hrd1:lipid ratio. With an
ApoE:Hrd1:lipid ratio of 1:0.25:160, the majority of the nanodiscs eluted in the void
(Figure 3.47B, black trace). Incrementally increasing the lipid and ApoE concentra-
tion resulted in a correspondingly lower fraction of nanodiscs in the void. Overall,
an ApoE:Hrd1:lipid ratio of 1:0.062:160 was determined to be optimal (Figure 3.47B,
magenta trace).
Figure 3.47: Optimization of ApoE:Hrd1:lipid ratio in nanodisc reconstitu-
tions
A: Size exclusion chromatography of empty nanodiscs with varying ApoE:POPC ratios.
Nanodiscs were injected onto a Superose 6 5/15 GL column and absorbance at 280 nm
was monitored to detect ApoE. B: Size exclusion chromatography of Hrd1 nanodiscs
with varying ApoE:Hrd1:POPC ratios on a Superose 6 5/15 GL column.
In order to further characterize the reconstitution, Hrd1 nanodiscs were prepared with
the optimal 1:0.062:160 ratio and rhodamine-PE was included in the lipid mix. Nan-
odiscs were injected onto a Superose 6 5/15 GL column and lipids were monitored by
measuring the rhodamine absorbance at 570 nm. The lipids displayed exactly the same
elution profile as the ApoE/Hrd1, measured by absorbance at 280 nm (Figure 3.48A).
Analysis of the size-exclusion fractions by SDS-PAGE showed that the lipid-containing
peak also contained Hrd1 and ApoE (Figure 3.48B). These results indicated that ApoE
and Hrd1 were reconstituted into lipid-containing nanodiscs. The gel showed a higher
ratio of ApoE:Hrd1 in the second half of the peak than in the first half, which likely cor-
responded to smaller, empty nanodiscs. This result demonstrated that Hrd1-containing
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nanodiscs could in principle be further separated from empty nanodiscs by size or den-
sity. Finally, the void also contained lipids, Hrd1, and ApoE, indicative of either very
large or aggregated nanodiscs.
Figure 3.48: Characterization of lipid and protein content in Hrd1 nanodiscs
A: Size-exclusion chromatography of Hrd1 nanodiscs with an ApoE:Hrd1:POPC ratio
of 1:0.062:160, with 0.5% rhodamine-PE included in the lipid mix. Nanodiscs were
injected onto a Superose 6 5/15 GL column and lipids were monitored by measuring
absorbance at 570 nm. ApoE and Hrd1 were monitored by measuring absorbance at
280 nm. B: Fractions from size exclusion chromatography in (A) were analyzed by
SDS-PAGE and coomassie staining.
3.11.3 Reconstitution of Hrd1 into nanodiscs using DM
Using DMNG to solubilize performed liposomes was a viable method to reconstitute
Hrd1 into ApoE nanodiscs, but there was a potential for liposome contamination from
incomplete solubilization of the liposomes. In the meantime, I observed that DM
was a viable detergent for Hrd1 reconstitution into liposomes (Section 3.3.1). DM
is also capable of fully solubilizing a lipid film at high concentrations, which avoids
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the contamination of partially-solubilized liposomes. Therefore, a POPC lipid film
containing 0.5% rhodamine PE was solubilized with 2% DM and was used as the lipid
source, modifying the nanodisc reconstitution described in sections 3.11.1-3.11.2. After
detergent removal, DM nanodiscs were analyzed by size exclusion chromatography
using a Superose 6 10/300 GL column. DM-mediated reconstitution resulted in fewer
nanodiscs eluting in the void than the DMNG method (Figure 3.49A). Additionally,
lipids coeluted with ApoE and Hrd1, as determined by absorbance of rhodamine-PE
at 560 nm. Therefore, I proceeded from here on with DM-mediated reconstitution of
Hrd1 into nanodiscs.
In order to better separate Hrd1-containing nanodiscs from empty nanodiscs, the nan-
odiscs were purified by glycerol gradient centrifugation. This method separates nan-
odiscs based on density, whereas size-exclusion chromatography separates nanodiscs
based on the hydrodynamic radius. Hrd1 and ApoE were present in two overlap-
ping peaks after gradient centrifugation, indicating that Hrd1-containing nanodiscs
were separated from empty nanodiscs (Figure 3.49B). This demonstrated that Hrd1-
containing nanodiscs were denser than empty nanodiscs, in addition to having a larger
hydrodynamic radius (Figure 3.48). The Hrd1-containing fractions were pooled and
further characterized.
Figure 3.49: Reconstitution of Hrd1 into nanodiscs with DM
A: Hrd1 was reconstituted into nanodiscs using either DMNG-solubilized POPC lipo-
somes (red) or a DM-solubilized POPC lipid film (black). Both lipid sources contained
0.5% rhodamine PE. Nanodiscs were injected onto a Superose 6 10/300 GL column
and protein and lipid content were monitored by absorbance at 280 and 560 nm, re-
spectively. B: Hrd1 was reconstituted into nanodiscs using the DM-lipid film method
and the nanodiscs were centrifuged in a 10-30% (w/v) glycerol gradient. Fractions were
analyzed by SDS-PAGE and coomassie staining.
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3.11.4 Structural and biochemical characterization of Hrd1
nanodiscs
After purification of Hrd1 nanodiscs by glycerol gradient centrifugation, they were
structurally characterized by negative stain electron microscopy (Dr. Dietmar Riedel,
Department of Structural Dynamics, Max Planck Institute for Biophysical Chemistry).
The nanodiscs were heterogeneous in size, primarily ranging from 20-60 nm in diameter
(Figure 3.50A, B). The heterogeneity was most likely because Hrd1 is in a heterogeneous
oligomeric state after purification. The electron microscopy analysis also showed that
the preparation was almost entirely free of liposome contamination, because liposomes
normally appear as deflated spheres in negative stain electron microscopy (Franken
et al., 2017). The discoidal structures we observed were completely flat.
Gradient-purified Hrd1 nanodiscs were additionally characterized by a pull-down ex-
periment to check for the fraction of empty nanodiscs in the sample. Nanodiscs were
immobilized on streptavidin magnetic beads through the SBP tag of Hrd1. ApoE
was almost completely co-depleted with Hrd1, indicating that empty nanodiscs were
efficiently removed by gradient centrifugation (Figure 3.50C).
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Figure 3.50: Structural and biochemical characterization of Hrd1 nanodiscs
A: Representative negative-stain electron microscopy image of Hrd1 nanodiscs. B: Size
distribution histogram of Hrd1 nanodiscs. Electron microscopy and size distribution
analysis was performed by Dr. Dietmar Riedel, Department of Structural Dynamics,
Max Planck Institute for Biophysical Chemistry. C: Hrd1 nanodiscs at two different
concentrations of Hrd1 were immobilized on streptavidin magnetic beads through the
SBP-tag of Hrd1. BSA was included to reduce non-specific binding to the beads.
Input and unbound fractions (In and Sup) were analyzed by SDS-PAGE and coomassie
staining.
3.11.5 Hrd1 ubiquitination activity in nanodiscs
The activity of Hrd1 reconstituted in nanodiscs was determined by a ubiquitination
assay in the presence of CPY*. Hrd1 autoubiquitination in nanodiscs was compa-
rable in both kinetics and overall efficiency to Hrd1 in liposomes (Figure 3.51A, C).
Likewise, Hrd1 ubiquitinated CPY* with similar efficiency and kinetics in nanodiscs
compared to Hrd1 in liposomes (Figure 3.51B, C). The presence of CPY* did not affect
Hrd1 autoubiquitination kinetics compared to Hrd1 nanodiscs alone. Therefore, Hrd1
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reconstituted in ApoE nanodiscs is active.
Figure 3.51: Ubiquitination activity of Hrd1 in nanodiscs
A, B: Hrd1 nanodiscs (200 nM Hrd1) were incubated with ubiquitination machin-
ery in the presence of CPY* (100 nM). Timepoints were analyzed by SDS-PAGE and
fluorescence scanning. C: Quantification of Hrd1 autoubiquitination and CPY* ubiqui-
tination in nanodiscs and liposomes, from three experiments. The data for the liposome
experiments is the same as in Figure 3.34, plotted here for comparison purposes. Shown
are means ± standard deviations. The data was fit with a single-exponential decay
function for visualization of ubiquitination kinetics.
3.11.6 CPY* binds to nonubiquitinated Hrd1 in nanodiscs
Using Hrd1 reconstituted in nanodiscs, binding of CPY* to non-ubiquitinated Hrd1
was investigated. Hrd1 nanodiscs were immobilized onto streptavidin magnetic beads
and incubated with increasing concentrations of CPY* or CPY WT. Strikingly, CPY*
bound to non-ubiquitinated Hrd1, and the apparent KD of the interaction was approx-
imately 150 nM (Figure 3.52). In contrast, CPY WT showed almost no binding to
non-ubiquitinated Hrd1 across the range of Hrd1 concentrations tested. Considering
that non-ubiquitinated Hrd1 in liposomes (where only the cytoplasmic side is accessi-
ble) showed no affinity to CPY*, the binding to Hrd1 nanodiscs most likely originated
from the luminal side of Hrd1. This result demonstrates that Hrd1 alone can differen-
tiate misfolded proteins from correctly folded proteins with its luminal domain.
When Hrd1 nanodiscs were ubiquitinated on beads, the affinity for CPY* drastically
increased (Figure 3.52), mirroring what was observed with ubiquitinated Hrd1 in lipo-
somes (Figure 3.36). CPYWT also partially bound to ubiquitinated Hrd1 in nanodiscs,
similar to what was observed with ubiquitinated Hrd1 in liposomes. The binding ob-
served to ubiquitinated Hrd1 in nanodiscs is most likely from the cytosolic binding
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site, although it cannot be excluded that binding to the luminal side also occurs in
the ubiquitinated state. Because data points at very low Hrd1 concentrations were
missing, it was not possible to determine a reliable KD value for ubiquitinated Hrd1 in
nanodiscs and CPY*.
Overall, these data indicated that CPY* most likely binds to the luminal side of Hrd1,
with a KD one order of magnitude lower than the cytosolic binding observed with ubiq-
uitinated Hrd1 in liposomes (approximately 150 nM vs 7 nM, respectively. Compare
Figure 3.52 with Figure 3.36). This affinity gradient for substrates from the luminal
to the cytosolic side may provide the initial driving force and directionality during
retrotranslocation of misfolded proteins through Hrd1 (see Discussion, section 4.6 for
further details).
Figure 3.52: Differential binding of CPY* to nonubiquitinated and ubiqui-
tinated Hrd1 in nanodiscs
Increasing concentrations of Hrd1 were immobilized onto streptavidin magnetic beads
and incubated with 20 nM CPY* or 20 nM CPY WT (referred to as nonubiq.). Al-
ternatively, Hrd1 nanodiscs were poly-ubiquitinated on beads with ubiquitination mix
and then incubated with 20 nM CPY* or 20 nM CPY WT (referred to as ubiq.). The
input and unbound fractions were analyzed by fluorescence scanning in a 384 well plate.
Fraction bound was quantified from the unbound fraction, normalized to the unbound
fraction in the beads-only control. Shown are means ± standard deviation from three
experiments. Data were fit with a single-exponential one-site binding model, from




4.1 The fusion system as a method to study
retrotranslocation
This thesis concerned itself with understanding how luminal misfolded proteins get
retrotranslocated by the Hrd1 complex during ERAD. Of the different classes of sub-
strates degraded by the Hrd1 complex, luminal soluble misfolded proteins are of par-
ticular interest because they require a protein-conducting channel spanning the entire
ER membrane. As it is not clear how the Hrd1 complex accomplishes this feat, I
aimed to reconstitute the process with purified components to investigate the mecha-
nism of retrotranslocation in detail. Reconstitution with purified components was the
method of choice, because this allows for the sufficiency of individual components to
be addressed, as well as direct mechanistic details to be drawn.
A substantial amount of evidence has led to the hypothesis that the Hrd1 ubiquitin
ligase forms the retrotranslocon, while the other components in the complex perform
regulatory functions (Carvalho et al., 2010; Stein et al., 2014; Baldridge and Rapoport,
2016; Schoebel et al., 2017) (see section 1.9). Two previous reconstitutions of Hrd1-
mediated retrotranslocation with purified components formed the basis for much of the
current biochemical understanding of Hrd1. However, these studies did not faithfully
recapitulate the retrotranslocation of luminal substrates due to technical reasons or
experimental design (Stein et al., 2014; Baldridge and Rapoport, 2016). In the study
by Stein and colleagues, a Hrd1 and CPY* complex was formed in detergent, which
was coreconstituted into liposomes. Although CPY* was ubiquitinated by Hrd1 and
extracted from the membrane by the Cdc48 complex, CPY* was accessible to proteases,
indicating that it was not encapsulated in the lumen (Stein et al., 2014). In the study
by Baldridge and Rapoport, CPY* was encapsulated into liposomes through the use of
a transmembrane domain. Thereafter, the liposomes were solubilized with detergent
in order to incorporate Hrd1. Strikingly, CPY* was exposed to the cytosol upon
Hrd1 autoubiquitination, showing that Hrd1 retrotranslocates CPY* (Baldridge and
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Rapoport, 2016). However, due to the possibility that the transmembrane domains of
Hrd1 interacted with CPY* during detergent-mediated Hrd1 incorporation, it is still
not clear if Hrd1 can retrotranslocate a luminal substrate “de novo” (see section 1.10.1).
To overcome these limitations, I encapsulated CPY* into liposomes and delivered it
to Hrd1-containing liposomes by SNARE-mediated fusion (see section 3.1.1). This fu-
sion system recapitulates retrotranslocation faithfully because it allows Hrd1 to access
a substrate on its luminal side without the use of detergent. I then initiated retro-
translocation by adding components of the cytosolic ubiquitination machinery, as Hrd1
autoubiquitination was demonstrated to open the channel (Baldridge and Rapoport,
2016). I monitored the ubiquitination status of the substrate as a readout for retro-
translocation, since it can only be ubiquitinated when it emerges into the cytosol. I was
not able to conclusively demonstrate with this system that Hrd1 can retrotranslocate
luminal substrates. However, several technical limitations such as substrate aggrega-
tion made it difficult to draw conclusions about the role of Hrd1 in retrotranslocation.
In addition, developing the system was not trivial and required significant optimiza-
tion. Several of the techniques I established, including mixing membrane proteins and
encapsulated proteins via SNARE-mediated fusion, are applicable in many fields of
membrane protein research. I believe that the fusion system will be a useful method
for studying retrotranslocation once certain technical issues are solved. The advance-
ments I made in developing the fusion system and its limitations are described in the
following sections.
4.1.1 Soluble substrates can be efficiently encapsulated into
liposomes
One of the novelties in the fusion system is that soluble ERAD-L substrates are effi-
ciently encapsulated into liposomes without the use of a transmembrane domain. There
were several challenges to overcome to accomplish this. First, the luminal volume of
the liposomes is very small. As an example, an 8 mM solution of POPC liposomes
with 100 nm diameter, assuming a bilayer thickness of 2.5 nm, has only 2% of the total
volume entrapped in the lumen (based on the calculation in Adamala et al., 2016).
The actual entrapped volume is likely even lower because the liposomes I used con-
tained cholesterol, which increases the thickness of the bilayer (Nezil and Bloom, 1992).
Overall, this means that for efficient encapsulation, a large excess of the protein is re-
quired in the reconstitution mix, as is normally the case when encapsulating smaller
compounds such as fluorescent dyes or oligonucleotides (Kyoung et al., 2011; Nickel
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et al., 1999). Alternatively, one can increase the entrapped volume by using a high
lipid concentration, as was done in a previous study that successfully encapsulated
GFP and streptavidin (Heo et al., 2017). There, the lipid concentration was very high,
at 100 mM. Another possibility is to use liposomes with larger diameters.
The encapsulation of tightly-folded, highly-soluble proteins such as GFP is more straight-
forward than misfolded proteins. Misfolded proteins aggregate in a concentration-
dependent manner in the absence of detergent or denaturing agent. This meant that I
could not use a high starting concentration in the reconstitutions. My initial trials of
using excess sCPY* during detergent solubilization resulted in no encapsulation (Fig-
ure 3.4). I therefore turned to an affinity-based approach. By using NiNTA-labeled
phospholipids and a His-tagged substrate, I was able to overcome the inefficiencies
of encapsulation at relatively low substrate concentrations, by tethering the substrate
to the lipids during reconstitution. The NiNTA approach resulted in encapsulation
efficiencies of up to 30% for CPY* (Figure 3.6), and was compatible with ΔN com-
plex reconstitution protocols, resulting in efficient lipid mixing (Figures 3.13, 3.14)
and content mixing (Figure 3.15). Non-encapsulated CPY* was efficiently removed by
flotation in a Nycodenz gradient containing imidazole and urea, resulting in 85% of
CPY* protected from proteinase K (Figure 3.7). This provides a good starting point
for detection of retrotranslocation.
The NiNTA method was also broadly applicable for the encapsulation of other sub-
strates and enzymes. His-tagged PrA*, sCPY*-GFP, and the SUMO protease Ulp1
were efficiently encapsulated (Figures 3.23, 3.21, 3.15). Ulp1 was active after encap-
sulation (Figure 3.15), showing that the NiNTA encapsulation protocol is compatible
with experiments where enzymatic activity needs to be maintained.
4.1.2 SNARE-mediated fusion delivers substrates to the luminal
side of Hrd1
I characterized both lipid mixing and content mixing between Hrd1 and substrate
liposomes to exclude the possibility that fusion was the bottleneck in the system.
Overall, the fusion system effectively mixes both membrane and luminal compartments.
Standard fluorescence dequenching assays showed efficient membrane mixing (Figure
3.13). Additionally, I developed two methods that allow for biochemical detection of
membrane and content mixing. This was important because bulk assays involving
fluorescence dequenching and FRET do not give information about subpopulations of
liposomes or the activity of the proteins within them.
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4.1.2.1 Ubc6 autoubiquitination assay demonstrates mixing of membrane
components
The membrane mixing assay using Ubc6 and Hrd1 in separate liposomes showed
that Hrd1 efficiently autoubiquitinated in a SNARE-dependent manner (Figure 3.14).
Autoubiquitination was strongly reduced when fusion was inhibited with Sybsol, show-
ing that SNARE complex formation and membrane mixing were required for efficient
Hrd1 autoubiquitination. There was some residual autoubiquitination in the inhibited
fusion reaction, showing that Ubc6 has some E2 activity in trans. This assay does not
exclude that tight docking of liposomes increases the trans E2 activity of membrane-
anchored Ubc6. However, taken together with the lipid mixing observed in fluorescence
dequenching assays as well as the substrate cleavage in luminal content mixing assays,
this was likely not the case.
Other biochemical assays for membrane mixing are present in the literature. One study
demonstrated the reconstitution of reactions in the bacterial respiratory chain using
SNARE-mediated fusion of liposomes (Nordlund et al., 2014). This study monitored
ATP synthesis as a readout for fusion. Although useful, monitoring the appearance
of ATP over time, without a positive control, does not report on the overall efficiency
of fusion. The Ubc6 autoubiquitination assay shows both the appearance of a signal
(ubiquitinated Hrd1) and the disappearance of the starting product (unmodified Hrd1),
allowing conclusions to be drawn about the overall efficiency of membrane mixing.
4.1.2.2 Luminal contents are efficiently mixed upon fusion
I developed a biochemical content-mixing assay using encapsulated His-SUMO-tagged
sCPY*-GFP in one population of liposomes and and encapsulated SUMO protease
(Ulp1) in another (Figure 3.15). This assay allowed me to monitor content mixing
in substrate-containing liposomes and it also reported on the activity of the proteins
encapsulated within. The SUMO tag was efficiently cleaved from the sCPY*-GFP in a
SNARE-dependent manner, and cleavage was not observed when fusion was inhibited
(Figure 3.15). I concluded from this experiment that the contents were efficiently
mixed. Because sCPY*-GFP was cleaved by Ulp1, this shows that it was not in an
aggregated state, which is a problem that I observed for CPY* (see section 4.3.2 for
detailed discussion).
It must be noted however, that I observed leakage of luminal contents during fusion,
which may have contributed to the SNARE-dependent Ulp1 cleavage of substrate (Fig-
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ure 3.20, see section 4.1.2.3). For this reason, the luminal content mixing may not have
been as efficient as expected.
4.1.2.3 Leakage during fusion
A potential issue with the fusion system is the leakage observed during fusion (Figures
3.20 and 3.21). Experiments with Doa10, which is not involved in ERAD-L, showed
similar exposure of encapsulated sCPY*-GFP to the outside as Hrd1 (Figure 3.21). The
leakage may be caused by high membrane protein concentration in the liposomes. In-
deed, leakage during fusion has been previously observed in proteoliposomes containing
SNARE:lipid densities of 1:1000 or higher (Dennison et al., 2006; Bhalla et al., 2006),
indicating that high protein:lipid ratios destabilize membranes during fusion. Multi-
pass transmembrane proteins like Hrd1 and Doa10 likely contribute more to membrane
instability than single-TM containing SNAREs, at similar molar ratios. Leakage could
be reduced by decreasing SNARE concentration (Bhalla et al., 2006; van den Bogaart
et al., 2010). Therefore, an optimal concentration of Hrd1 and SNAREs that reduces
leakage while maintaining fusion efficiency needs to be determined.
4.2 Ubc6 functions as an E2 enzyme for Hrd1 in vitro
The Ubc6 membrane mixing assay demonstrated that Ubc6 can act as an E2 enzyme
for Hrd1 in a reconstituted system. Additionally, coreconstitution of Ubc6 with Hrd1
resulted in efficient autoubiquitination, even in the KRK mutant (Figure 3.45). This
was somewhat surprising, because Ubc7 and Ubc1 were shown to be the E2s involved
in ERAD-L and ERAD-M (Friedlander et al., 2000; Bays et al., 2001). However,
one studied implicated Ubc6 as being partially required for CPY* degradation (Hiller
et al., 1996). I observed that the presence of Ubc6 resulted in short ubiquitin chains
and more efficient Hrd1 autoubiquitination than with Ubc7 alone (Figures 3.14, 3.38).
As the KRK mutant was efficiently autoubiquitinated in the presence of Ubc6 (Figure
3.45), Ubc6 likely primes Hrd1 on non-lysine residues for chain extension by Ubc7.
This result is consistent with a previous observation that Ubc6 catalyzes monoubiq-
uitination on lysines as well as on serine and threonine residues of Doa10 substrates
(Weber et al., 2016). This monoubiquitination is thought to prime ERAD substrates
for further polyubiquitination by Ubc7, much like the Ubc4 and Ubc1 combination that
functions with the anaphase promoting complex (APC) (Rodrigo-Brenni and Morgan,
2007). One possible role for Ubc6 in the Hrd1 complex is the priming of substrates
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that have a low lysine content, as Ubc6 was absolutely required for degradation of
an ERAD-C substrate that lacked lysine residues (Weber et al., 2016). Interestingly,
Ube2J1, a mammalian homolog of Ubc6, is a core component of the mammalian Hrd1
complex and is required for ERAD-L (Christianson et al., 2011; Leto et al., 2019). The
mammalian Hrd1 complex was also shown to ubiquitinate substrates on serine and
threonine residues, presumably through Ube2J1 (Ishikura et al., 2010; Shimizu et al.,
2010). Further experiments testing the role of Ubc6 in degradation of substrates lack-
ing lysines are needed to provide greater insight into the role of Ubc6 in Hrd1-mediated
ERAD.
4.3 Potential issues with the fusion system
Because the fusion was likely not the limiting factor in the fusion system, the question
remains as to why encapsulated substrates were not efficiently retrotranslocated by
Hrd1. This could have been caused by multiple factors, the most important of which
are listed below:
1. Hrd1 was inactive or not in the correct oligomeric state.
2. The substrates were aggregated, oxidized, or not in a state conducive for retro-
translocation.
3. Retrotranslocation occurred but was very inefficient.
4. Hrd1 may be insufficient for retrotranslocation of luminal substrates.
These possibilities are discussed in detail in the following sections.
4.3.1 Was Hrd1 inactive or in the incorrect oligomeric state?
It is unlikely that Hrd1 activity was the problem because Hrd1 autoubiquitinated to
acceptable levels (approximately 60%) and the efficiency was independent of fusion
(Figures 3.12, 3.24). Neither fusion nor the presence of SNAREs inhibited Hrd1 ac-
tivity. Hrd1 autoubiquitination reached higher efficiencies when reconstituted with
DMNG compared to DM, which was used in the fusion system (Figure 3.42A com-
pared to Figure 3.12). However, when Hrd1 was reconstituted directly into CPY*
liposomes with DMNG, its autoubiquitination efficiency was very high, yet CPY* was
inefficiently ubiquitinated (Figure 3.26).
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It is possible that Hrd1 was not in the correct oligomeric state for retrotranslocation.
In normal conditions, ERAD-L requires Usa1, which causes Hrd1 oligomerization and
recruits Der1 (Horn et al., 2009; Carvalho et al., 2010). It is not clear if ERAD-
L requires a higher oligomeric state of Hrd1 for retrotranslocation. However, it has
been shown that the ability for Hrd1 to compensate for the deletion of the other
components of the complex depends on its overexpression levels. When Hrd1 is very
highly overexpressed from a Gal1 promoter, CPY* is degraded with kinetics similar to
the wild-type strain (Carvalho et al., 2010). When Hrd1 is only modestly overexpressed,
it shows an intermediate compensation for Hrd3 deletion (Plemper et al., 1999; Denic
et al., 2006; Vashistha et al., 2016). It may be that spontaneous Hrd1 oligomerization
requires a higher concentration in the absence of Usa1. In vivo, this effect could be due
to other factors, such as the decreased affinity for substrates in the absence of Hrd3. In
any case, Hrd1 is already in a heterogenous oligomeric state after purification in DMNG
(Stein et al., 2014). I used a protein to lipid ratio of 1:2000 in retrotranslocation
experiments, identical to what was used in the study by Baldridge and Rapoport
(2016). I did not use higher Hrd1 concentrations because of leakage during fusion,
which appeared to be dependent on the concentration of transmembrane domains in
the liposomes (Figure 3.21).
4.3.2 Substrate aggregation
It appears likely that CPY* and the other ERAD-L substrates used in the fusion system
irreversibly aggregated during reconstitution. First, it is important to keep in mind that
ERAD does not efficiently degrade aggregated proteins, highlighting the importance
of chaperones in keeping misfolded proteins in a soluble state before retrotranslocation
(Needham et al., 2019). The main indication of aggregation is that outside-bound
CPY* was inefficiently ubiquitinated by Hrd1 during fusion (Figure 3.27). After the
first step of the encapsulation protocol, 70% of CPY* was accessible to proteinase K,
but only roughly 30% was ubiquitinated by Hrd1. In contrast, when CPY* and PrA*
were added to the outside of Hrd1 liposomes, approximately 90% was ubiquitinated
(Figure 3.34).
Experience in our lab indicates that CPY* aggregates within a couple of hours after
dilution from 2.5 M urea. For this reason, encapsulation was always performed in the
presence of 1 or 2 M urea. Reconstitution was performed as quickly as possible. How-
ever, because the reconstitution protocol for optimal ΔN complex activity required
dialysis for detergent removal, the time-factor could not be considerably shortened.
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Even with reconstitution in the presence of urea, CPY* was inefficiently ubiquitinated
(Figures 3.16, 3.18). I attempted to resolubilize aggregated luminal CPY* by includ-
ing 3 M urea in the Nycodenz flotation (Figure 3.28). However, I did not observe
any retrotranslocation in this case. It is not clear if the urea successfully penetrated
into the lumen of liposomes or whether higher concentrations were required. Because
PrA* behaved similarly to CPY* during purification, it likely also aggregated during
encapsulation. The substrate H14-SUMO-sCPY*-GFP was apparently not in an ag-
gregated state, because it could be cleaved by Ulp1 (Figure 3.15). However, it also
was not ubiquitinated by Hrd1, despite the fact that it leaked to the outside during
fusion (Figure 3.19). The tightly-folded SUMO and GFP flanking the sCPY* domain
likely preserved solubility, but the substrate may have aggregated after cleavage of the
SUMO tag by Ulp1.
It is possible that in the presence of liposomes, the exposed hydrophobic regions in
CPY* and PrA* insert like an amphipathic helix into the bilayer. The may bury
the degron that is likely required for initiation of retrotranslocation and ubiquitina-
tion. Alternatively, the high protein concentration in the liposome lumen may cause
irreversible aggregation. These factors may have contributed to why I was unable to
encapsulate transmembrane domain-containing versions of CPY* (section 3.5.8).
4.3.3 Ideas for overcoming substrate aggregation
How can this be solved? Chemical chaperones such as glycerol or sucrose, or harsher
denaturing agents like guanidine hydrochloride may help reduce aggregation. Addi-
tionally, chaperones such as the Hsp70 Kar2 and its Hsp40 cofactors, which have been
shown to be required for CPY* degradation in vivo (Nishikawa et al., 2001), may keep
substrates in a soluble state. One issue with Hsp70 chaperones is that their affinity
for substrates is relatively low, with KD values in the micromolar range (Bukau et al.,
2000). This may be overcome by using high concentrations of chaperone. Alternatively,
it may be possible to co-encapsulate a His-tagged chaperone along with the substrate.
Another possibility is to use inducible misfolded substrates. The advantage would be
that encapsulation and fusion can be performed with a well-folded, soluble protein.
After fusion, the substrate would be induced to misfold in the lumen, where hopefully
Hrd1 can capture it and initiate retrotranslocation before it has the chance to aggregate.
An elegant system of inducible misfolding was developed by the Crews lab, using
the modified bacterial dehalogenase protein (HaloTag), which forms a covalent bond
with chloroalkane ligands (Los et al., 2008). They synthesized a ligand that causes
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proteasomal degradation of HaloTag fusion proteins in vivo, and induces the UPR
when fused to an ER-localized protein (Neklesa et al., 2011; Raina et al., 2014). Most
importantly, the ligand is membrane-permeable, which would allow it to access the
lumen of liposomes. Of course, a prerequisite would be that the HaloTag has to become
a Hrd1 substrate upon ligand binding.
As an alternative, temperature-sensitive mutants of soluble cytosolic proteins have
been developed, which are degraded by the UPS upon shifting to non-permissive tem-
peratures (Schneider et al., 2018). The temperature-sensitive form of Ubc9 (Ubc9ts),
has been shown to misfold at temperatures above 30 °C (Betting and Seufert, 1996;
Kaganovich et al., 2008). Interestingly, Hrd1 and Doa10 are involved in its degradation
in the cytosol upon misfolding (Samant et al., 2018). Because temperature shifting is
very straight-forward and rapid, it could be applied to induce misfolding of encapsu-
lated Ubc9ts. It would have to be first tested whether ER-imported Ubc9ts is a Hrd1
substrate in vivo.
4.3.4 Retrotranslocation may have occurred but was very
inefficient
Retrotranslocation experiments showed that approximately 25% of CPY*-H14 was
ubiquitinated after fusion, while 18% was accessible to proteinase K before fusion (Fig-
ures 3.17 and 3.18). Only 15% of CPY*-H14 was ubiquitinated in the inhibited fusion
control. This means that 7-10% of CPY*-H14 was potentially retrotranslocated. It is
possible that retrotranslocation is very inefficient after taking into account potential
substrate aggregation and the lack of other components such as Der1. Further repeti-
tions are required for more definitive conclusions. However, between experiments with
slightly different reconstitution conditions, the amount of CPY* protected from pro-
teinase K ranged between 80-90%, while ubiquitination after fusion was also variable,
ranging between 10-20%. Therefore, I focused my attention on improving retrotranslo-
cation efficiency. Because I was interested in understanding mechanistic details about
the process, I required a more efficient reaction.
4.3.5 Is Hrd1 is insufficient for retrotranslocation?
The final possibility is that Hrd1 is insufficient for efficient retrotranslocation of luminal
substrates. Perhaps other components in the Hrd1 complex are required to efficiently
insert substrates into the retrotranslocon. One strong candidate for this role is Der1,
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which interacts with luminal substrates with its transmembrane domains their way
to Hrd1 (Carvalho et al., 2010; Mehnert et al., 2013). As Der1 is recruited to Hrd1
by Usa1 (Carvalho et al., 2006; Horn et al., 2009), a subcomplex of Hrd1/Usa1/Der1
would need to be reconstituted into the fusion system to test the effect of Der1 on
retrotranslocation.
4.4 Hrd1 forms an ion-conducting channel upon
autoubiquitination
When we incubated Hrd1 liposomes with ubiquitination machinery and added them
to PLBs, we detected ion currents at different holding potentials (Figure 3.30), indi-
cating that Hrd1 forms a channel. Autoubiquitination was clearly required for channel
formation because Hrd1 liposomes incubated with ubiquitination mix lacking ATP did
not fuse to the bilayer, nor did Hrd1 liposomes alone (Figure 3.30C). Additionally,
the Hrd1 KRR mutant, which shows almost no autoubiquitination (Figures 3.41 and
3.42A), did not fuse to the lipid bilayer (Figure 3.44A). This result supports the previ-
ous observation that autoubiquitination is required for retrotranslocation of CPY*-TM
in vitro (Baldridge and Rapoport, 2016). The channel on its own was dormant and
small, because the gating events were relatively infrequent and the conductance states
were in the range of 50 pS (Figure 3.31D). Conductances in this regime correspond
to a pore diameter of approximately 0.4 nm, which is significantly smaller than the
diameter of a single alpha helix (see materials and methods for details on calculat-
ing pore diameter). In order for Hrd1 to retrotranslocate substrates which may have
folded domains with various topologies, we expected that it would need to open to a
larger pore size. This is supported by previous electrophysiological measurements of
the protein translocases Sec61, Tim23 and SecY, which translocate unfolded proteins
across the ER membrane, inner mitochondrial membrane and bacterial inner mem-
brane, respectively. These proteins show gating events with conductances in the range
of 200-600 pS, which correspond to average pore diameters of approximately 1-2 nm
(Wirth et al., 2003; Truscott et al., 2001; Saparov et al., 2007).
Strikingly, the addition of CPY* specifically to the luminal side of Hrd1 stimulated
rapid channel gating, with conductances in the range of 200-600 pS observed (Figures
3.31, 3.33). Thus, upon interaction with substrate, the Hrd1 pore expanded to a
similar diameter as the aforementioned protein translocases. This result indicates that
Hrd1 is dynamic, substrate-responsive channel. This would make sense, as it would
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be detrimental to have a constitutively open channel in the ER. We hypothesize that
the expansion of the pore may correlate with substrate size, as was demonstrated for
the peroxisomal importer Pex5/Pex14 (Meinecke et al., 2010). It was interesting that
CPY* addition stimulated further opening of the channel, as presequence addition to
open Tim23 and Tom40 channels from mitochondria as well as the Toc75 channel from
chloroplasts blocked the flow of ions (Truscott et al., 2001; Hill et al., 1998; Hinnah
et al., 2002). It may reflect on the type of interaction of the substrate with the channel.
CPY* may not completely insert into the channel. Despite the differences in channel
conductance after substrate binding, CPY* increased Hrd1 gating frequency, an effect
which has been observed with substrate binding to other translocation channels (Hill
et al., 1998; Truscott et al., 2001; Kovermann et al., 2002). Importantly, we observed
conductances in the range of 600 pS without the presence of CPY*, but they were very
rare (Figure 3.31D). This indicates that the non-stimulated channel has the ability to
open to larger pore diameters, and that substrate binding possibly reduces the energy
barrier for this further opening. A similar mechanism of activation energy reduction
was proposed for signal sequence binding to the SecY channel (Gouridis et al., 2009).
What does the pore diameter tell us about retrotranslocation mechanism? The max-
imum conductance states we observed after CPY* addition were in the range of 800
pS (Figure 3.31D), which corresponds to pore diameters of roughly 2.5 nm. This is
certainly large enough to accommodate two alpha helices side by side, which would be
expected if the substrate inserts as a loop, such as in translocation by SecY and Sec61
(Rapoport et al., 2017). This pore size indicates that larger folded domains would
probably not be able to pass through the retrotranslocon, and would likely require
Cdc48 for unfolding. However, the pore sizes from the theoretical calculations should
be confirmed with an experimental approach such as the polymer-exclusion method
(Krasilnikov et al., 1992).
4.4.1 Channel closure by deubiquitination
Remarkably, we observed that deubiquitination of Hrd1 irreversibly closed the channel
(Figure 3.32). In the cell, a similar deubiquitination mechanism may inactivate Hrd1
channels after retrotranslocation is complete. The identity of the DUB responsible
for this is still unknown. The DUB OTU1 (YOD1 in mammals) may be involved,
as knockdown of YOD1 stimulated cholera toxin retrotranslocation (Bernardi et al.,
2013). Interestingly, cholera toxin is not ubiquitinated but nevertheless requires Hrd1
for retrotranslocation, indicating that Hrd1 may be a target of YOD1 (Bernardi et al.,
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2010). However, OTU1 normally functions with Cdc48 (Stein et al., 2014; Bodnar and
Rapoport, 2017b), so this effect may have been connected to Cdc48 activity. USP19
is another DUB that was shown to be involved in mammalian ERAD and is localized
to the ER membrane (Hassink et al., 2009). Overexpression of USP19 stabilized Hrd1
levels and was shown to reduce the accumulation of ubiquitinated Hrd1 (Harada et al.,
2016). Deubiquitination of Hrd1 likely has to be tightly-regulated not just for channel
closure, but because prolonged Hrd1 autoubiquitination may trigger its own degrada-
tion. Additionally, I raise the possibility that deubiquitination also serves to release
the substrate from the cytoplasmic binding site, which may be especially important for
nonubiquitinated substrates (Figure 3.40).
4.5 Autoubiquitination in the Hrd1 RING domain
creates a high affinity cytosolic binding site
Hrd1 autoubiquitination led to binding of CPY* and PrA* to the cytoplasmic side of
Hrd1 with high affinity (Figure 3.36). The binding was specific for misfolded proteins,
as CPY WT bound inefficiently and PrA WT did not bind at all to autoubiquitinated
Hrd1. Interestingly, both misfolded proteins did not bind to the cytoplasmic side of
nonubiquitinated Hrd1 (Figure 3.36). Thus, it appears that a conformational change
occurs upon Hrd1 autoubiquitination that creates a cytosolic binding site, which is
normally occluded in the nonubiquitinated state. Cytosolic binding positions the sub-
strate for efficient ubiquitination, because Hrd1 lysine mutants that bound CPY* with
lower affinity ubiquitinated CPY* less efficiently (Figures 3.43 and Figures 3.41, 3.42).
Using lysine to arginine mutants of Hrd1, I identified that Hrd1 autoubiquitination
in the RING domain was critical for high-affinity CPY* binding and efficient CPY*
polyubiquitination (Figure 3.43 for binding and Figures 3.41, 3.42 for ubiquitination).
I observed that the RING domain lysines are the predominant attachment sites for long
ubiquitin chains by Hrd1. This was evident because the overall autoubiquitination ef-
ficiency was not markedly different between Hrd1 mutants lacking lysines in the RING
domain and mutants lacking lysines in the C-terminal extension (Figure 3.42A). How-
ever, the ubiquitin chains appeared longer when the RING domain lysines were present
(Figure 3.41). Thus, Hrd1 autoubiquitinates across its entire cytoplasmic region, with
short chains in the C-terminal extension and long chains in the RING domain. The 3K
RING domain mutant, which was previously shown to be defective in retrotransloca-
tion in vitro and CPY* degradation in vivo (Baldridge and Rapoport, 2016), showed
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almost identical autoubiquitination efficiency and ubiquitin chain length as the KRK
mutant (Figures 3.41, 3.42). Therefore, the primary ubiquitination sites in the RING
domain are lysines 373, 387 and 407. I hypothesize that reintroducing any one of these
three lysines back into the KRK mutant would rescue Hrd1 autoubiquitination, sub-
strate binding and substrate ubiquitination. This is based on the observation in the
Baldridge study which showed that simply mutating combinations of two of these three
lysines did not abolish CPY* degradation, indicating that they are redundant and can
substitute for each other (Baldridge and Rapoport, 2016).
4.6 Cytosolic binding site may provide the driving force
in retrotranslocation
What is the purpose of the cytosolic binding site? The intuitive reasoning is that sub-
strate binding on the cytosolic side is a prerequisite for substrate ubiquitination, as E3
ligases need to bind to substrate to catalyze their ubiquitination (Deshaies and Joazeiro,
2009). However, I propose that an additional effect of the cytosolic substrate binding
site is to provide the driving force during retrotranslocation. An overarching principle
in protein translocation is that the translocon forms a passive pore in the membrane
through which polypeptide segments diffuse by Brownian motion, and a driving force is
necessary to provide directionality (Rapoport et al., 2017). In cotranslational protein
translocation into the ER and across the bacterial plasma membrane, Sec61/SecY form
the passive pore and the ribosome provides the driving force by preventing backsliding
of the polypeptide into the cytosol as it is elongated through the channel (Rapoport
et al., 2017; Connolly and Gilmore, 1986). In post translational translocation across the
ER membrane, the luminal Hsp70 BiP acts as a Brownian ratchet to drive translocation
of a polypeptide into the ER lumen (Matlack et al., 1999). It binds the polypeptide
loosely in its ATP-bound state, after which the J domain of the accessory protein
Sec63 stimulates ATP hydrolysis, causing BiP to bind more tightly to the translocat-
ing substrate. This tight association prevents backsliding into the channel. Through
multiple cycles of binding and release by sequential BiP molecules, the polypeptide is
ratcheted into the ER lumen (Matlack et al., 1999; Liebermeister et al., 2001). In post
translational translocation across the bacterial plasma membrane, the SecA ATPase
pushes segments of a translocating polypeptide into the SecY channel. SecA associates
with the polypeptide in the ATP-bound state. Upon ATP hydrolysis, the polypeptide
slides back and forth in the SecY channel until subsequent ADP-ATP exchange, and
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SecA in the ATP-bound form pushes the polypeptide further into the channel (Bauer
et al., 2014; Rapoport et al., 2017). In the translocation of proteins from the cytosol
into the mitochondrial matrix, the driving force through the Tim23 pore is provided
by the membrane potential and the PAM motor in the matrix (Wiedemann and Pfan-
ner, 2017). The PAM motor contains an Hsp70 protein (mtHsp70), a J protein and
a nucleotide exchange factor. The mtHsp70 acts as a Brownian ratchet and may also
provide a direct pulling force into the matrix (Wiedemann and Pfanner, 2017).
During Hrd1-mediated retrotranslocation, a polypeptide would be free to slide back
and forth through Hrd1 unless it encounters a trap on the cytosolic side. The sub-
strate binding site on the cytoplasmic side of Hrd1 would serve as this trap, prevent-
ing backsliding into the channel. Polyubiquitination of the substrate further prevents
backsliding, but it mainly serves to recruit Cdc48, which hydrolyzes ATP to pull the
substrate out of the membrane (Flierman et al., 2003) (see section 4.11 for model and
further discussion).
4.7 The nature of the conformational change in Hrd1
Hrd1 autoubiquitination appears to cause a conformational change, and our results
show that this conformational change is most efficiently stabilized when Hrd1 autoubiq-
uitinates in its RING domain. Consistent with this interpretation was the observation
that the Hrd1 KRK mutant was able to form channels, but these channels were ex-
tremely short-lived and unstable (Figure 3.44). In our experiments, we were unable
to uncouple the conformational change leading to channel formation from that which
causes cytosolic substrate binding. Both experiments may have indeed been reporting
on the same conformational change, which serves multiple purposes: opening the chan-
nel and providing a cytosolic binding site as the driving force for retrotranslocation. It
is possible that the combination of channel instability coupled with inefficient substrate
binding on the cytosolic side contributes to a defect in ERAD-L when lysines are not
present in the RING domain. These results may provide an explanation to the ERAD-
L defect that was previously observed with the KRK and 3K mutants (Baldridge and
Rapoport, 2016; Neal et al., 2018).
The nature of the conformational change in Hrd1 upon autoubiquitination remains
mysterious. The Hrd1/Hrd3 cryo-EM structure does not show a density for the RING
domain, indicating that it is part of a flexible region (Schoebel et al., 2017). However,
the RING domain is located closer to the last transmembrane domain than previously
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appreciated, due to the fact that Hrd1 was shown to have eight TMs instead of six
(Deak and Wolf, 2001; Schoebel et al., 2017). The RING domain is approximately 25
amino acids away from the last TM, indicating that it may be in proximity to affect
the conformation of the transmembrane domains of Hrd1 after autoubiquitination. A
recent NMR structure of the Hrd1 RING domain from S. cerevisiae shows that the
three primary acceptor lysines in the RING domain (K373, K387 and K407) all face
away from the canonical E2 binding site, close to the C-terminus of the RING domain
(Kniss et al., 2019) (Figure 4.1). The four other lysines in the Hrd1 RING domain,
which are not required for ERAD-L (Baldridge and Rapoport, 2016), are located in a
loop and beta strand before the three primary acceptor lysines, facing 90° away from
them. It is not clear why the three terminal lysines are preferentially ubiquitinated, but
the structure explains why they can substitute each for other, as they are all located
on the same side of the RING domain and are perhaps better positioned for ubiquitin
transfer after E2 binding.
Figure 4.1: NMR Stucture of the Hrd1 RING domain
Structure created with PyMOL from PDB ID 6F98 (Kniss et al., 2019). Zinc ions that
coordinate conserved cysteine and histidine residues are indicated. The canonical E2
binding pocket was derived from the structure of the c-Cbl E3 ligase in complex with
the E2 UbcH7 (Zheng et al., 2000), with additional input from alignments in Deshaies
and Joazeiro (2009).
Interestingly, homologs of Hrd1 in other species have significantly fewer lysines in the
cytosolic region than in S. cerevisiae. K373 from S. cerevisiae is highly conserved, and
in some species, this is the only lysine present in the RING domain (Baldridge and
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Rapoport, 2016). This indicates that K373 is probably sufficient for channel formation
and cytosolic substrate binding. The other lysines may have been lost to minimize non-
specific autoubiquitination and degradation, as seems to be the case in other RING
E3s (Boomsma et al., 2016).
4.7.1 Hrd1 autoubiquitination may facilitate monomerization
One idea is that autoubiquitination might facilitate dissociation of the Hrd1 dimers or
oligomers into monomers. In this case, the dimer found in the Hrd1/Hrd3 structure
would be the inactive form (Schoebel et al., 2017). This is supported by in vivo
evidence that a retrotranslocating ERAD-L substrate crosslinked to Hrd1 efficiently
even in the absence of Usa1, which is required for Hrd1 oligomerization (Carvalho
et al., 2010). Other translocation channels share a monomerization mechanism. Tim23
is normally present as a dimer and it dissociates upon presequence binding into the
active monomeric channel (Bauer et al., 1996). SecY is a dimer that contains only one
active pore, with the other SecY molecule involved in targeting the polypeptide into
the active channel (Osborne and Rapoport, 2007). Autoubiquitination of Hrd1 may
similarly lead to monomerization.
In the cell, Hrd1 is present in a multi-subunit complex, whose components likely regu-
late its autoubiquitination. It is logical that Hrd1 only autoubiquitinate when substrate
is present. Hrd3 may regulate Hrd1 autoubiquitination by linking it to substrate bind-
ing. It interacts with substrate upstream of Hrd1 and binds to the loop between TMs
1 and 2 of Hrd1 (Carvalho et al., 2010; Schoebel et al., 2017). In the absence of Hrd3,
Hrd1 autoubiquitination levels increase and Hrd1 is rapidly degraded (Gardner et al.,
2000). Recent evidence shows that Hrd3 may directly influence Hrd1 ubiquitination
activity (Vashistha et al., 2016). Additionally, Usa1 binds to the C-terminus of Hrd1
and may block access to ubiquitination sites in the C-terminal extension. Accordingly,
Hrd3 may block autoubiquitination of the Hrd1 RING domain until substrate binding,
where it would release this inhibition.
4.8 Possible mechanisms of cytosolic substrate binding
by Hrd1
An important question remaining is what forms the cytoplasmic substrate binding site
in Hrd1? It is unlikely that a misfolded protein binds to the RING domain itself, as
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RING domains are globular, soluble domains (Zheng et al., 2000). Interestingly, apart
from the RING domain, the Hrd1 C-terminal region is largely unstructured and is
predicted to be intrinsically disordered (Schulz et al., 2017). Other E3 ubiquitin ligases,
like the nuclear-localized San1 in yeast, bind substrates directly through intrinsically-
disordered regions flanked by short ordered regions (Rosenbaum et al., 2011; Boomsma
et al., 2016). This is thought to provide a broad spectrum of substrate specificity,
which is especially important in ERAD, as substrates do not have defined degrons.
Perhaps Hrd1 autoubiquitination triggers a conformational change which leads to the
formation of hydrophobic pocket or clamp, which may be surrounded by intrinsically
disordered domains.
It is difficult to completely rule out that the substrate binding is contributed by long
poylubiquitin chains attached to Hrd1. Although I observed no CPY* binding to
polyubiquitinated Ubc6, the chain length appeared to shorter than the chains on Hrd1
(Figure 3.39). Ubiquitin contains a hydrophobic patch which normally interacts with
ubiquitin binding domains (Winget and Mayor, 2010). It is possible that long chains
create a distributed hydrophobic binding surface for misfolded proteins. It could be
that a combination of the aforementioned mechanisms contributes to overall substrate
affinity upon Hrd1 autoubiquitination. Autoubiquitination as a mechanism to increase
substrate affinity has been observed in other E3 ligases such as TRAF6 and NEDD4
(de Bie and Ciechanover, 2011), indicating that it may be a conserved mechanism.
4.9 Autoubiquitination of Hrd1 as an allosteric
post-translational modification
Autoubiquitination of Hrd1 induces a conformational change leading to channel activity
(Figure 3.30), and this modification is completely reversible (Figure 3.32). Addition-
ally, cytosolic substrate binding was induced by autoubiquitination and was reversible,
as CPY* was partially released after deubiquitination (Figure 3.40). These results im-
ply that Hrd1 autoubiquitination acts as an allosteric post-translational modification,
affecting channel activity and cytosolic binding from an external site. Interestingly,
ubiquitination is rarely utilized as an allosteric modulator, unlike phosphorylation,
which is prevalent in many processes (Nussinov et al., 2012). Autoubiquitination is
not uncommon in E3 ligases, and is usually a self-regulation mechanism, resulting
in proteasomal degradation (de Bie and Ciechanover, 2011). Autoubiquitination of
E3 ligases has also been shown to increase ubiquitination activity and recruit sub-
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strates (de Bie and Ciechanover, 2011), a mechanism which may have commonality
with Hrd1 cytosolic substrate binding. What makes the allosteric modification of Hrd1
by autoubiquitination a unique case is that it affects channel activity in addition to
substrate binding and ubiquitination. One example in the literature shows a similar
situation. The epithelial sodium channel ENaC is partly-regulated by extracellular
proteolysis. Ubiquitination of the channel on the cytosolic side causes it to adopt a
more tightly-folded conformation on the extracellular side, making it more resistant to
extracellular proteases (Ruffieux-Daidié and Staub, 2010). This supports the idea that
ubiquitination can result in conformational changes across the membrane.
As monoubiquitination resulted neither in channel activity (Figure 3.44) nor cytosolic
substrate binding (Figure 3.37), one question that remains is what is the minimal
ubiquitin chain length for these effects? Because loading of presynthesized ubiquitin
chains of varying lengths onto the E1 enzyme was inefficient (data not shown), one idea
to synthesize shorter chains is to use a mutant of Cue1 lacking the CUE domain, as
has been previously demonstrated (Bagola et al., 2013). Another idea is to titrate low
concentrations of Ubc7 and Cue1, and to stop the ubiquitination reaction with a zinc
chelator after short timepoints. Knowledge of the minimum ubiquitin chain length will
help in deducing the nature of the conformational change.
4.10 Substrate binding on the luminal side of Hrd1
Hrd1 contains a luminal binding site for misfolded proteins, because CPY*, but not
CPY WT, bound to nonubiquitinated Hrd1 in nanodiscs (Figure 3.52), but not in lip-
somes (Figure 3.36). As this is an indirect determination of luminal binding, detection
of direct substrate binding to the luminal side of Hrd1 awaits site-specific crosslinking
and FRET experiments. This is the first time substrate binding has been detected on
the luminal side of Hrd1 in a reconstituted system. It offers an explanation as to why
overexpressed Hrd1 compensates for the deletion of other ERAD components, includ-
ing the substrate receptor Hrd3 (Carvalho et al., 2010). Hrd1 has a weaker affinity for
CPY* on its luminal side in the nonubiquitinated state than on the cytosolic side in its
autoubiquitinated state, which may contribute to the driving force in retrotranslocation
by an affinity gradient mechanism (Figure 4.2).
We observed CPY* activation of the channel on the luminal side of ubiquitinated Hrd1
(Figures 3.33, 3.31). Since it is difficult to differentiate cytosolic from luminal binding
to ubiquitinated Hrd1 in nanodiscs, it is unclear what the substrate affinity for the
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luminal side of Hrd1 is in the autoubiquitinated state. Another question that arises
is where substrates bind on the luminal side, as the structure shows mainly loops on
that side of Hrd1 (Schoebel et al., 2017) (Figure 1.6). Perhaps a combination of weak
interactions with luminal loops of multiple Hrd1 molecules contributes to the overall
affinity. Finally, it will also be interesting to test the luminal binding of substrates
to the Hrd1/Hrd3 complex in nanodiscs, particularly in combination with subsequent
autoubiquitination experiments.
4.11 Proposed mechanism of retrotranslocation by
Hrd1
Based on the evidence presented in this thesis, an updated model of retrotranslocation
of misfolded luminal proteins by Hrd1 is presented in Figure 4.2. In step 1, the substrate
binds to the luminal side of Hrd1. Autoubiquitination of Hrd1 on lysine residues in its
RING domain leads to channel opening (step 2). Substrate binding to the luminal side
stimulates channel gating and expansion (step 2). Subsequently, the substrate inserts
in to the channel and is free to slide back and forth until it encounters the substrate
binding site, which locks the substrate into place and prevents backsliding (step 3).
The substrate is polyubiquitinated by Hrd1 on the cytosolic side of the membrane,
which in turn recruits the Cdc48 complex (step 4). The Cdc48 complex hydrolyzes
ATP to extract the substrate out of the membrane. Finally, a DUB removes ubiquitin
chains from Hrd1, which closes the channel.
Figure 4.2: Updated mechanism of retrotranslocation by Hrd1
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